

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

**Comparison of combined lumbar and sacral plexus block with sedation versus general endotracheal anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery: study protocol for a prospective, multicenter, randomized controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022898
Article Type:	Protocol
Date Submitted by the Author:	16-Mar-2018
Complete List of Authors:	zhang, junfeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology wang, xiaofeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology zhang, hui; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology shu, zhuolin; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology jiang, wei; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology
Keywords:	Hip fracture, Elderly, Lumbar plexus block, Sacral plexus block, General anesthesia

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Comparison of combined lumbar and sacral plexus block with sedation versus**  
5  
6 **general endotracheal anesthesia on postoperative outcomes in elderly patients**  
7  
8 **undergoing hip fracture surgery: study protocol for a prospective, multicenter,**  
9  
10 **randomized controlled trial**  
11  
12  
13  
14

15  
16 Junfeng Zhang<sup>#</sup>, Xiaofeng Wang<sup>#</sup>, Hui Zhang, Zhuolin Shu, Wei Jiang\*  
17  
18

19  
20 Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
21  
22 People's Hospital, Shanghai 200233, China  
23  
24

25  
26  
27  
28 \*Corresponding author: Wei Jiang MD, PhD. Address: 600 Yishan Road, Shanghai  
29  
30 200233, China. Tel: +86 21 64369181 ext. 58328; Fax: +86 21 64369181 ext. 58330.  
31  
32  
33 E-mail: jiangw@sjtu.edu.cn.  
34  
35

36  
37  
38 <sup>#</sup>These authors contributed equally to this work.  
39  
40

41  
42  
43 Email address of all authors:

44  
45 JZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
46  
47 People's Hospital, Email: zhangjunfeng@sjtu.edu.cn  
48

49  
50 XW: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
51  
52 People's Hospital, Email: 240483680@qq.com  
53

54  
55 HZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
56  
57

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

People's Hospital, Email: zhanghui12179@163.com

ZS: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth

People's Hospital, Email:5883434@qq.com

WJ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth

People's Hospital, Email: jiangw@sjtu.edu.cn

For peer review only

## ABSTRACT

**Introduction** Hip fracture in elderly people is a global public health problem, with substantial associated mortality and disability. Nearly all patients with hip fracture undergo surgical treatment, but choice of anesthesia for hip fracture surgery in elderly patients is still inconclusive. Ultrasound-guided combined lumbar and sacral plexus block has been widely used in hip fracture surgery in recent years, especially for some high-risk patients. However, it is not clear whether it can improve the postoperative prognosis of elderly patients with hip fracture.

**Method and analysis** This research project is a two-arm, parallel, multicenter, prospective randomized controlled trial. 1086 aged 77 and older scheduled for hip fracture surgery in five clinical trial centers will be randomized in a 1:1 ratio to receive either combined lumbar and sacral plexus block plus sedation or general endotracheal anesthesia. The primary outcome will be the postoperative 1-year all-cause mortality. The secondary outcomes will be the incidence of postoperative complications, high-sensitivity cardiac troponin, postoperative acute pain scores, early mobility after surgery, postoperative delirium, satisfaction with anesthesia, length of stay in ICU and hospital, and cost-effective outcomes. Assessments will be conducted in four steps: preoperative, intraoperative and in-hospital data collection and post-discharge telephone follow-up.

**Ethics and dissemination** This study has been supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103) and approved by the Ethics Committee of Shanghai Sixth

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

People's Hospital [No: 2016-28-(2)]. At the time of manuscript submission, the protocol version is v1.6 (March 2nd, 2018) with one subsequent approved amendment. Results will be disseminated via an international peer-reviewed publication.

**Trial registration number** NCT03318133.

**Key words** Elderly; Hip fracture; Lumbar plexus block; Sacral plexus block; General anesthesia

### **Strengths and limitations of this study**

- ▶ This study will be the first prospective, multicenter, randomized controlled clinical trial to investigate the effect of the two anesthesia techniques on long-term prognostic indicators in elderly patients with hip fracture.
- ▶ The results of this study will help elucidate whether ultrasound-guided CLSB with sedative anesthesia can be safely used in hip fracture surgery and reduce the incidence of perioperative complications and improve long-term prognosis in elderly patients.
- ▶ Our study results will be limited to a Chinese population, and further studies on other ethnic backgrounds will be required.

## **1.BACKGROUND**

Hip fracture is a global public health problem with an incidence of more than 1.6 million worldwide each year<sup>[1]</sup>. Owing to the global increase of the population aged 65 years and over, the total number of hip fracture is expected to surpass 6 million by 2050<sup>[2]</sup>. While early surgery is the most effective treatment method, the postoperative

1  
2  
3 mortality and disability rates are still high <sup>[3]</sup>. Patients with hip fracture often have  
4  
5 concurrent organ dysfunction, making anesthesia extremely risky, which is mainly  
6  
7 associated with the high rates of pulmonary and cardiovascular complications <sup>[4, 5]</sup>.  
8  
9  
10 Seeking appropriate anesthesia technique is in urgent need to ensure that these  
11  
12 patients can safely and effectively get through the perioperative period.  
13  
14

15  
16 Most studies assessing the relationship between anesthesia technique and  
17  
18 outcomes mainly focus on the comparisons between neuraxial anesthesia (including  
19  
20 spinal and epidural anesthesia) and general endotracheal anesthesia. A previous study  
21  
22 has shown that neuraxial anesthesia can avoid endotracheal intubation, reduce  
23  
24 intraoperative blood loss and improve postoperative analgesia, while general  
25  
26 endotracheal anesthesia can maintain a more stable hemodynamic state<sup>[6]</sup>. Some other  
27  
28 investigations have shown that neuraxial anesthesia for hip fracture can reduce  
29  
30 postoperative morbidity<sup>[7, 8]</sup>, but two recent large-sample size observational studies  
31  
32 deemed that neuraxial anesthesia could not significantly improve the prognosis of  
33  
34 patients <sup>[9, 10]</sup>. However, all of the above are retrospective observational studies, in  
35  
36 which anesthesiologists might have selected the anesthesia technique based on their  
37  
38 practice style and a variety of patient-related factors. For example, patients with  
39  
40 coagulation dysfunction would have contraindication to neuraxial anesthesia and must  
41  
42 receive general anesthesia. Neuraxial anesthesia is thought to be less postoperative  
43  
44 complications, so elderly or critically ill patients might be more likely to receive  
45  
46 neuraxial anesthesia <sup>[11]</sup>, rather than being randomly assigned to different anesthesia  
47  
48 groups. Therefore, there could be selective bias that affected the clinical significance  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3  
4 of those results. In addition to general anesthesia and neuraxial anesthesia,  
5  
6 ultrasound-guided lumbar and sacral plexus block has been widely used in hip  
7  
8 fracture surgeries in recent years, especially for some high-risk patients with  
9  
10 cardiopulmonary dysfunction [12-14]. Compared with neuraxial anesthesia, combined  
11  
12 lumbar and sacral plexus block is associated with less sympathetic block and better  
13  
14 cardiovascular function stability. In addition, combined lumbar and sacral plexus  
15  
16 block plus sedation could avoid endotracheal intubation and thereby might reduce the  
17  
18 complications related to the general endotracheal anesthesia. A recent small sample  
19  
20 size retrospective study [14] compared the effect of general endotracheal anesthesia,  
21  
22 neuraxial anesthesia and lumbar and sacral plexus block on the prognosis of patients  
23  
24 with hip fracture, and the results showed that neuraxial anesthesia and lumbar and  
25  
26 sacral plexus block anesthesia could reduce the total mortality, and there was no  
27  
28 significant difference between neuraxial anesthesia and lumbar and sacral plexus  
29  
30 block. But the number of elderly and high-ASA-grade patients in the lumbar and  
31  
32 sacral plexus block group was significantly greater than that in the neuraxial  
33  
34 anesthesia group, suggesting that when comparing the effect of these two anesthetic  
35  
36 methods in similar conditions, combined lumbar and sacral plexus block might have  
37  
38 more advantages. However, it is not clear whether ultrasound-guided combined  
39  
40 lumbar and sacral plexus block with sedation can improve outcomes of elderly  
41  
42 patients with hip fracture.  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 This paper describes the design of a prospective, multicenter, parallel,  
53  
54 randomized controlled clinical trial to assess the effect of ultrasound-guided combined  
55  
56  
57  
58  
59  
60



1  
2  
3 lumbar and sacral plexus block plus sedation versus general endotracheal anesthesia  
4  
5  
6 on the postoperative outcome in elderly patients with hip fracture.  
7

## 8 **2. METHODS AND ANALYSIS**

### 9 **2.1. Study design**

10  
11 This will be a two-arm, parallel, multicenter, prospective, randomized controlled  
12  
13 trial and the design of this study protocol has referred to the SPIRIT 2013 guideline <sup>[15,</sup>  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 2.2. Study location

The study will be conducted in five teaching hospitals including Shang Sixth People's Hospital (Shanghai, China), Beijing Chaoyang Hospital (Beijing, China), Beijing Jishuitan Hospital (Beijing, China), First Affiliated Hospital of Wenzhou Medical University (Wenzhou, China), and Foshan Hospital of Traditional Chinese Medicine (Foshan, China).

### 2.3. Study population

Elderly patients scheduled for hip fracture surgery will be recruited voluntarily according to the inclusion and exclusion criteria below. All included patients are suitable for either general endotracheal anesthesia or combined lumbar and sacral plexus block plus sedation, which will not bring tendency to choose a specific type of anesthesia.

#### 2.3.1. Inclusion criteria:

- Age  $\geq 77$  years old;
- First unilateral surgery for hip fracture including femoral neck, intertrochanteric

1  
2  
3  
4 or subtrochanteric fracture;

- 5  
6 ● Patient with planned hip fracture surgery within 24-72 h;
- 7  
8 ● Patient without peripheral nerve block within 24 h prior to surgery;
- 9  
10  
11 ● The ability to receive written informed consent from the patient or patient's legal  
12  
13 representative.

14  
15  
16 **2.3.2. Exclusion criteria:**

- 17  
18 ● Refuse to participate;
- 19  
20 ● Unable to perform nerve block;
- 21  
22 ● Multiple trauma, multiple fractures or other fractures outside the inclusion criteria,  
23  
24 such as pathological fractures, pelvic fractures, femur fractures;
- 25  
26 ● Prosthetic fracture;
- 27  
28 ● Scheduled for bilateral hip fracture surgery;
- 29  
30 ● Usage of bone-cement fixation in the surgery;
- 31  
32 ● With recent cerebral stroke (<3 months);
- 33  
34 ● Combined with active heart disease (unstable angina, acute myocardial infarction,  
35  
36 recent myocardial infarction; decompensated heart failure; symptomatic  
37  
38 arrhythmia; severe mitral or aortic stenotic heart disease);
- 39  
40 ● Patient with known severe lung and/or airway disease, acute respiratory failure,  
41  
42 acute pulmonary infection, and acute attack of bronchial asthma;
- 43  
44 ● Current enrolment in another clinical trial;
- 45  
46 ● Contraindication for general endotracheal anesthesia(drug allergies to general  
47  
48 anesthesia, difficult airway);
- 49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- Contraindication for lumbar and sacral plexus block (infection at the site of needle insertion, coagulopathy, allergy to local anesthetics).

#### 2.4. Interventions

Eligible patients will be randomly assigned into either CLSB group receiving combined lumbar and sacral plexus block plus sedation or GA group receiving general anesthesia with endotracheal intubation (Figure 1). Standard anesthetic and surgical methods will be applied to ensure the consistency of treatment in the participating centers.

#### Figure legend

Fig. 1 CONSORT flowchart designed for subject enrollment (supplementary file)

In the CLSB group (combined lumbar and sacral plexus block with sedative anesthesia), the procedures will be performed as followed.

- Peripheral venous access for fluid infusion will be established;
- In the lateral decubitus position with the operated side uppermost, ultrasound-guided lumbar plexus block (L<sub>2-3</sub> or/and L<sub>3-4</sub> vertebral space level, 0.375% ropivacaine 25ml) will be performed, followed by sacral plexus block (0.375 % ropivacaine 20ml);
- 2.4.3. Radial arterial catheterization under local lidocaine anesthesia and arterial blood pressure monitoring will be performed. Blockade effectiveness will be evaluated 30 minutes after nerve block;
- After confirmation of satisfactory blockade, target-controlled infusion of propofol

will be used to maintain Ramsay sedation score between 5-6 points.  $P_{ET}CO_2$  will be monitored through nasopharyngeal airway. Small-dose sufentanil (1-5 $\mu$ g each time) will be titrated to maintain spontaneous breathing.

- Experienced and qualified anesthesiologist will be designated to perform lumbar and sacral plexus block in order to ensure effective blockade. The intervention will be discontinued for a given patient and convert to general endotracheal anesthesia if the satisfactory blockade is not acquired. Patients will not be included for analysis if the surgical procedure changes during the operation.

In the GA group, the procedures will be performed as followed.

- Peripheral venous access for fluid infusion will be established;
- Radial arterial catheterization under local lidocaine anesthesia and arterial blood pressure monitoring will be conducted;
- Anesthesia will be induced with propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg), and sufentanil(0.2-0.6 $\mu$ g/kg) for tracheal intubation. Mechanical ventilation will be performed to maintain normal  $P_{ET}CO_2$ .
- Sevoflurane, propofol and sufentanil will be used to maintain anesthesia during surgery, while cis-atracurium will be added as needed.

During surgery, fluid infusion and blood transfusion will be used to maintain stable hemodynamics. Perioperative arterial pressure lower than 30% of the baseline will be defined as hypotension, upon which ephedrine or phenylephrine will be administrated. The type and dosage of infusion depends on anesthesiologist's experience. Blood transfusion will be given according to blood loss and Hb level

(80-100g/L)<sup>[17]</sup>. Following surgery, patients will be sent to the postanesthesia care unit (PACU) and then transferred to orthopedic ward or ICU according to the local procedures of each clinical centre. Postoperative analgesia can be administered with regard to the routine clinical practice of each trial site, aiming to maintain a VAS pain score  $\leq 3$ .

To improve adherence to intervention protocols, fixed protocols will be used and relevant staff will be trained.

## **2.5. Endpoints**

### **2.5.1. Primary endpoint**

Postoperative 1-year all-cause mortality (follow-up time points are set as 1 month, 3 months, 6 months and 1 year after surgery);

### **2.5.2. Secondary endpoints**

**2.5.2.1.** Duration of surgery;

**2.5.2.2.** Occurrence of intraoperative complications, including:

- Intraoperative hypotension and vasopressor dosage;
- Intraoperative arrhythmia, myocardial ischemia, myocardial infarction, massive hemorrhage, pulmonary embolism and hypoxemia;
- Intraoperative blood loss and blood transfusion volume;

**2.5.2.3.** High-sensitivity cardiac troponin T (hs-cTnT), measured on 1 day before surgery, 1 and 3 days after surgery;

**2.5.2.4.** MMSE assessed on 1 day before surgery;

**2.5.2.5.** Early mobility after surgery;

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2.5.2.6. Incidence of various complications and CCI during hospitalization after surgery;

2.5.2.7. Postoperative analgesic effectiveness within two days after the surgery;

2.5.2.8. Incidence of delirium on 1, 2 and 3 days after surgery, diagnosed by CAM-CR;

2.5.2.9. SOFA, assessed on 1 day before surgery, 1 and 3 after surgery;

2.5.2.10. Length of stay in ICU and hospital;

### 2.5.3. Other observational variables:

2.5.3.1. Satisfaction with anesthesia care on day 3 after surgery.

2.5.3.2. Economic parameters including total cost in hospital and expenditure for anesthesia;

2.5.3.3. Functional recovery on day 30 after discharge and surgery, evaluated by Barthel Activities of Daily Living Index;

2.5.3.4. Post-discharge destination, and incidence of complications and adverse events.

## 2.6. Participant timeline

For a given participant, assessment will be performed one day prior to surgery and again on the day of surgery to confirm whether qualified for enrollment. Randomization will perform on the day of surgery. And then intervention will be performed. The patients will be followed up 1, 2 and 3 days after surgery and on the day of discharge. Telephone follow-up will be conducted at 1, 3, 6 and 12 months after surgery.

## 2.7. Power and Sample Size Calculation

We estimate the sample size under the assumption of the validity of the proportional-hazards regression model [18, 19]. We take significance level 0.05 and power 0.80. Patients will be randomly assigned to one of the two anesthesia groups in five different centers (hospitals). The total number of patients needed for this study is 868 (with 434 patients in each of the two groups). With that many patients, we can ensure a power of 0.8 with level of significance 0.05 when the mortality rate of 55% for the GA group and a decrease of mortality rate for the GLSB group as low as 15%. In this study, only patients with age 77 years or older will be included, so we expect the actual mortality rate of the GA group will be higher than 55% [14]. When the mortality rate of the GA group is only 45%, the above calculated sample size can still detect a 20% improvement in the CLSB group with the power of at least 0.80. In consideration of the possible lost to follow up, we add an additional 20% to the above calculated sample size. So the total number of patients needed for this study is 1086.

## 2.8. Randomization and blinding

Upon the receipt of informed consents, patients will be randomly assigned to the two groups in any one of the five centers. Sequentially numbered sealed opaque envelopes with group allocation inside altered anesthetist to use CLSB or GA. The R program (other software packages) will be used to generate randomization with a 1:1 allocation stratified by the treatment hospital by variable block algorithm with random blocks of size four, six or eight. The envelopes will be placed in the patient's chart before the start of each procedure by a doctor of the research team. The research staff

1  
2  
3 who will interview patients postoperatively are blinded for the allocated treatment.  
4  
5  
6 The statistician will be blinded. A spreadsheet linking the patient number and name  
7  
8 will be password protected and kept on a research computer. The blind can be lift  
9  
10 upon the patient's request at the end of the follow up. The recruitment will stop when  
11  
12 the total number of patients reaches 1086. The subjects and intervention performers  
13  
14 (anesthesiologists) know the grouping, but the follow-up personnel and statistical  
15  
16 analysts do not know the randomized grouping and intervention.  
17  
18  
19

## 20 **2.9. Data collection and management**

21  
22  
23 Data will be collected in four steps: preoperative, intraoperative and in-hospital  
24  
25 data collection and post-discharge telephone follow-up.  
26  
27

### 28 **2.9.1. Preoperative data:**

29  
30 **2.9.1.1.** Basic information including name, admission number, height, weight, gender,  
31  
32 age, blood pressure, heart rate and ASA grade.  
33  
34

35 **2.9.1.2.** Preoperative information including diagnosis, type of surgery, type and  
36  
37 dosage of anticoagulants, and days passed until surgery.  
38  
39

40 **2.9.1.3.** Preoperative complications and medication related to cardiovascular disease,  
41  
42 stroke, respiratory disease, kidney disease, diabetes, Parkinson's disease, and deep  
43  
44 venous thrombosis of lower extremity if any.  
45  
46

47 **2.9.1.4.** Preoperative examination results including blood gas analysis, ECG,  
48  
49 echocardiography, blood routine testing, liver and kidney function testing, coagulation  
50  
51 testing (D-dimer), Pro-BNP, hs-cTnT, lower extremity vascular ultrasonography.  
52  
53

54 **2.9.1.5.** Preoperative evaluation results including MMSE, CAM-CR, SOFA and  
55  
56



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Barthel Index.

## **2.9.2. Intraoperative data**

**2.9.2.1.** Duration of surgery, incidence of intraoperative hypotension, and vasoactive drug dosage.

**2.9.2.2.** Intraoperative blood loss, blood transfusion volume, and intraoperative fluid infusion volume.

**2.9.2.3.** Intraoperative arrhythmia (sinus bradycardia, sinus tachycardia, ventricular arrhythmia, atrial arrhythmia, etc.), myocardial ischemia, and myocardial infarction,.

**2.9.2.4.** Intraoperative complications: massive hemorrhage, pulmonary embolism, allergic reaction, hypoxemia, bronchospasm, gastric reflux and aspiration.

**2.9.2.5.** Intraoperative conversion of anesthesia and the relevant causes.

## **2.9.3. In-hospital data**

**2.9.3.1.** Postoperative complications including incidence and severity of various complications and the CCI <sup>[20]</sup> value at discharge. Complications were assessed and graded using the Clavien-Dindo classification. CCI will be derived from these features at discharge, using the CCI calculator available online ([www.assessurgery.com](http://www.assessurgery.com)). Complications include:

- Myocardial ischemia, myocardial infarction, heart failure, arrhythmia;
- Pulmonary infection, respiratory failure, pulmonary embolism;
- Postoperative delirium;
- Cerebral ischemia, cerebrovascular accident;
- Renal failure, urinary retention;

- Regurgitation and pulmonary aspiration;
- Postoperative nausea and vomiting (PONV);
- Postoperative bleeding and 24h postoperative drainage volume;
- Reoperation.

**2.9.3.2.** The intensity of postoperative pain at rest and on movement will be assessed with Visual Analogue Scale (VAS) (0 no pain, 10 worst possible pain) at 24 and 48 hours after surgery.

**2.9.3.3.** Earlier mobilization and postoperative hip rehabilitation: the daily degree of maximal hip flexion and abduction will be recorded <sup>[21]</sup>. The day after surgery, all 2 groups will start an identical physical therapy regimen. The patients will perform passive and active hip flexion and abduction exercises twice daily. Patients will be encouraged to get out of bed as soon as possible and try ambulation with a walker. The maximal degree of hip flexion and abduction tolerated by each patient will be recorded for three days. The day of first ambulation will be also recorded for each group.

**2.9.3.4.** SOFA <sup>[22]</sup> will be evaluated on 1 and 3 day after surgery.

**2.9.3.5.** CAM-CR will be evaluated on 1, 2 and 3 day after surgery <sup>[23]</sup>.

**2.9.3.6.** Length of ICU stay, length of hospital stay, total hospitalization cost, and expenditure for anesthesia.

**2.9.3.7.** Satisfaction with anesthesia care will be assessed on postoperative day 3 or the day of discharge (whichever occurs first) via the Bauer Patient Satisfaction Questionnaire <sup>[24]</sup>.

## 2.9.4. Post-discharge follow-up data

2.9.4.1. Telephone follow-up will be performed on 1, 3, 6 and 12 months after surgery to collect the following information.

- Discharge destinations. Disposition status after discharge will be classified as follows: dead, nursing home (e.g., skilled nursing facility, intermediate care facility, extended care facility, nursing home), community dwelling (e.g., home alone, home with others), or other.
- Dead or not, specific cause and time.
- Incidence of complications and adverse events: heart, lungs, brain, liver, kidney, four limbs, hospitalization, etc.

2.9.4.2. Barthel Index for evaluation of functional recovery will be collected on day 30 after surgery.

Preoperative, intraoperative and in-hospital data will be collected from the electronic medical record, monitor machines and relevant manual records by one of the research staff. Telephone follow-up will be conducted by the research team. Data will be securely managed by an independent contract research organization (Shanghai Ruihui Biotech Co., Ltd, Shanghai). Data monitoring will be conducted by an independent third party, who will direct safety oversight and convene a meeting to review adverse events at 25%, 50% and 75% of enrolment or earlier if so needed. Sites will report any related adverse events to the Ethics Committee.

## 2.10. Statistical analysis

Demographics information will be compared for patients of the two groups to

1  
2  
3 ensure the data are balanced. Student t-test will be used for quantitative variables such  
4  
5 as age, delay in surgery and heart rate, blood pressure. Chi-square test will be used for  
6  
7 categorical variables such as Sex, ASA classification grades. The intensity pain VAS  
8  
9 scores will be analyzed using repeated measure ANOVA. The effects of different  
10  
11 covariates on the mortality rates measured at 1month, 3 months, 6 months and 12  
12  
13 months will be assessed using a logistic regression model. Logistic regression or  
14  
15 ordinary multiple regression method will also be used to assess the effects of the  
16  
17 covariate on the secondary and other outcomes as well. The proportional-hazards  
18  
19 regression model will be used to compare the survival times of the patients in the two  
20  
21 groups and to assess the effects of the covariates.  
22  
23  
24  
25  
26

### 27 28 **2.11. Access to data**

29  
30 During the study, data will be stored in a password-protected system and can be  
31  
32 accessed by the research staff who sign the confidential disclosure agreements. Data  
33  
34 without patient identification will be publicly accessible after the study.  
35  
36

### 37 38 **2.12. Confidentiality**

39  
40 Each participant will be given an identification number and referred by the  
41  
42 identification number throughout the study and in all study-related information. Those  
43  
44 information will be securely stored in a password-protected access system provided  
45  
46 by a local supplier. Relevant paper records will be stored in a locked cabinet in an  
47  
48 access-controlled room. All records containing any patients' personal identifiers will  
49  
50 be separately stored similarly as above.  
51  
52  
53

### 54 55 **2.13. Trial status**

1  
2  
3  
4 At the time of manuscript submission, the study is in the preparation phase for  
5  
6 recruitment.  
7

### 8 **3. DISCUSSION**

9

10  
11 Choice of anesthesia for hip fracture surgery in elderly patients is still  
12  
13 inconclusive. General anesthesia with endotracheal intubation is a common procedure  
14  
15 for hip fracture surgery, with advantages of wide indications and maintaining  
16  
17 relatively stable hemodynamics. Compared with general endotracheal anesthesia,  
18  
19 neuraxial anesthesia avoids endotracheal intubation. But vertebral degeneration and  
20  
21 anatomical abnormalities in elderly patients often make neuraxial anesthesia puncture  
22  
23 difficult, and most of these patients are taking anticoagulants, which are the  
24  
25 contraindication of neuraxial anesthesia. So the neuraxial anesthesia has limitations in  
26  
27 application for the elderly patient. The principle for anesthesia selection is to reduce  
28  
29 or avoid the effect of anesthesia on systemic and vital organ functions as much as  
30  
31 possible when meeting the needs of surgery. Previous lumbar and sacral plexus block  
32  
33 depends on blind puncture technique and cannot ensure the clinical effectiveness.  
34  
35 However, ultrasound visualization technology has promoted the wide application of  
36  
37 lumbar and sacral plexus block. Combined lumbar and sacral plexus block with  
38  
39 sedative anesthesia has gradually become alternative approach for hip fracture surgery  
40  
41 in elderly patients, and this anesthetic technique has been massively applied in our  
42  
43 department and achieved satisfactory clinical results in recent years, but there is few  
44  
45 reliable clinical evidence on whether it can be safely used for hip fracture surgery in  
46  
47 elderly patients and improve the short-term or long-term prognosis. Thus, we have  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3  
4 designed this trial protocol to illustrate the clinical value of combined lumbar and  
5  
6 sacral plexus block with sedative anesthesia in elderly patients undergoing hip  
7  
8 fracture surgery. In this study, we will observe the effect of the two anesthetic  
9  
10 methods (general endotracheal anesthesia or combined lumbar and sacral plexus block  
11  
12 plus sedation on the early prognostic indicators in elderly patients with hip fracture,  
13  
14 including postoperative complications, postoperative analgesic effect, postoperative  
15  
16 early mobility, postoperative delirium, patient's satisfaction to anesthesia and length  
17  
18 of stay in ICU and hospital. This study will be the first prospective, multicenter,  
19  
20 randomized controlled clinical trial to investigate the effect of the two anesthesia  
21  
22 techniques on long-term prognostic indicators in elderly patients with hip fracture,  
23  
24 including postoperative 1-year all-cause mortality and incidence of complications and  
25  
26 adverse events. The results of this study will help elucidate whether ultrasound-guided  
27  
28 combined lumbar and sacral plexus block with sedative anesthesia can be safely used  
29  
30 in hip fracture surgery in elderly patients and can reduce the incidence of  
31  
32 perioperative complications and improve long-term prognosis, so as to solve the  
33  
34 troubling clinical problem and provide a theoretical basis for elderly patients  
35  
36 undergoing hip fracture surgery to choose the best anesthetic method.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Abbreviations**

49  
50 ASA: American Society of Anesthesiologists; GA: General anesthesia; CLSB:

51  
52 Combined lumbar plexus and sacral plexus block; PACU: Postanesthesia care unit;

53  
54 ICU: Intensive care unit; CCI : Comprehensive complication index; SOFA: Sequential  
55  
56

organ failure assessment; CAM-CR: The confusion assessment method Chinese reversion; MMSE: Mini-mental state examination; ECG: echocardiography; Pro-BNP: Pro brain natriuretic peptide; hs-cTnT: High-sensitivity cardiac troponin T; PONV: Postoperative nausea and vomiting; VAS: Visual analog scale

**Contributors** JZ and WJ designed the study and wrote the protocol. HZ and XW performed statistical analysis. HZ, XW and ZS were involved in protocol conception and design and manuscript revision. WJ is the principal investigator of this clinical trial. All authors read and approved the final version of the manuscript.

**Acknowledgements** Not applicable.

**Funding** This study is supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103).

**Data sharing statement** No additional data are available.

**Patient consent** Obtained.

**Competing interests** None declared.

## REFERENCES

1. Johnell O, Kanis JA: **An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.** *Osteoporos Int* 2006, **17**(12):1726-1733.
2. Cooper C, Campion G, Melton LJ, 3rd: **Hip fractures in the elderly: a world-wide projection.** *Osteoporos Int* 1992, **2**(6):285-289.
3. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB: **Incidence and**

- 1  
2  
3 **mortality of hip fractures in the United States.** *JAMA* 2009,  
4  
5  
6 **302(14):1573-1579.**  
7
- 8 4. Roche JJ, Wenn RT, Sahota O, Moran CG: **Effect of comorbidities and**  
9  
10 **postoperative complications on mortality after hip fracture in elderly**  
11 **people: prospective observational cohort study.** *BMJ* 2005,  
12  
13 **331(7529):1374.**  
14  
15
- 16 5. Lawrence VA, Hilsenbeck SG, Noveck H, Poses RM, Carson JL: **Medical**  
17  
18 **complications and outcomes after hip fracture repair.** *Arch Intern Med*  
19  
20 2002, **162(18):2053-2057.**  
21  
22
- 23 6. Parker MJ, Handoll HH, Griffiths R: **Anaesthesia for hip fracture surgery in**  
24  
25 **adults.** *Cochrane Database Syst Rev* 2004(4):CD000521.  
26  
27
- 28 7. Memtsoudis SG, Sun X, Chiu YL, Stundner O, Liu SS, Banerjee S, Mazumdar  
29  
30 M, Sharrock NE: **Perioperative comparative effectiveness of anesthetic**  
31  
32 **technique in orthopedic patients.** *Anesthesiology* 2013, **118(5):1046-1058.**  
33  
34
- 35 8. Neuman MD, Silber JH, Elkassabany NM, Ludwig JM, Fleisher LA:  
36  
37 **Comparative effectiveness of regional versus general anesthesia for hip**  
38  
39 **fracture surgery in adults.** *Anesthesiology* 2012, **117(1):72-92.**  
40  
41
- 42 9. Patomo E, Neuman MD, Schneeweiss S, Mogun H, Bateman BT:  
43  
44 **Comparative safety of anesthetic type for hip fracture surgery in adults:**  
45  
46 **retrospective cohort study.** *BMJ* 2014, **348:g4022.**  
47  
48
- 49 10. Neuman MD, Rosenbaum PR, Ludwig JM, Zubizarreta JR, Silber JH:  
50  
51 **Anesthesia technique, mortality, and length of stay after hip fracture**  
52  
53  
54  
55  
56




- surgery. *JAMA* 2014, **311**(24):2508-2517.
11. White SM, Moppett IK, Griffiths R: **Outcome by mode of anaesthesia for hip fracture surgery. An observational audit of 65 535 patients in a national dataset.** *Anaesthesia* 2014, **69**(3):224-230.
12. Gamli M, Sacan O, Baskan S, Ozciftci S, Gogus N: **Combined lumbar plexus and sciatic nerve block for hip fracture surgery in a patient with severe aortic stenosis.** *J Anesth* 2011, **25**(5):784-785.
13. Ho AM, Karmakar MK: **Combined paravertebral lumbar plexus and parasacral sciatic nerve block for reduction of hip fracture in a patient with severe aortic stenosis.** *Canadian Journal of Anesthesia* 2002, **49**(9):946-950.
14. Saffet K, Egemen A, Hayrettin K, Omer U: **Hip Fracture Mortality: Is It Affected by Anesthesia Techniques?** *Anesthesiology Research & Practice* 2012, **2012**(2012):708754.
15. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA *et al*: **SPIRIT 2013 statement: defining standard protocol items for clinical trials.** *Ann Intern Med* 2013, **158**(3):200-207.
16. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR *et al*: **SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.** *BMJ* 2013, **346**:e7586.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
17. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K *et al*: **Liberal or restrictive transfusion in high-risk patients after hip surgery.** *N Engl J Med* 2011, **365**(26):2453-2462.
  18. Cox DR: **Regression Models and Life-Tables.** *Journal of the Royal Statistical Society* 1992, **34**(2):187-220.
  19. Schoenfeld DA: **Sample-size formula for the proportional-hazards regression model.** *Biometrics* 1983, **39**(2):499-503.
  20. Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, Oberkofler CE, Graf R, Puhani MA, Clavien PA: **The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials.** *Ann Surg* 2014, **260**(5):757-762; discussion 762-753.
  21. Singelyn FJ, Ferrant T, Malisse MF, Joris D: **Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty.** *Reg Anesth Pain Med* 2005, **30**(5):452-457.
  22. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL: **Serial evaluation of the SOFA score to predict outcome in critically ill patients.** *JAMA* 2001, **286**(14):1754-1758.
  23. Mu DL, Zhang DZ, Wang DX, Wang G, Li CJ, Meng ZT, Li YW, Liu C, Li

1  
2  
3  
4 XY: **Parecoxib Supplementation to Morphine Analgesia Decreases**  
5  
6 **Incidence of Delirium in Elderly Patients After Hip or Knee Replacement**  
7  
8 **Surgery: A Randomized Controlled Trial.** *Anesth Analg* 2017,  
9  
10  
11 **124(6):1992-2000.**

- 12  
13 24. Bauer M, Bohrer H, Aichele G, Bach A, Martin E: **Measuring patient**  
14 **satisfaction with anaesthesia: perioperative questionnaire versus**  
15 **standardised face-to-face interview.** *Acta Anaesthesiol Scand* 2001,  
16  
17 **45(1):65-72.**  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




87x84mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## CONSORT 2010 Flow Diagram





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 20 ___
	2b	All items from the World Health Organization Trial Registration Data Set	_____
Protocol version	3	Date and version identifier	___ 20 ___
Funding	4	Sources and types of financial, material, and other support	___ 21 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 20 ___
	5b	Name and contact information for the trial sponsor	___ 1 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____

### Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	2-3
	6b	Explanation for choice of comparators	3-4
Objectives	7	Specific objectives or hypotheses	5-6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5-6

### Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6-7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-9
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	9
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	9-10
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	10

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____10-11_____
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____6_____
6				
7				

### 8 **Methods: Assignment of interventions (for controlled trials)**

#### 9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____11-12_____
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____11-12_____
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____11-12_____
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____11-12_____
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____12-15_____
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____12-15_____
39				
40				
41				
42				
43				
44				
45				
46				
47				



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____16_____
-----------------	----	---	--------------

Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_____16_____
---------------------	-----	--	--------------

	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____16_____
--	-----	--	--------------

	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____16_____
--	-----	---	--------------

**Methods: Monitoring**

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____15_____
-----------------	-----	---	--------------

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____15_____
--	-----	---	--------------

Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____
-------	----	---	-------

Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____
----------	----	---	-------

**Ethics and dissemination**

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____19-20_____
--------------------------	----	---	-----------------

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____20_____
---------------------	----	--	--------------



1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____19-20_____
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____16-17_____
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____21_____
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____16_____
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____20_____
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	_____20_____
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____20_____
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40

# BMJ Open

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022898.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Jun-2018
Complete List of Authors:	zhang, junfeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology wang, xiaofeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology zhang, hui; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology shu, zhuolin; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology jiang, wei; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	Hip fracture, Elderly, Lumbar plexus block, Sacral plexus block, General anesthesia

SCHOLARONE™  
Manuscripts

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Junfeng Zhang<sup>#</sup>, Xiaofeng Wang<sup>#</sup>, Hui Zhang, Zhuolin Shu, Wei Jiang\*

Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China

\*Corresponding author: Wei Jiang MD, PhD. Address: 600 Yishan Road, Shanghai 200233, China. Tel: +86 21 64369181 ext. 58328; Fax: +86 21 64369181 ext. 58330.

E-mail: jiangw@sjtu.edu.cn.

<sup>#</sup>These authors contributed equally to this work.

Email address of all authors:

JZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: zhangjunfeng@sjtu.edu.cn

XW: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: 240483680@qq.com

HZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: zhanghui12179@163.com

ZS: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email:5883434@qq.com

WJ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: jiangw@sjtu.edu.cn

## ABSTRACT

**Introduction** Hip fracture in elderly people is a global public health problem, with substantial associated mortality and disability. Nearly all patients with hip fracture undergo surgical treatment, but optimal anesthesia for hip fracture surgery in elderly patients is still inconclusive. Ultrasound-guided combined lumbar and sacral plexus block has been widely used in hip fracture surgery in recent years, especially for some high-risk patients. However, it is not clear whether it can improve the postoperative outcomes of elderly patients with hip fracture.

**Method and analysis** This research project is a two-arm, parallel, multicenter, prospective randomized controlled trial. A total of 1086 patients aged 77 and older scheduled for hip fracture surgery in five clinical trial centers of China will be randomized in a 1:1 ratio to receive either combined lumbar and sacral plexus block plus sedation or general anesthesia. The primary outcome will be the postoperative 1-year all-cause mortality. The secondary outcomes will be the incidence of postoperative complications, high-sensitivity cardiac troponin T, early mobility after surgery, postoperative VAS pain scores, postoperative delirium, length of stay in ICU and hospital, cost-effective outcomes, Barthel Index and incidence of adverse events after discharge. Assessments will be conducted in four steps: preoperative, intraoperative and in-hospital data collection and post-discharge telephone follow-up.

**Ethics and dissemination** This study has been supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103) and approved by the Ethics Committee of Shanghai Sixth

1  
2  
3  
4 People's Hospital [No: 2016-28-(2)]. At the time of manuscript submission, the  
5  
6 protocol version is v1.6 (March 2nd, 2018) with one subsequent approved amendment.  
7  
8 Results will be disseminated via an international peer-reviewed publication.  
9

10  
11 **Trial registration number** NCT03318133.  
12

13  
14 **Key words** Elderly; Hip fracture; Lumbar plexus block; Sacral plexus block; General  
15  
16 anesthesia  
17

### 18 **Strengths and limitations of this study**

- 19  
20  
21 ▶ This study will be the first prospective, multicenter, randomized controlled  
22  
23 clinical trial to investigate the effect of the two anesthesia techniques on  
24  
25 long-term prognostic indicators in elderly patients with hip fracture.  
26  
27  
28 ▶ The results of this study will help elucidate whether CLSB plus sedation could be  
29  
30 safely used in hip fracture surgery and reduce the incidence of perioperative  
31  
32 complications and improve long-term outcome in elderly patients.  
33  
34  
35 ▶ Our study results will be limited to Chinese population, and further studies on  
36  
37 other ethnic backgrounds will be required.  
38  
39

## 40 **1.BACKGROUND**

41  
42 Hip fracture is a global public health problem with an incidence of more than 1.6  
43  
44 million worldwide each year.<sup>1</sup> Owing to the global increase of the population aged 65  
45  
46 years and over, the total number of hip fracture is expected to surpass 6 million by  
47  
48 2050.<sup>2</sup> While early surgery is the most effective treatment method, the postoperative  
49  
50 mortality and disability rates are still high.<sup>3</sup> The elderly patients with hip fracture  
51  
52 frequently have multiple comorbidities, which put these patients at high risk of  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 morbidity and mortality after anesthesia.<sup>4 5</sup> Seeking appropriate anesthesia technique  
4  
5  
6 is in urgent need to ensure that these patients can safely and effectively get through  
7  
8 the perioperative period.  
9

10  
11 Most studies assessing the relationship between anesthesia technique and  
12  
13 outcomes mainly focus on the comparisons between neuraxial anesthesia (including  
14  
15 spinal and epidural anesthesia) and general anesthesia (with an endotracheal tube or a  
16  
17 laryngeal mask airway). A recently updated systematic review and meta-analysis has  
18  
19 found no difference between regional versus general anesthesia, but they also  
20  
21 supposed that the number of participants included in the review was insufficient to  
22  
23 eliminate a difference between the two techniques in the majority of outcomes  
24  
25 studied.<sup>6</sup> Some other investigations have shown that neuraxial anesthesia for hip  
26  
27 fracture can reduce postoperative morbidity,<sup>7 8</sup> but two recent large-sample size  
28  
29 observational studies deemed that neuraxial anesthesia could not significantly  
30  
31 improve the prognosis of patients.<sup>9 10</sup> However, all of the above are retrospective  
32  
33 observational studies, in which anesthesiologists might have selected the anesthesia  
34  
35 technique based on their practice style and a variety of patient-related factors. For  
36  
37 example, patients with coagulation dysfunction would have contraindication to  
38  
39 neuraxial anesthesia and must receive general anesthesia. Neuraxial anesthesia is  
40  
41 thought to be less postoperative complications, so elderly or critically ill patients  
42  
43 might be more likely to receive neuraxial anesthesia,<sup>11</sup> rather than being randomly  
44  
45 assigned to different anesthesia groups. Therefore, there could be selective bias that  
46  
47 affected the clinical significance of those results. In addition to general anesthesia and  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 neuraxial anesthesia, ultrasound-guided lumbar and sacral plexus block has been  
5  
6 widely used in hip fracture surgeries in recent years, especially for some high-risk  
7  
8 patients with cardiopulmonary dysfunction.<sup>12-14</sup> Compared with neuraxial anesthesia,  
9  
10 combined lumbar and sacral plexus block is associated with less sympathetic block  
11  
12 and better cardiovascular function stability. In addition, combined lumbar and sacral  
13  
14 plexus block plus sedation could avoid endotracheal intubation or laryngeal mask  
15  
16 airway(LMA) insertion and thereby might reduce the complications related to the  
17  
18 general anesthesia. A recent small sample size retrospective study compared the effect  
19  
20 of general endotracheal anesthesia, neuraxial anesthesia and lumbar and sacral plexus  
21  
22 block on the prognosis of patients with hip fracture, and the results showed that  
23  
24 neuraxial anesthesia and combined lumbar and sacral plexus block could reduce the  
25  
26 total mortality, and there was no significant difference between neuraxial anesthesia  
27  
28 and combined lumbar and sacral plexus block.<sup>14</sup> But the number of elderly and  
29  
30 high-ASA-grade patients in the combined lumbar and sacral plexus block group was  
31  
32 significantly greater than that in the neuraxial anesthesia group, suggesting that when  
33  
34 comparing the effect of these two anesthetic methods in similar conditions, combined  
35  
36 lumbar and sacral plexus block might have more advantages. However, it is not clear  
37  
38 whether ultrasound-guided combined lumbar and sacral plexus block plus sedation  
39  
40 could improve outcomes of elderly patients with hip fracture.

41  
42 This paper describes the design of a prospective, multicenter, parallel,  
43  
44 randomized controlled clinical trial to assess the effect of ultrasound-guided combined  
45  
46 lumbar and sacral plexus block plus sedation versus general anesthesia on the  
47  
48  
49



1  
2  
3  
4 postoperative outcomes in elderly patients with hip fracture.

## 5 6 **2. METHODS AND ANALYSIS**

### 7 8 **2.1. Patient and public involvement**

9  
10 Patients and public were not involved in the design or conduct of the study.

11  
12 Dissemination of the general results (no personal data) would be made on demand.

### 13 14 15 **2.2. Study design**

16  
17 This will be a two-arm, parallel, multicenter, prospective, randomized controlled  
18  
19 trial and the design of this study protocol has referred to the SPIRIT 2013 guideline.<sup>15</sup>

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **2.3. Study location**

The study will be conducted in five teaching hospitals including Shanghai Sixth  
People's Hospital (Shanghai, China), Beijing Chaoyang Hospital (Beijing, China),  
Beijing Jishuitan Hospital (Beijing, China), First Affiliated Hospital of Wenzhou  
Medical University (Wenzhou, China), and Foshan Hospital of Traditional Chinese  
Medicine (Foshan, China).

### **2.4. Study population**

Although elderly population was considered to be people older than 65 years in  
the present studies, introduction to aging population is latening owing to increasing  
life expectancy. As shown in a recent study, age is the primary risk factor on first year  
mortality in patients older than 75 years old with hip fracture. In addition, China  
wants to increase its citizens' average life expectancy to 77.3 by 2020 and 79 by 2030,  
up from 76.34 in 2015, according to "Plan of Health China 2030" published in 2015.

We thus used 77 years as an age cutoff for inclusion criteria in this study because optimal selection of anesthesia technique in this age group might have more clinical significance.

Elderly patients above 77 years scheduled for hip fracture surgery will be recruited voluntarily according to the inclusion and exclusion criteria. All included patients are suitable for either general anesthesia or combined lumbar and sacral plexus block plus sedation, which will not bring tendency to choose a specific type of anesthesia.

#### **2.4.1. Inclusion criteria:**

- Age  $\geq 77$  years old;
- First unilateral surgery for hip fracture including femoral neck, intertrochanteric or subtrochanteric fracture;
- Patient with planned hip fracture surgery within 24-72 h;
- Patient without peripheral nerve block within 24 h prior to surgery or patients with preoperative peripheral nerve blockade but its effect had faded away at the beginning of the operation.
- The ability to receive written informed consent from the patient or patient's legal representative.

#### **2.4.2. Exclusion criteria:**

- Refuse to participate;
- Unable to perform nerve block;
- Multiple trauma, multiple fractures or other fractures outside the inclusion criteria,

such as pathological fractures, pelvic fractures, femur fractures;

- Prosthetic fracture;
- Scheduled for bilateral hip fracture surgery;
- Usage of bone-cement fixation in the surgery;
- With recent cerebral stroke (<3 months);
- Concomitant active heart disease (unstable angina, acute myocardial infarction, recent myocardial infarction; decompensated heart failure; symptomatic arrhythmia; severe mitral or aortic stenotic heart disease);
- Patient with known severe lung and/or airway disease, acute respiratory failure, acute pulmonary infection, and acute attack of bronchial asthma;
- Current enrolment in another clinical trial;
- Contraindication for general anesthesia (drug allergies to general anesthesia, difficult airway);
- Contraindication for lumbar and sacral plexus block (infection at the site of needle insertion, coagulopathy, allergy to local anesthetics).

## 2.5. Interventions

Eligible patients will be randomly assigned into either CLSB group receiving combined lumbar and sacral plexus block plus sedation or GA group receiving general anesthesia with endotracheal intubation or LMA (Figure 1). Standard anesthetic and surgical methods will be applied to ensure the consistency of treatment in the participating centers. Experienced and qualified anesthesiologists in every clinical centers will be specifically designated to perform combined lumbar-sacral plexus

1  
2  
3  
4 block plus sedative anesthesia or GA in order to minimize the potential bias. To  
5  
6 improve adherence to intervention protocol, study personnel are trained to follow the  
7  
8 study protocol in accordance with the Good Clinical Practice (GCP) principles.  
9

10  
11 In the CLSB group (Combined lumbar-sacral plexus block with sedative  
12  
13 anesthesia), the procedures will be performed as followed.

- 14  
15 ● Peripheral venous access for fluid infusion will be established;
- 16  
17 ● In the lateral decubitus position with the operated side uppermost,  
18  
19 ultrasound-guided lumbar plexus block (L<sub>2-3</sub> or/and L<sub>3-4</sub> vertebral space level,  
20  
21 0.375% ropivacaine 25ml) will be performed, followed by sacral plexus block  
22  
23 (0.375 % ropivacaine 20ml); We used the nerve stimulator to confirm the needle's  
24  
25 correct position by a quadratus femoris twitch for lumbar plexus block and  
26  
27 hamstring, leg, or foot twitches for sacral plexus block at a current within 0.4–0.6  
28  
29 mA, followed by relevant volume of 0.375% ropivacaine that was slowly injected  
30  
31 in 5 ml increments to surround the target nerve under ultrasound monitoring.  
32  
33 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
34  
35 pressure monitoring will be performed. Blockade effectiveness will be evaluated  
36  
37 30 minutes after nerve block; The intervention will be discontinued for a given  
38  
39 patient and convert to general anesthesia with endotracheal intubation or LMA if  
40  
41 the satisfactory blockade is not acquired. These patients are still followed up for  
42  
43 further statistical analysis according to the formal protocol because they have  
44  
45 been randomly allocated.  
46  
47 ● After confirmation of satisfactory blockade, target-controlled infusion of propofol  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 will be used to maintain Ramsay sedation score between 4-5 points.  $P_{ET}CO_2$  will  
4  
5 be monitored through nasopharyngeal airway. Small-dose sufentanil (1-5 $\mu$ g each  
6  
7 time) will be titrated to maintain spontaneous breathing.  
8  
9

10 In the GA group, the procedures will be performed as followed.

- 11 ● Peripheral venous access for fluid infusion will be established;
- 12
- 13 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
14  
15 pressure monitoring will be conducted;
- 16
- 17 ● Anesthesia will be induced with propofol (1.5-3mg/kg),  
18  
19 rocuronium(0.3-0.9mg/kg), and sufentanil (0.2-0.6 $\mu$ g/kg) for tracheal intubation  
20  
21 or LMA insertion. Mechanical ventilation will be performed to maintain normal  
22  
23  $P_{ET}CO_2$ . Sevoflurane, propofol and sufentanil will be used to maintain anesthesia,  
24  
25 while rocuronium will be added as needed.  
26  
27  
28  
29  
30  
31

32 During surgery, fluid infusion and blood transfusion will be used to maintain  
33  
34 stable hemodynamics. Perioperative arterial pressure lower than 30% of the baseline  
35  
36 will be defined as hypotension, upon which ephedrine or phenylephrine will be  
37  
38 administrated. The type and dosage of infusion depends on anesthesiologist's  
39  
40 experience. Blood transfusion will be given according to blood loss and hemoglobin  
41  
42 concentration(Hb) level (80-100g/L).<sup>17</sup> Following surgery, patients will be sent to the  
43  
44 postanesthesia care unit (PACU) and then transferred to orthopedic ward or intensive  
45  
46 care unit(ICU) according to the local procedures of each clinical center. Postoperative  
47  
48 analgesia can be administrated with regard to the routine clinical practice of each trial  
49  
50 site, aiming to maintain a Visual Analogue Scale (VAS) pain score  $\leq 3$ .  
51  
52  
53  
54  
55  
56

## 2.6. Outcomes and measurements

### 2.6.1. Primary outcome

Postoperative 1-year all-cause mortality (follow-up time points are set as 1 month, 3 months, 6 months and 1 year after surgery);

### 2.6.2. Secondary outcomes

#### 2.6.2.1. Occurrence of intraoperative complications, including:

- Intraoperative hypotension and vasopressor dosage;
- Intraoperative arrhythmia, myocardial ischemia, myocardial infarction, massive hemorrhage, pulmonary embolism and hypoxemia;
- Intraoperative blood loss and blood transfusion volume;

2.6.2.2. High-sensitivity cardiac troponin T (hs-cTnT), measured on the 1 and 3 days after surgery;

2.6.2.3. Early mobility after surgery;

2.6.2.4. Incidence of various complications and Comprehensive Complication Index (CCI)<sup>18</sup> during hospitalization after surgery;

2.6.2.5. Postoperative analgesic effectiveness within three days after the surgery;

2.6.2.6. Incidence of delirium on the 1, 2 and 3 days after surgery, diagnosed with Confusion Assessment Method (CAM);<sup>19</sup>

2.6.2.7. Sequential Organ Failure Assessment (SOFA),<sup>20</sup> assessed on the 1 and 3 days after surgery;

2.6.2.8. Length of stay in ICU and hospital;

### 2.6.3. Other observational variables:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**2.6.3.1.** Economic parameters including total cost in hospital and expenditure for anesthesia;

**2.6.3.2.** Functional recovery on the 30 days after surgery, evaluated by Barthel Activities of Daily Living Index (Barthel Index);

**2.6.3.3.** Post-discharge destination, and incidence of complications and adverse events after discharge.

## **2.7. Participant timeline**

For a given participant, assessment will be performed one day prior to surgery and again on the day of surgery to confirm whether qualified for enrollment. Randomization will perform on the day of surgery. And then intervention will be performed. The patients will be followed up on the 1, 2 and 3 days after surgery and on the day of discharge. Telephone follow-up will be conducted at the 1, 3, 6 and 12 months after surgery.

## **2.8. Power and Sample Size Calculation**

We estimate the sample size using the formula by Schoendeld under the assumption of the validity of the proportional-hazards regression model.<sup>21 22</sup> We take significance level 0.05 and power 0.80. Patients will be randomly assigned to one of the two anesthesia groups in five different clinical centers. The total number of patients needed for this study is 868 (with 434 patients in each of the two groups). With these patients, we can ensure a power of 0.8 with level of significance 0.05 when the mortality rate of 55% for the GA group and a decrease of mortality rate for the GLSB group as low as 15%. In this study, only patients with age 77 years or older

1  
2  
3  
4 will be included, so we expect the actual mortality rate of the GA group will be higher  
5  
6 than 55%.<sup>14</sup> When the mortality rate of the GA group is only 45%, the above  
7  
8 calculated sample size can still detect a 20% improvement in the CLSB group with  
9  
10 the power of at least 0.80. In consideration of the possible lost to follow up, we add an  
11  
12 additional 20% to the above calculated sample size. So the total number of patients  
13  
14 needed for this study is 1086.  
15  
16

## 17 **2.9. Randomization and blinding**

18  
19  
20 Upon the receipt of informed consents, the patients will be randomly assigned to  
21  
22 the two groups in any one of the five centers. Sequentially numbered sealed opaque  
23  
24 envelopes with group allocation inside altered anesthesiologist to use CLSB or GA.  
25  
26 The R program will be used to generate randomization block allocation for each of the  
27  
28 five centers with randomly selected block sizes of four, six, and eight. The envelopes  
29  
30 will be placed in the patient's chart before the start of each procedure by a doctor of  
31  
32 the research team. The research staff who will interview patients postoperatively are  
33  
34 blinded for the allocated treatment. The statistician will be blinded. A spreadsheet  
35  
36 linking the patient number and name will be password protected and kept on a  
37  
38 research computer. The recruitment will stop when the total number of patients  
39  
40 reaches 1086. The subjects and intervention performers (anesthesiologists) know the  
41  
42 randomized allocation, but the follow-up personnel and statistician was blinded to the  
43  
44 randomized allocation and intervention.  
45  
46  
47  
48  
49  
50  
51

## 52 **2.10. Data collection and management**

53  
54  
55 Data will be collected in four steps: preoperative, intraoperative and in-hospital  
56  
57



1  
2  
3  
4 data collection and post-discharge telephone follow-up.

5  
6 **2.10.1. Preoperative data:**

7  
8 **2.10.1.1.** Basic information including name, admission number, height, weight, gender,  
9  
10 age, blood pressure, heart rate and ASA grade (American Society of Anesthesiologists  
11  
12 grade).

13  
14  
15 **2.10.1.2.** Preoperative information including diagnosis, type of surgery, type and  
16  
17 dosage of anticoagulants, and days passed until surgery.

18  
19  
20 **2.10.1.3.** Preoperative complications and medication related to cardiovascular disease,  
21  
22 stroke, respiratory disease, kidney disease, diabetes, Parkinson's disease, and deep  
23  
24 venous thrombosis of lower extremity if any.

25  
26  
27 **2.10.1.4.** Preoperative examination results including blood gas analysis, ECG,  
28  
29 echocardiography, blood routine testing, liver and kidney function testing, coagulation  
30  
31 testing (D-dimer), Pro-BNP, hs-cTnT, and lower extremity vascular ultrasonography.

32  
33  
34 **2.10.1.5.** Preoperative evaluation including MMSE (Mini-mental State Examination),  
35  
36 SOFA and Barthel Index, all of which might be associated with the postoperative  
37  
38 complications.

39  
40  
41 **2.10.2. Intraoperative data**

42  
43  
44 **2.10.2.1.** Duration of surgery, incidence of intraoperative hypotension or hypertension,  
45  
46 and vasoactive drug dosage.

47  
48  
49 **2.10.2.2.** Intraoperative blood loss, blood transfusion volume, and intraoperative fluid  
50  
51 infusion volume.

52  
53  
54 **2.10.2.3.** Intraoperative arrhythmia (sinus bradycardia, sinus tachycardia, ventricular  
55  
56

1  
2  
3 arrhythmia, atrial arrhythmia, etc.), myocardial ischemia, and myocardial infarction.

4  
5  
6 **2.10.2.4.** Intraoperative complications: massive hemorrhage, pulmonary embolism,  
7  
8 allergic reaction, hypoxemia, bronchospasm, gastric reflux and aspiration.

9  
10  
11 **2.10.2.5.** Intraoperative conversion of anesthesia and the relevant causes.

### 12 13 **2.10.3. In-hospital data**

14  
15  
16 **2.10.3.1.** High-sensitivity cardiac troponin T(hs-cTnT), measured on the 1 and 3 days  
17  
18 after surgery;

19  
20  
21 **2.10.3.2.** Earlier mobilization and postoperative hip rehabilitation: the daily degree of  
22  
23 maximal hip flexion and abduction will be recorded.<sup>23</sup> The day after surgery, all 2  
24  
25 groups will start an identical physical therapy regimen. The patients will perform  
26  
27 passive and active hip flexion and abduction exercises twice daily. Patients will be  
28  
29 encouraged to get out of bed as soon as possible and try ambulation with a walker.  
30  
31 The maximal degree of hip flexion and abduction tolerated by each patient will be  
32  
33 recorded for three days. The day of first ambulation will be also recorded for each  
34  
35 group.

36  
37  
38 **2.10.3.3.** Postoperative complications including incidence and severity of various  
39  
40 complications and the CCI<sup>18</sup> value at discharge. Complications were assessed and  
41  
42 graded using the Clavien-Dindo classification. CCI will be derived from these  
43  
44 features at discharge, using the CCI calculator available online  
45  
46 (www.assessurgery.com). Complications include:

- 47  
48  
49  
50  
51  
52
  - 53 ● Myocardial ischemia, myocardial infarction, heart failure, arrhythmia;
  - 54 ● Pulmonary infection, respiratory failure, pulmonary embolism;

55  
56  
57

- Postoperative delirium;
- Cerebral ischemia, cerebrovascular accident;
- Renal failure, urinary retention;
- Regurgitation and pulmonary aspiration;
- Postoperative nausea and vomiting (PONV);
- Postoperative bleeding and 24h postoperative drainage volume;
- Reoperation.

**2.10.3.4.** The intensity of postoperative pain at rest and on movement will be assessed with Visual Analogue Scale (VAS) (0 no pain, and 10 worst possible pain) at the 24, 48, and 72 hours after surgery.

**2.10.3.6.** CAM will be evaluated on the 1, 2 and 3 days after surgery.

**2.10.3.7.** SOFA<sup>20</sup> will be evaluated on the 1 and 3 days after surgery.

**2.10.3.8.** Length of ICU stay, length of hospital stay, total hospitalization cost, and expenditure for anesthesia.

#### **2.10.4. Post-discharge follow-up data**

**2.10.4.1.** Telephone follow-up will be performed on the 1, 3, 6 and 12 months after surgery to collect the following information.

- Discharge destinations. Disposition status after discharge will be classified as follows: dead, nursing home (e.g., skilled nursing facility, intermediate care facility, extended care facility, nursing home), community dwelling (e.g., home alone, home with others), or other.
- Dead or not, specific cause and time.

- Incidence of complications and adverse events: heart, lungs, brain, liver, kidney, four limbs, and hospitalization, etc.

**2.10.4.2.** Barthel Index for evaluation of functional recovery will be collected on the 30 days after surgery.

## **2.11. Data and safety monitoring**

Preoperative, intraoperative and in-hospital data will be collected from the electronic medical record, monitor machines and relevant manual records by one of the research staff. Telephone follow-up will be conducted by the research team. Data will be securely managed by an independent contract research organization (Shanghai Ruihui Biotech Co., Ltd, Shanghai). All serious adverse events, as well as all non-serious adverse events that are unexpected and judged to be related to the study treatment, will be recorded in the study database and reported as required to local IRBs and to the Shanghai Jiao Tong University Affiliated Sixth People's Hospital IRB. Data and safety monitoring will be the responsibility of the study director/principle investigator(PI), the study biostatistician, site clinical directors and an independent Data and Safety Monitoring Board(DSMB) selected by the study PI. The DSMB will be composed of 5-7 independent, multidisciplinary experts who are not have subordinate relationships with the PI or any member of the study team. The DSMB will review study implementation and the occurrence of adverse events.

## **2.12. Statistical analysis**

The data will be analyzed using intention-to-treat approach. Demographics information will be compared between the two groups to ensure the data are balanced.

1  
2  
3 Student t-test will be used for quantitative variables such as age, and heart rate, blood  
4  
5  
6 pressure. Chi-square test will be used for categorical variables such as Sex, ASA  
7  
8 classification grades. The VAS pain scores will be analyzed using repeated measure  
9  
10 ANOVA to test the effects of treatment, time, and the interaction effect. The effects of  
11  
12 different covariates on the mortality rates measured at 1 month, 3 months, 6 months  
13  
14 and 12 months will be assessed using a logistic regression model. Either logistic  
15  
16 regression or ordinary multiple regression method will also be used to assess the  
17  
18 effects of the covariate on the secondary and other outcomes as well depending on the  
19  
20 type of dependent variable. The proportional-hazards regression model will be used to  
21  
22 compare the survival time of the patients in the two groups and to assess the effects of  
23  
24 the covariates.  
25  
26  
27  
28  
29

### 30 **2.13. Access to data**

31  
32  
33 During the study, data will be stored in a password-protected system and can be  
34  
35 accessed by the research staff who sign the confidential disclosure agreement. Data  
36  
37 without patient identification will be publicly accessible after the study.  
38  
39

### 40 **2.14. Confidentiality**

41  
42 Each participant will be given an identification number and referred by the  
43  
44 identification number throughout the study and in all study-related information. This  
45  
46 information will be securely stored in a password-protected access system provided  
47  
48 by a local supplier. Relevant paper records will be stored in a locked cabinet in an  
49  
50 access-controlled room. All records containing any patients' personal identifiers will  
51  
52 be separately stored similarly as above.  
53  
54  
55  
56  
57  
58  
59  
60

### 2.15. Trial status

At the time of manuscript submission, the study is in the preparation phase for recruitment. It is planned to be completed by 2021.

## 3. DISCUSSION

Choice of anesthesia for hip fracture surgery in elderly patients is still inconclusive. General anesthesia with endotracheal intubation or LMA is a common procedure for hip fracture surgery, with advantages of wide indications and maintaining relatively stable hemodynamics. Compared with general anesthesia, neuraxial anesthesia avoids endotracheal intubation or LMA insertion. Vertebral degeneration and anatomical abnormalities in elderly patients often make neuraxial anesthesia puncture difficult, and most of these patients are taking anticoagulants, which are the contraindication of neuraxial anesthesia. So the neuraxial anesthesia has limitations in application for the elderly patient. The principle for anesthesia selection is to reduce or avoid the effect of anesthesia on systemic and vital organ functions as much as possible when meeting the needs of surgery. Previous lumbar and sacral plexus block depends on blind puncture technique and cannot ensure the clinical effectiveness. However, ultrasound visualization technology has promoted the wide application of lumbar and sacral plexus block. Combined lumbar and sacral plexus block with sedative anesthesia has gradually become alternative approach for hip fracture surgery in elderly patients, and this anesthetic technique has been extensively applied in our department and achieved satisfactory clinical results in recent years, but there is few reliable clinical evidence on whether it can be safely used for hip fracture

1  
2  
3  
4 surgery in elderly patients and improve the short-term or long-term outcomes. Thus,  
5  
6 we have designed this protocol to illustrate the clinical significance of combined  
7  
8 lumbar and sacral plexus block with sedative anesthesia in elderly patients undergoing  
9  
10 hip fracture surgery. In this study, we will observe the effect of the two anesthetic  
11  
12 methods (general anesthesia or combined lumbar and sacral plexus block plus  
13  
14 sedation on the early prognostic indicators in elderly patients with hip fracture,  
15  
16 including postoperative complications, postoperative analgesic effect, postoperative  
17  
18 early mobility, postoperative delirium, and length of stay in ICU and hospital. This  
19  
20 study will be the first prospective, multicenter, randomized controlled clinical trial to  
21  
22 investigate the effect of the two anesthesia techniques on long-term prognostic  
23  
24 outcomes in elderly patients with hip fracture, including postoperative 1-year  
25  
26 all-cause mortality and incidence of complications and adverse events. The results of  
27  
28 this study will help elucidate whether ultrasound-guided combined lumbar and sacral  
29  
30 plexus block with sedative anesthesia can be safely used in hip fracture surgery in  
31  
32 elderly patients and can reduce the incidence of perioperative complications and  
33  
34 improve long-term prognosis, so as to solve the troubling clinical problem and  
35  
36 provide a theoretical basis for elderly patients undergoing hip fracture surgery to  
37  
38 choose the optimal anesthetic method.  
39  
40  
41  
42  
43  
44  
45  
46

#### 47 **Abbreviations**

48 ASA grade: American Society of Anesthesiologists grade; GA: General anesthesia;

49 CLSB: Combined Lumbar and Sacral Plexus Block; PACU: Postanesthesia Care Unit;

50 Hb: Hemoglobin Concentration; ICU: Intensive Care Unit; CCI: Comprehensive

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Complication Index; SOFA: Sequential Organ Failure Assessment; CAM: The Confusion Assessment method; MMSE: Mini-mental State Examination; ECG: Echocardiography; Pro-BNP: Pro Brain Natriuretic Peptide; hs-cTnT: High-sensitivity cardiac Troponin T; PONV: Postoperative Nausea and Vomiting; VAS: Visual Analog Scale

**Contributors** JZ and WJ designed the study and wrote the protocol. HZ and XW performed statistical analysis. HZ, XW and ZS were involved in protocol conception and design and manuscript revision. WJ is the principal investigator of this clinical trial. All authors read and approved the final version of the manuscript.

**Acknowledgements** Not applicable.

**Funding** This study is supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103).

**Data sharing statement** No additional data are available.

**Patient consent** Obtained.

**Competing interests** None declared.

## REFERENCES

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 2006;17:1726-33.
2. Cooper C, Campion G, Melton LJ, 3rd. Hip fractures in the elderly: a world-wide projection. *Osteoporos Int* 1992;2:285-9.
3. Brauer CA, Coca-Perraillon M, Cutler DM, *et al.* Incidence and mortality of hip fractures in the United States. *JAMA* 2009;302:1573-9.
4. Roche JJ, Wenn RT, Sahota O, *et al.* Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective



- 1  
2  
3 observational cohort study. *BMJ* 2005; 331:1374.  
4  
5 5. Lawrence VA, Hilsenbeck SG, Noveck H, *et al.* Medical complications and  
6 outcomes after hip fracture repair. *Arch Intern Med* 2002;162:2053-7.  
7  
8 6. Guay J, Parker MJ, Gajendragadkar PR, *et al.* Anaesthesia for hip fracture  
9 surgery in adults. *Cochrane Database Syst Rev* 2016;2:CD000521.  
10  
11 7. Memtsoudis SG, Sun X, Chiu YL, *et al.* Perioperative comparative effectiveness  
12 of anesthetic technique in orthopedic patients. *Anesthesiology* 2013;118:1046-58.  
13  
14 8. Neuman MD, Silber JH, Elkassabany NM, *et al.* Comparative effectiveness of  
15 regional versus general anesthesia for hip fracture surgery in adults.  
16 *Anesthesiology* 2012;117:72-92.  
17  
18 9. Patorno E, Neuman MD, Schneeweiss S, *et al.* Comparative safety of anesthetic  
19 type for hip fracture surgery in adults: retrospective cohort study. *BMJ*  
20 2014;348:g4022.  
21  
22 10. Neuman MD, Rosenbaum PR, Ludwig JM, *et al.* Anesthesia technique, mortality,  
23 and length of stay after hip fracture surgery. *JAMA* 2014;311:2508-17.  
24  
25 11. White SM, Moppett IK, Griffiths R. Outcome by mode of anaesthesia for hip  
26 fracture surgery. An observational audit of 65 535 patients in a national dataset.  
27 *Anaesthesia* 2014;69:224-30.  
28  
29 12. Gamli M, Sacan O, Baskan S, *et al.* Combined lumbar plexus and sciatic nerve  
30 block for hip fracture surgery in a patient with severe aortic stenosis. *J Anesth*  
31 2011;25:784-5.  
32  
33 13. Ho AM, Karmakar MK. Combined paravertebral lumbar plexus and parasacral  
34 sciatic nerve block for reduction of hip fracture in a patient with severe aortic  
35 stenosis. *Can J Anesth* 2002; 49:946-50.  
36  
37 14. Karaca S, Ayhan E, Kesmezacar H, *et al.* Hip Fracture Mortality: Is It Affected by  
38 Anesthesia Techniques? *Anesthesiol Res Pract* 2012;2012:708754.  
39  
40 15. Chan AW, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining  
41 standard protocol items for clinical trials. *Ann Internal Med* 2013;158:200-7.  
42  
43 16. Chan AW, Tetzlaff JM, Gotzsche PC, *et al.* SPIRIT 2013 explanation and  
44 elaboration: guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


17. Carson JL, Terrin ML, Noveck H, *et al.* Liberal or restrictive transfusion in high-risk patients after hip surgery. *N Engl J Med* 2011; 365:2453-62.
18. Slankamenac K, Nederlof N, Pessaux P, *et al.* The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials. *Ann Surg* 2014;260:757-62; discussion 762-3.
19. Inouye SK, van Dyck CH, Alessi CA, *et al.* Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med* 1990;113:941-8.
20. Ferreira FL, Bota DP, Bross A, *et al.* Serial evaluation of the SOFA score to predict outcome in critically ill patients. *JAMA* 2001;286:1754-8.
21. Cox DR. Regression Models and Life-Tables. *J R Stat Soc* 1992;34:187-220.
22. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. *Biometrics* 1983;39:499-503.
23. Singelyn FJ, Ferrant T, Malisse MF, *et al.* Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty. *Reg Anesth Pain Med* 2005;30:452-7.

## Figure legend

Fig. 1 CONSORT flowchart designed for subject enrollment

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



100x99mm (300 x 300 DPI)



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	3-6
	2b	Specific objectives or hypotheses	5-6
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6-10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	n/a
Participants	4a	Eligibility criteria for participants	7-8
	4b	Settings and locations where the data were collected	n/a
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	8-11
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	11-12
	6b	Any changes to trial outcomes after the trial commenced, with reasons	n/a
Sample size	7a	How sample size was determined	12-13
	7b	When applicable, explanation of any interim analyses and stopping guidelines	n/a
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	13
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	13
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	13
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	13
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	13

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	n/a
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	17-18
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	n/a
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	n/a
	13b	For each group, losses and exclusions after randomisation, together with reasons	n/a
Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
	14b	Why the trial ended or was stopped	n/a
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	n/a
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	n/a
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	n/a
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	n/a
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	n/a
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	n/a
<b>Discussion</b>			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	n/a
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	n/a
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	n/a
<b>Other information</b>			
Registration	23	Registration number and name of trial registry	2-3
Protocol	24	Where the full trial protocol can be accessed, if available	3
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	21

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

# BMJ Open

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022898.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Sep-2018
Complete List of Authors:	zhang, junfeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology wang, xiaofeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology zhang, hui; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology shu, zhuolin; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology jiang, wei; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	Hip fracture, Elderly, Lumbar plexus block, Sacral plexus block, General anesthesia

SCHOLARONE™  
Manuscripts

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Junfeng Zhang<sup>#</sup>, Xiaofeng Wang<sup>#</sup>, Hui Zhang, Zhuolin Shu, Wei Jiang\*

Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China

\*Corresponding author: Wei Jiang MD, PhD. Address: 600 Yishan Road, Shanghai 200233, China. Tel: +86 21 64369181 ext. 58328; Fax: +86 21 64369181 ext. 58330.

E-mail: [jiangw@sjtu.edu.cn](mailto:jiangw@sjtu.edu.cn).

<sup>#</sup>These authors contributed equally to this work.

Email address of all authors:

JZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: [zhangjunfeng@sjtu.edu.cn](mailto:zhangjunfeng@sjtu.edu.cn)

XW: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: [240483680@qq.com](mailto:240483680@qq.com)

HZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: [zhanghui12179@163.com](mailto:zhanghui12179@163.com)

ZS: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: [5883434@qq.com](mailto:5883434@qq.com)

WJ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: [jiangw@sjtu.edu.cn](mailto:jiangw@sjtu.edu.cn)



## ABSTRACT

**Introduction** Hip fracture in elderly people is a global public health problem, with substantial associated mortality and disability. Nearly all patients with hip fracture undergo surgical treatment, but optimal anesthesia for hip fracture surgery in elderly patients is still inconclusive. Ultrasound-guided combined lumbar and sacral plexus block has been widely used in hip fracture surgery in recent years, especially for some high-risk patients. However, it is not clear whether it can improve the postoperative outcomes of elderly patients with hip fracture.

**Method and analysis** This research project is a two-arm, parallel, multicenter, prospective randomized controlled trial. A total of 1086 patients aged 75 and older scheduled for hip fracture surgery in five clinical trial centers of China will be randomized in a 1:1 ratio to receive either combined lumbar and sacral plexus block plus sedation or general anesthesia. The primary outcome will be the postoperative 1-year all-cause mortality. The secondary outcomes will be the incidence of postoperative complications, high-sensitivity cardiac troponin T, early mobility after surgery, postoperative VAS pain scores, postoperative delirium, length of stay in ICU and hospital, cost-effective outcomes, Barthel Index and incidence of adverse events after discharge. Assessments will be conducted in four steps: preoperative, intraoperative and in-hospital data collection and post-discharge telephone follow-up.

**Ethics and dissemination** This study has been supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103) and approved by the Ethics Committee of Shanghai Sixth

1  
2  
3  
4 People's Hospital [No: 2016-28-(2)]. At the time of manuscript submission, the  
5  
6 protocol version is v1.6 (March 2nd, 2018) with one subsequent approved amendment.  
7  
8 Results will be disseminated via an international peer-reviewed publication.  
9

10  
11 **Trial registration number** NCT03318133.  
12

13 **Key words** Elderly; Hip fracture; Lumbar plexus block; Sacral plexus block; General  
14  
15 anesthesia  
16

### 17 18 **Strengths and limitations of this study** 19

- 20  
21 ▶ This study will be the first prospective, multicenter, randomized controlled  
22  
23 clinical trial to investigate the effect of the two anesthesia techniques on  
24  
25 long-term prognostic indicators in elderly patients with hip fracture.  
26  
27  
28 ▶ The results of this study will help elucidate whether CLSB plus sedation could be  
29  
30 safely used in hip fracture surgery and reduce the incidence of perioperative  
31  
32 complications and improve long-term outcome in elderly patients.  
33  
34  
35 ▶ Our study results will be limited to Chinese population, and further studies on  
36  
37 other ethnic backgrounds will be required.  
38  
39

## 40 41 **1.BACKGROUND** 42

43 Hip fracture is a global public health problem with an incidence of more than 1.6  
44  
45 million worldwide each year <sup>[1]</sup>. Owing to the global increase of the population aged  
46  
47 65 years and over, the total number of hip fracture is expected to surpass 6 million by  
48  
49 2050 <sup>[2]</sup>. While early surgery is the most effective treatment method, the postoperative  
50  
51 mortality and disability rates are still high <sup>[3]</sup>. The elderly patients with hip fracture  
52  
53 frequently have multiple comorbidities, which put these patients at high risk of  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 morbidity and mortality after anesthesia [4, 5]. Seeking appropriate anesthesia  
4  
5  
6 technique is in urgent need to ensure that these patients can safely and effectively get  
7  
8  
9 through the perioperative period.

10  
11 Most studies assessing the relationship between anesthesia technique and  
12  
13 outcomes mainly focus on the comparisons between neuraxial anesthesia (including  
14  
15 spinal and epidural anesthesia) and general anesthesia (with an endotracheal tube or a  
16  
17 laryngeal mask airway). A recently updated systematic review and meta-analysis has  
18  
19 found no difference between regional versus general anesthesia, but they also  
20  
21 supposed that the number of participants included in the review was insufficient to  
22  
23 eliminate a difference between the two techniques in the majority of outcomes  
24  
25 studied[6]. Some other investigations have shown that neuraxial anesthesia for hip  
26  
27 fracture can reduce postoperative morbidity<sup>[7, 8]</sup>, but two recent large-sample size  
28  
29 observational studies deemed that neuraxial anesthesia could not significantly  
30  
31 improve the prognosis of patients<sup>[9, 10]</sup>. However, all of the above are retrospective  
32  
33 observational studies, in which anesthesiologists might have selected the anesthesia  
34  
35 technique based on their practice style and a variety of patient-related factors. For  
36  
37 example, patients with coagulation dysfunction would have contraindication to  
38  
39 neuraxial anesthesia and must receive general anesthesia. Neuraxial anesthesia is  
40  
41 thought to be less postoperative complications, so elderly or critically ill patients  
42  
43 might be more likely to receive neuraxial anesthesia<sup>[11]</sup>, rather than being randomly  
44  
45 assigned to different anesthesia groups. Therefore, there could be selective bias that  
46  
47 affected the clinical significance of those results. In addition to general anesthesia and  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 neuraxial anesthesia, ultrasound-guided lumbar and sacral plexus block has been  
4  
5 widely used in hip fracture surgeries in recent years, especially for some high-risk  
6  
7 patients with cardiopulmonary dysfunction [12-14]. Compared with neuraxial anesthesia,  
8  
9 combined lumbar and sacral plexus block is associated with less sympathetic block  
10  
11 and better cardiovascular function stability. In addition, combined lumbar and sacral  
12  
13 plexus block plus sedation could avoid endotracheal intubation or laryngeal mask  
14  
15 airway(LMA) insertion and thereby might reduce the complications related to the  
16  
17 general anesthesia. A recent small sample size retrospective study [14] compared the  
18  
19 effect of general endotracheal anesthesia, neuraxial anesthesia and lumbar and sacral  
20  
21 plexus block on the prognosis of patients with hip fracture, and the results showed  
22  
23 that neuraxial anesthesia and combined lumbar and sacral plexus block could reduce  
24  
25 the total mortality, and there was no significant difference between neuraxial  
26  
27 anesthesia and combined lumbar and sacral plexus block. But the number of elderly  
28  
29 and high-ASA-grade patients in the combined lumbar and sacral plexus block group  
30  
31 was significantly greater than that in the neuraxial anesthesia group, suggesting that  
32  
33 when comparing the effect of these two anesthetic methods in similar conditions,  
34  
35 combined lumbar and sacral plexus block might have more advantages. However, it is  
36  
37 not clear whether ultrasound-guided combined lumbar and sacral plexus block plus  
38  
39 sedation could improve outcomes of elderly patients with hip fracture.

40  
41 This paper describes the design of a prospective, multicenter, parallel,  
42  
43 randomized controlled clinical trial to assess the effect of ultrasound-guided combined  
44  
45 lumbar and sacral plexus block plus sedation versus general anesthesia on the  
46  
47  
48  
49

1  
2  
3  
4 postoperative outcomes in elderly patients with hip fracture.

## 5 6 **2. METHODS AND ANALYSIS**

### 7 8 **2.1. Patient and public involvement**

9  
10 Patients and public were not involved in the design or conduct of the study. We  
11 do not have any specific plans to disseminate our results to patients.  
12  
13

### 14 15 **2.2. Study design**

16 This will be a two-arm, parallel, multicenter, prospective, randomized controlled  
17 trial and the design of this study protocol has referred to the SPIRIT 2013 guideline [15,  
18  
19  
20  
21  
22  
23 16].

### 24 25 **2.3. Study location**

26 The study will be conducted in five teaching hospitals including Shang Sixth  
27  
28 People's Hospital (Shanghai, China), Beijing Chaoyang Hospital (Beijing, China),  
29  
30  
31 Beijing Jishuitan Hospital (Beijing, China), First Affiliated Hospital of Wenzhou  
32  
33  
34 Medical University (Wenzhou, China), and Foshan Hospital of Traditional Chinese  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

### 2.4. Study population

Although elderly population was considered to be people older than 65 years in the present studies, introduction to aging population is latening owing to increasing life expectancy. As shown in a recent study[17], age is the primary risk factor on first year mortality in patients older than 75 years old with hip fractures. In addition, China wants to increase its citizens' average life expectancy to 77.3 by 2020 and 79 by 2030, up from 76.34 in 2015, according to "Plan of Health China 2030" published in 2015.

We thus used 75 years as an age cutoff for inclusion criteria in this study because optimal selection of anesthesia technique in this age group might have more clinical significance.

Elderly patients above 75 years scheduled for hip fracture surgery will be recruited voluntarily according to the inclusion and exclusion criteria below. All included patients are suitable for either general endotracheal anesthesia or combined lumbar and sacral plexus block plus sedation, which will not bring tendency to choose a specific type of anesthesia.

#### **2.4.1. Inclusion criteria:**

- Age  $\geq 75$  years old;
- First unilateral surgery for hip fracture including femoral neck, intertrochanteric or subtrochanteric fracture;
- Patient with planned hip fracture surgery within 24-72 h;
- Patient without peripheral nerve block within 24 h prior to surgery or patients with preoperative peripheral nerve blockade but its effect had faded away at the beginning of the operation.
- The ability to receive written informed consent from the patient or patient's legal representative.

#### **2.4.2. Exclusion criteria:**

- Refuse to participate;
- Unable to perform nerve block;
- Multiple trauma, multiple fractures or other fractures outside the inclusion criteria,

such as pathological fractures, pelvic fractures, femur fractures;

- Prosthetic fracture;
- Scheduled for bilateral hip fracture surgery;
- Usage of bone-cement fixation in the surgery;
- With recent cerebral stroke (<3 months);
- Concomitant active heart disease (unstable angina, acute myocardial infarction, recent myocardial infarction; decompensated heart failure; symptomatic arrhythmia; severe mitral or aortic stenotic heart disease);
- Patient with known severe lung and/or airway disease, acute respiratory failure, acute pulmonary infection, and acute attack of bronchial asthma;
- Current enrolment in another clinical trial;
- Contraindication for general endotracheal anesthesia (drug allergies to general anesthesia, difficult airway);
- Contraindication for lumbar and sacral plexus block (infection at the site of needle insertion, coagulopathy, allergy to local anesthetics).

## 2.5. Interventions

Eligible patients will be randomly assigned into either CLSB group receiving combined lumbar and sacral plexus block plus sedation or GA group receiving general anesthesia with endotracheal intubation or LMA (Figure 1). Standard anesthetic and surgical methods will be applied to ensure the consistency of treatment in the participating centers. Experienced and qualified anesthesiologists in every clinical centers will be specifically designated to perform combined lumbar-sacral plexus

1  
2  
3  
4 block plus sedative anesthesia or GA in order to minimize the potential bias. To  
5  
6 improve adherence to intervention protocols, study personnel are trained to follow the  
7  
8 study protocol in accordance with the Good Clinical Practice (GCP) principles.  
9

10  
11 In the CLSB group (Combined lumbar-sacral plexus block with sedative  
12  
13 anesthesia), the procedures will be performed as followed.

- 14  
15 ● Peripheral venous access for fluid infusion will be established;
- 16  
17 ● In the lateral decubitus position with the operated side uppermost,  
18  
19 ultrasound-guided lumbar plexus block (L<sub>2-3</sub> or/and L<sub>3-4</sub> vertebral space level,  
20  
21 0.375% ropivacaine 25ml) will be performed, followed by sacral plexus block  
22  
23 (0.375 % ropivacaine 20ml); We used the nerve stimulator to confirm the needle's  
24  
25 correct position by a quadratus femoris twitch for lumbar plexus block and  
26  
27 hamstring, leg, or foot twitches for sacral plexus block at a current within 0.4–0.6  
28  
29 mA, followed by relevant volume of 0.375% ropivacaine that was slowly injected  
30  
31 in 5 ml increments to surround the target nerve under ultrasound monitoring.  
32  
33 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
34  
35 pressure monitoring will be performed. Blockade effectiveness will be evaluated  
36  
37 30 minutes after nerve block; The intervention will be discontinued for a given  
38  
39 patient and convert to general anesthesia with endotracheal intubation or LMA if  
40  
41 the satisfactory blockade is not acquired. These patient are still followed up for  
42  
43 further statistical analysis according to the formal protocol because they have  
44  
45 been randomly allocated.  
46  
47 ● After confirmation of satisfactory blockade, target-controlled infusion of propofol  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 will be used to maintain Ramsay sedation score between 3-4 points.  $P_{ET}CO_2$  will  
5  
6 be monitored through nasopharyngeal airway. Small-dose sufentanil (1-2 $\mu$ g each  
7  
8 time) will be titrated to maintain spontaneous breathing.  
9

10 In the GA group, the procedures will be performed as followed.

- 11 ● Peripheral venous access for fluid infusion will be established;
- 12
- 13 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
14  
15 pressure monitoring will be conducted;
- 16
- 17 ● Anesthesia will be induced with propofol (1.5-3mg/kg),  
18  
19 rocuronium(0.3-0.9mg/kg), and sufentanil (0.2-0.6 $\mu$ g/kg) for tracheal intubation  
20  
21 or LMA insertion. Mechanical ventilation will be performed to maintain normal  
22  
23  $P_{ET}CO_2$ .  
24  
25 ● Sevoflurane, propofol and sufentanil will be used to maintain anesthesia during  
26  
27 surgery, while rocuronium will be added as needed.  
28  
29  
30  
31  
32  
33  
34

35 During surgery, fluid infusion and blood transfusion will be used to maintain  
36  
37 stable hemodynamics. Perioperative arterial pressure lower than 30% of the baseline  
38  
39 will be defined as hypotension, upon which ephedrine or phenylephrine will be  
40  
41 administrated. The type and dosage of infusion depends on anesthesiologist's  
42  
43 experience. Blood transfusion will be given according to blood loss and hemoglobin  
44  
45 concentration(Hb) level (80-100g/L) [18]. Following surgery, patients will be sent to  
46  
47 the postanesthesia care unit (PACU) and then transferred to orthopedic ward or  
48  
49 intensive care unit(ICU) according to the local procedures of each clinical center.  
50  
51 Postoperative analgesia can be administrated with regard to the routine clinical  
52  
53  
54  
55  
56  
57  
58  
59  
60

practice of each trial site, aiming to maintain a Visual Analogue Scale (VAS) pain score  $\leq 3$ .

## 2.6. Outcomes and measurements

### 2.6.1. Primary outcome

Postoperative 1-year all-cause mortality (follow-up time points are set as 1 month, 3 months, 6 months and 1 year after surgery);

### 2.6.2. Secondary outcomes

#### 2.6.2.1. Occurrence of intraoperative complications, including:

- Intraoperative hypotension and vasopressor dosage;
- Intraoperative arrhythmia, myocardial ischemia, myocardial infarction, massive hemorrhage, pulmonary embolism and hypoxemia;
- Intraoperative blood loss and blood transfusion volume;

2.6.2.2. High-sensitivity cardiac troponin T(hs-cTnT), measured on the 1 and 3 days after surgery;

2.6.2.3. Early mobility after surgery;

2.6.2.4. Incidence of various complications and Comprehensive Complication Index (CCI)<sup>[19]</sup> during hospitalization after surgery;

2.6.2.5. Postoperative analgesic effectiveness within three days after the surgery;

2.6.2.6. Incidence of delirium on the 1, 2 and 3 days after surgery, diagnosed with Confusion Assessment Method(CAM)<sup>[20]</sup>;

2.6.2.7. Sequential Organ Failure Assessment(SOFA)<sup>[21]</sup>, assessed on the 1 and 3 days after surgery;

1  
2  
3  
4 **2.6.2.8.** Bauer Patient Satisfaction Questionnaire[22], assessed on the 3 days after surgery;

5  
6 **2.6.2.9.** Length of stay in ICU and hospital;

7  
8 **2.6.3. Other observational variables:**

9  
10  
11 **2.6.3.1.** Economic parameters including total cost in hospital and expenditure for  
12  
13 anesthesia;

14  
15  
16 **2.6.3.2.** Functional recovery on the 30 days after surgery, evaluated by Barthel  
17  
18 Activities of Daily Living Index (Barthel Index);

19  
20 **2.6.3.3.** Post-discharge destination, and incidence of complications and adverse events  
21  
22 after discharge.

23  
24  
25 **2.7. Participant timeline**

26  
27  
28 For a given participant, assessment will be performed one day prior to surgery  
29  
30 and again on the day of surgery to confirm whether qualified for enrollment.  
31  
32 Randomization will perform on the day of surgery. And then intervention will be  
33  
34 performed. The patients will be followed up on the 1, 2 and 3 days after surgery and  
35  
36 on the day of discharge. Telephone follow-up will be conducted at the 1, 3, 6 and 12  
37  
38 months after surgery.  
39  
40  
41

42  
43 **2.8. Power and Sample Size Calculation**

44  
45 We estimate the sample size using the formula by Schoendeld under the  
46  
47 assumption of the validity of the proportional-hazards regression model [23, 24]. We  
48  
49 take significance level 0.05 and power 0.80. Patients will be randomly assigned to one  
50  
51 of the two anesthesia groups in five different clinical centers. The total number of  
52  
53 patients needed for this study is 868 (with 434 patients in each of the two groups).  
54  
55  
56

1  
2  
3  
4 With that many patients, we can ensure a power of 0.8 with level of significance 0.05  
5  
6 when the mortality rate of 55% for the GA group and a decrease of mortality rate for  
7  
8 the GLSB group as low as 15%. In this study, only patients with age 75 years or older  
9  
10 will be included, so we expect the actual mortality rate of the GA group will be higher  
11  
12 than 55% <sup>[14]</sup>. When the mortality rate of the GA group is only 45%, the above  
13  
14 calculated sample size can still detect a 20% improvement in the CLSB group with  
15  
16 the power of at least 0.80. In consideration of the possible lost to follow up, we add an  
17  
18 additional 20% to the above calculated sample size. So the total number of patients  
19  
20 needed for this study is 1086.  
21  
22  
23  
24

## 25 **2.9. Randomization and blinding**

26  
27  
28 Upon the receipt of informed consents, patients will be randomly assigned to the  
29  
30 two groups in any one of the five centers. Sequentially numbered sealed opaque  
31  
32 envelopes with group allocation inside altered anesthetist to use CLSB or GA. The R  
33  
34 program will be used to generate randomization block allocation for each of the five  
35  
36 centers with randomly selected block sizes of four, six, and eight. The envelopes will  
37  
38 be placed in the patient's chart before the start of each procedure by a doctor of the  
39  
40 research team. The research staff who will interview patients postoperatively are  
41  
42 blinded for the allocated treatment. The statistician will be blinded. A spreadsheet  
43  
44 linking the patient number and name will be password protected and kept on a  
45  
46 research computer. The recruitment will stop when the total number of patients  
47  
48 reaches 1086. The subjects and intervention performers (anesthesiologists) know the  
49  
50 randomized allocation, but the follow-up personnel and statistician was blinded to the  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 randomized allocation and intervention.  
4

## 5 6 **2.10. Data collection and management** 7

8 Data will be collected in four steps: preoperative, intraoperative and in-hospital  
9 data collection and post-discharge telephone follow-up.  
10  
11

### 12 13 **2.10.1. Preoperative data:** 14

15 **2.10.1.1.** Basic information including name, admission number, height, weight, gender,  
16 age, blood pressure, heart rate and ASA grade (American Society of Anesthesiologists  
17 grade).  
18  
19

20 **2.10.1.2.** Preoperative information including diagnosis, type of surgery, type and  
21 dosage of anticoagulants, and days passed until surgery.  
22  
23

24 **2.10.1.3.** Preoperative complications and medication related to cardiovascular disease,  
25 stroke, respiratory disease, kidney disease, diabetes, Parkinson's disease, and deep  
26 venous thrombosis of lower extremity if any.  
27  
28

29 **2.10.1.4.** Preoperative examination results including blood gas analysis, ECG,  
30 echocardiography, blood routine testing, liver and kidney function testing, coagulation  
31 testing (D-dimer), Pro-BNP, hs-cTnT, and lower extremity vascular ultrasonography.  
32  
33

34 **2.10.1.5.** Preoperative evaluation results including MMSE (Mini-mental State  
35 Examination), SOFA and Barthel Index, all of which might be associated with the  
36 postoperative complications.  
37  
38

### 39 40 **2.10.2. Intraoperative data** 41

42 **2.10.2.1.** Duration of surgery, incidence of intraoperative hypotension or hypertension,  
43 and vasoactive drug dosage.  
44  
45  
46  
47  
48  
49

1  
2  
3  
4 **2.10.2.2.** Intraoperative blood loss, blood transfusion volume, and intraoperative fluid  
5  
6 infusion volume.

7  
8 **2.10.2.3.** Intraoperative arrhythmia (sinus bradycardia, sinus tachycardia, ventricular  
9  
10 arrhythmia, atrial arrhythmia, etc.), myocardial ischemia, and myocardial infarction.

11  
12 **2.10.2.4.** Intraoperative complications: massive hemorrhage, pulmonary embolism,  
13  
14 allergic reaction, hypoxemia, bronchospasm, gastric reflux and aspiration.

15  
16 **2.10.2.5.** Intraoperative conversion of anesthesia and the relevant causes.

### 17 18 **2.10.3. In-hospital data**

19  
20 **2.10.3.1.** High-sensitivity cardiac troponin T(hs-cTnT), measured on the 1 and 3 days  
21  
22 after surgery;

23  
24 **2.10.3.2.** Earlier mobilization and postoperative hip rehabilitation: the daily degree of  
25  
26 maximal hip flexion and abduction will be recorded <sup>[25]</sup>. The day after surgery, all 2  
27  
28 groups will start an identical physical therapy regimen. The patients will perform  
29  
30 passive and active hip flexion and abduction exercises twice daily. Patients will be  
31  
32 encouraged to get out of bed as soon as possible and try ambulation with a walker.  
33  
34 The maximal degree of hip flexion and abduction tolerated by each patient will be  
35  
36 recorded for three days. The day of first ambulation will be also recorded for each  
37  
38 group.

39  
40 **2.10.3.3.** Postoperative complications including incidence and severity of various  
41  
42 complications and the CCI <sup>[19]</sup> value at discharge. Complications were assessed and  
43  
44 graded using the Clavien-Dindo classification. CCI will be derived from these  
45  
46 features at discharge, using the CCI calculator available online

(www.assessurgery.com). Complications include:

- Myocardial ischemia, myocardial infarction, heart failure, arrhythmia;
- Pulmonary infection, respiratory failure, pulmonary embolism;
- Postoperative delirium;
- Cerebral ischemia, cerebrovascular accident;
- Renal failure, urinary retention;
- Regurgitation and pulmonary aspiration;
- Postoperative nausea and vomiting (PONV);
- Postoperative bleeding and 24h postoperative drainage volume;
- Reoperation.

**2.10.3.4.** The intensity of postoperative pain at rest and on movement will be assessed with Visual Analogue Scale (VAS) (0 no pain, and 10 worst possible pain) at the 24, 48, and 72 hours after surgery.

**2.10.3.6.** CAM will be evaluated on the 1, 2 and 3 days after surgery.

**2.10.3.7.** SOFA<sup>[21]</sup> will be evaluated on the 1 and 3 days after surgery.

**2.10.3.8.** Bauer Patient Satisfaction Questionnaire will be assessed on the 3 days after surgery.

**2.10.3.9.** Length of ICU stay, length of hospital stay, total hospitalization cost, and expenditure for anesthesia.

#### **2.10.4. Post-discharge follow-up data**

**2.10.4.1.** Telephone follow-up will be performed on the 1, 3, 6 and 12 months after surgery to collect the following information.

- Discharge destinations. Disposition status after discharge will be classified as follows: dead, nursing home (e.g., skilled nursing facility, intermediate care facility, extended care facility, nursing home), community dwelling (e.g., home alone, home with others), or other.
- Dead or not, specific cause and time.
- Incidence of complications and adverse events: heart, lungs, brain, liver, kidney, four limbs, and hospitalization, etc.

**2.10.4.2.** Barthel Index for evaluation of functional recovery will be collected on the 30 days after surgery.

## **2.11. Data and safety monitoring**

Preoperative, intraoperative and in-hospital data will be collected from the electronic medical record, monitor machines and relevant manual records by one of the research staff. Telephone follow-up will be conducted by the research team. Data will be securely managed by an independent contract research organization (Shanghai Ruihui Biotech Co., Ltd, Shanghai). All serious adverse events, as well as all non-serious adverse events that are unexpected and judged to be related to the study treatment, will be recorded in the study database and reported as required to local IRBs and to the Shanghai Jiao Tong University Affiliated Sixth People's Hospital IRB. Data and safety monitoring will be the responsibility of the study director/principle investigator(PI), the study biostatistician, site clinical directors and an independent Data and Safety Monitoring Board(DSMB) selected by the study PI. The DSMB will be composed of 5-7 independent, multidisciplinary experts who are not have



subordinate relationships with the PI or any member of the study team. The DSMB will review study implementation and the occurrence of adverse events.

### 2.12. Statistical analysis

The data will be analyzed using intention-to-treat approach. Demographics information will be compared for patients of the two groups to ensure the data are balanced. Student t-test will be used for quantitative variables such as age, and heart rate, blood pressure. Chi-square test will be used for categorical variables such as Sex, ASA classification grades. The VAS pain scores will be analyzed using repeated measure ANOVA to test the effects of treatment, time, and the interaction effect. The effects of different covariates on the mortality rates measured at 1 month, 3 months, 6 months and 12 months will be assessed using a logistic regression model. The primary analysis model will be Cox regression model with covariates. Either logistic regression or ordinary multiple regression method will also be used to assess the effects of the covariate on the secondary and other outcomes as well depending on the type of dependent variable. The proportional-hazards regression model will be used to compare the survival times of the patients in the two groups and to assess the effects of the covariates.

### 2.13. Access to data

During the study, data will be stored in a password-protected system and can be accessed by the research staff who sign the confidential disclosure agreements. Data without patient identification will be publicly accessible after the study.

### 2.14. Confidentiality

1  
2  
3  
4 Each participant will be given an identification number and referred by the  
5  
6 identification number throughout the study and in all study-related information. This  
7  
8 information will be securely stored in a password-protected access system provided  
9  
10 by a local supplier. Relevant paper records will be stored in a locked cabinet in an  
11  
12 access-controlled room. All records containing any patients' personal identifiers will  
13  
14 be separately stored similarly as above.  
15  
16

### 17 18 **2.15. Trial status**

19  
20 At the time of manuscript submission, the study is in the preparation phase for  
21  
22 recruitment.  
23  
24

## 25 26 **3. DISCUSSION**

27  
28 Choice of anesthesia for hip fracture surgery in elderly patients is still  
29  
30 inconclusive. General anesthesia with endotracheal intubation or LMA is a common  
31  
32 procedure for hip fracture surgery, with advantages of wide indications and  
33  
34 maintaining relatively stable hemodynamics. Compared with general anesthesia,  
35  
36 neuraxial anesthesia avoids endotracheal intubation or LMA insertion. But vertebral  
37  
38 degeneration and anatomical abnormalities in elderly patients often make neuraxial  
39  
40 anesthesia puncture difficult, and most of these patients are taking anticoagulants,  
41  
42 which are the contraindication of neuraxial anesthesia. So the neuraxial anesthesia has  
43  
44 limitations in application for the elderly patient. The principle for anesthesia selection  
45  
46 is to reduce or avoid the effect of anesthesia on systemic and vital organ functions as  
47  
48 much as possible when meeting the needs of surgery. Previous lumbar and sacral  
49  
50 plexus block depends on blind puncture technique and cannot ensure the clinical  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 effectiveness. However, ultrasound visualization technology has promoted the wide  
4 application of lumbar and sacral plexus block. Combined lumbar and sacral plexus  
5 block with sedative anesthesia has gradually become alternative approach for hip  
6 fracture surgery in elderly patients, and this anesthetic technique has been massively  
7 applied in our department and achieved satisfactory clinical results in recent years, but  
8 there is few reliable clinical evidence on whether it can be safely used for hip fracture  
9 surgery in elderly patients and improve the short-term or long-term outcomes. Thus,  
10 we have designed this trial protocol to illustrate the clinical value of combined lumbar  
11 and sacral plexus block with sedative anesthesia in elderly patients undergoing hip  
12 fracture surgery. In this study, we will observe the effect of the two anesthetic  
13 methods (general endotracheal anesthesia or combined lumbar and sacral plexus block  
14 plus sedation on the early prognostic indicators in elderly patients with hip fracture,  
15 including postoperative complications, postoperative analgesic effect, postoperative  
16 early mobility, postoperative delirium, patient's satisfaction to anesthesia and length  
17 of stay in ICU and hospital. This study will be the first prospective, multicenter,  
18 randomized controlled clinical trial to investigate the effect of the two anesthesia  
19 techniques on long-term prognostic indicators in elderly patients with hip fracture,  
20 including postoperative 1-year all-cause mortality and incidence of complications and  
21 adverse events. The results of this study will help elucidate whether ultrasound-guided  
22 combined lumbar and sacral plexus block with sedative anesthesia can be safely used  
23 in hip fracture surgery in elderly patients and can reduce the incidence of  
24 perioperative complications and improve long-term prognosis, so as to solve the  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

troubling clinical problem and provide a theoretical basis for elderly patients undergoing hip fracture surgery to choose the optimal anesthetic method.

### Abbreviations

ASA grade: American Society of Anesthesiologists grade; GA: General anesthesia; CLSB: Combined Lumbar and Sacral Plexus Block; PACU: Postanesthesia Care Unit; Hb: Hemoglobin Concentration; ICU: Intensive Care Unit; CCI: Comprehensive Complication Index; SOFA: Sequential Organ Failure Assessment; CAM: The Confusion Assessment method; MMSE: Mini-mental State Examination; ECG: Echocardiography; Pro-BNP: Pro Brain Natriuretic Peptide; hs-cTnT: High-sensitivity cardiac Troponin T; PONV: Postoperative Nausea and Vomiting; VAS: Visual Analog Scale

**Contributors** JZ and WJ designed the study and wrote the protocol. HZ and XW performed statistical analysis. HZ, XW and ZS were involved in protocol conception and design and manuscript revision. WJ is the principal investigator of this clinical trial. All authors read and approved the final version of the manuscript.

**Acknowledgements** Not applicable.

**Funding** This study is supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103).

**Data sharing statement** No additional data are available.

**Patient consent** Obtained.

**Competing interests** None.

### REFERENCES


1. Johnell O, Kanis JA: **An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.** *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 2006, **17**(12):1726-1733.
2. Cooper C, Campion G, Melton LJ, 3rd: **Hip fractures in the elderly: a world-wide projection.** *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 1992, **2**(6):285-289.
3. Brauer CA, Coca-Perrillon M, Cutler DM, Rosen AB: **Incidence and mortality of hip fractures in the United States.** *Jama* 2009, **302**(14):1573-1579.
4. Roche JJ, Wenn RT, Sahota O, Moran CG: **Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study.** *Bmj* 2005, **331**(7529):1374.
5. Lawrence VA, Hilsenbeck SG, Noveck H, Poses RM, Carson JL: **Medical complications and outcomes after hip fracture repair.** *Archives of internal medicine* 2002, **162**(18):2053-2057.
6. Guay J, Parker MJ, Gajendragadkar PR, Kopp S: **Anaesthesia for hip fracture surgery in adults.** *The Cochrane database of systematic reviews* 2016, **2**:Cd000521.
7. Memtsoudis SG, Sun X, Chiu YL, Stundner O, Liu SS, Banerjee S, Mazumdar M, Sharrock NE: **Perioperative comparative effectiveness of anesthetic technique in orthopedic patients.** *Anesthesiology* 2013, **118**(5):1046-1058.
8. Neuman MD, Silber JH, Elkassabany NM, Ludwig JM, Fleisher LA: **Comparative effectiveness of regional versus general anesthesia for hip fracture surgery in adults.** *Anesthesiology* 2012, **117**(1):72-92.
9. Patorno E, Neuman MD, Schneeweiss S, Mogun H, Bateman BT: **Comparative safety of anesthetic type for hip fracture surgery in adults: retrospective cohort study.** *Bmj* 2014, **348**:g4022.
10. Neuman MD, Rosenbaum PR, Ludwig JM, Zubizarreta JR, Silber JH: **Anesthesia technique, mortality, and length of stay after hip fracture surgery.** *Jama* 2014, **311**(24):2508-2517.
11. White SM, Moppett IK, Griffiths R: **Outcome by mode of anaesthesia for hip fracture surgery. An observational audit of 65 535 patients in a national dataset.** *Anaesthesia* 2014, **69**(3):224-230.
12. Gamli M, Sacan O, Baskan S, Ozciftci S, Gogus N: **Combined lumbar plexus and sciatic nerve block for hip fracture surgery in a patient with severe aortic stenosis.** *Journal of anesthesia* 2011, **25**(5):784-785.
13. Ho AM, Karmakar MK: **Combined paravertebral lumbar plexus and parasacral sciatic nerve block for reduction of hip fracture in a patient with severe aortic stenosis.** *Canadian Journal of Anesthesia* 2002, **49**(9):946-950.
14. Saffet K, Egemen A, Hayrettin K, Omer U: **Hip Fracture Mortality: Is It Affected by Anesthesia Techniques?** *Anesthesiology Research & Practice* 2012, **2012**(2012):708754.
15. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA *et al*: **SPIRIT 2013 statement: defining standard protocol items for clinical trials.** *Annals of internal medicine* 2013, **158**(3):200-207.
16. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR *et al*: **SPIRIT 2013 explanation and elaboration: guidance for**

- 1  
2  
3 **protocols of clinical trials.** *Bmj* 2013, **346**:e7586.
- 4 17. Karademir G, Bilgin Y, Ersen A, Polat G, Buget MI, Demirel M, Balci HI: **Hip fractures in**  
5 **patients older than 75 years old: Retrospective analysis for prognostic factors.** *International*  
6 *journal of surgery (London, England)* 2015, **24**(Pt A):101-104.
- 7  
8 18. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K,  
9 Beaupre L, Hildebrand K *et al*: **Liberal or restrictive transfusion in high-risk patients after hip**  
10 **surgery.** *The New England journal of medicine* 2011, **365**(26):2453-2462.
- 11  
12 19. Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, Oberkofler  
13 CE, Graf R, Puhan MA, Clavien PA: **The comprehensive complication index: a novel and more**  
14 **sensitive endpoint for assessing outcome and reducing sample size in randomized**  
15 **controlled trials.** *Annals of surgery* 2014, **260**(5):757-762; discussion 762-753.
- 16  
17 20. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI: **Clarifying confusion: the**  
18 **confusion assessment method. A new method for detection of delirium.** *Annals of internal*  
19 *medicine* 1990, **113**(12):941-948.
- 20  
21 21. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL: **Serial evaluation of the SOFA score to**  
22 **predict outcome in critically ill patients.** *Jama* 2001, **286**(14):1754-1758.
- 23  
24 22. Bauer M, Bohrer H, Aichele G, Bach A, Martin E: **Measuring patient satisfaction with**  
25 **anaesthesia: perioperative questionnaire versus standardised face-to-face interview.** *Acta*  
26 *anaesthesiologica Scandinavica* 2001, **45**(1):65-72.
- 27  
28 23. Cox DR: **Regression Models and Life-Tables.** *Journal of the Royal Statistical Society* 1992,  
29 **34**(2):187-220.
- 30  
31 24. Schoenfeld DA: **Sample-size formula for the proportional-hazards regression model.**  
32 *Biometrics* 1983, **39**(2):499-503.
- 33  
34 25. Singelyn FJ, Ferrant T, Malisse MF, Joris D: **Effects of intravenous patient-controlled analgesia**  
35 **with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block**  
36 **on rehabilitation after unilateral total-hip arthroplasty.** *Regional anesthesia and pain*  
37 *medicine* 2005, **30**(5):452-457.
- 38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11 **Figure legend**  
12

13 Fig. 1 CONSORT flowchart designed for subject enrollment  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



100x99mm (300 x 300 DPI)





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>3</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>n/a</u>
Protocol version	3	Date and version identifier	<u>3</u>
Funding	4	Sources and types of financial, material, and other support	<u>2-3</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>21</u>
	5b	Name and contact information for the trial sponsor	<u>n/a</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>n/a</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>6</u>

1				
2				
3	<b>Introduction</b>			
4				
5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>3-6</u>
6				
7				
8		6b	Explanation for choice of comparators	<u>4-5</u>
9				
10	Objectives	7	Specific objectives or hypotheses	<u>5-6</u>
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>6</u>
13				
14				
15	<b>Methods: Participants, interventions, and outcomes</b>			
16				
17	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>6</u>
18				
19				
20	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>7-8</u>
21				
22				
23	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>8-11</u>
24				
25				
26		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>9</u>
27				
28				
29		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>n/a</u>
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>9-11</u>
33				
34	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>11-12</u>
35				
36				
37				
38				
39	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>10,12,24</u>
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>12-13</u>
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>6-7</u>
6				
7				

## 8 **Methods: Assignment of interventions (for controlled trials)**

### 9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>13-14</u>
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>13-14</u>
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>13-14</u>
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>13-14</u>
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>13-14</u>
28				
29				
30				

## 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>14-18</u>
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>n/a</u>
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>17-18</u>
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>18</u>
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>18</u>
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>n/a</u>
13				
14				
15	<b>Methods: Monitoring</b>			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>17-18</u>
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>n/a</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>17-18</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>n/a</u>
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>2-3</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>2-3</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>18-19</u>
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>n/a</u>
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>18-19</u>
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>21</u>
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>18</u>
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>n/a</u>
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>3</u>
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	<u>n/a</u>
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>n/a</u>
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>n/a</u>
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>n/a</u>
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40

# BMJ Open

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022898.R3
Article Type:	Protocol
Date Submitted by the Author:	24-Nov-2018
Complete List of Authors:	zhang, junfeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology wang, xiaofeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology zhang, hui; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology shu, zhuolin; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology jiang, wei; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	Hip fracture, Elderly, Lumbar plexus block, Sacral plexus block, General anesthesia

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Comparison of combined lumbar and sacral plexus block with sedation versus**  
5  
6 **general anesthesia on postoperative outcomes in elderly patients undergoing hip**  
7 **fracture surgery (CLSB-HIPELD): study protocol for a prospective, multicenter,**  
8  
9 **randomized controlled trial**  
10  
11  
12

13  
14 Junfeng Zhang<sup>#</sup>, Xiaofeng Wang<sup>#</sup>, Hui Zhang, Zhuolin Shu, Wei Jiang\*

15  
16  
17 Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
18  
19 People's Hospital, Shanghai 200233, China  
20

21  
22 \*Corresponding author: Wei Jiang MD, PhD. Address: 600 Yishan Road, Shanghai  
23  
24 200233, China. Tel: +86 21 64369181 ext. 58328; Fax: +86 21 64369181 ext. 58330.  
25

26  
27 E-mail: jiangw@sjtu.edu.cn.  
28

29  
30 <sup>#</sup>These authors contributed equally to this work.  
31

32  
33 Email address of all authors:  
34

35  
36 JZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
37  
38 People's Hospital, Email: zhangjunfeng@sjtu.edu.cn  
39

40  
41 XW: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
42  
43 People's Hospital, Email: 240483680@qq.com  
44

45  
46 HZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
47  
48 People's Hospital, Email: zhanghui12179@163.com  
49

50  
51 ZS: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
52  
53 People's Hospital, Email: 5883434@qq.com  
54

55  
56 WJ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
57  
58 People's Hospital, Email: jiangw@sjtu.edu.cn  
59  
60

## ABSTRACT

**Introduction** Hip fracture in elderly people is a global public health problem, with substantial associated mortality and disability. Nearly all patients with hip fracture undergo surgical treatment, but optimal anesthesia for hip fracture surgery in elderly patients is still inconclusive. Ultrasound-guided combined lumbar and sacral plexus block has been widely used in hip fracture surgery in recent years, especially for some high-risk patients. However, it is not clear whether it can improve the postoperative outcomes of elderly patients with hip fracture.

**Method and analysis** This research project is a two-arm, parallel, multicenter, prospective randomized controlled trial. A total of 1086 patients aged 75 and older scheduled for hip fracture surgery in five clinical trial centers of China will be randomized in a 1:1 ratio to receive either combined lumbar and sacral plexus block plus sedation or general anesthesia. The primary outcome will be the postoperative 1-year all-cause mortality. The secondary outcomes will be the incidence of postoperative complications, high-sensitivity cardiac troponin T, early mobility after surgery, postoperative VAS pain scores, postoperative delirium, length of stay in ICU and hospital, cost-effective outcomes, Barthel Index and incidence of adverse events after discharge. Assessments will be conducted in four steps: preoperative, intraoperative and in-hospital data collection and post-discharge telephone follow-up.

**Ethics and dissemination** This study has been supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103) and approved by the Ethics Committee of Shanghai Sixth



1  
2  
3  
4 People's Hospital [No: 2016-28-(2)]. At the time of manuscript submission, the  
5  
6 protocol version is v1.6 (March 2nd, 2018) with one subsequent approved amendment.  
7  
8  
9 Results will be disseminated via an international peer-reviewed publication.  
10

11  
12 **Trial registration number** NCT03318133.  
13

14 **Key words** Elderly; Hip fracture; Lumbar plexus block; Sacral plexus block; General  
15  
16 anesthesia  
17

### 18 19 **Strengths and limitations of this study** 20

- 21  
22 ▶ This study will be the first prospective, multicenter, randomized controlled clinical  
23  
24 trial to investigate the effect of the two anesthesia techniques on long-term  
25  
26 prognostic indicators in elderly patients with hip fracture.  
27  
28  
29 ▶ The results of this study will help elucidate whether CLSB plus sedation could be  
30  
31 safely used in hip fracture surgery and reduce the incidence of perioperative  
32  
33 complications and improve long-term outcome in elderly patients.  
34  
35  
36 ▶ Our study results will be limited to Chinese population, and further studies on other  
37  
38 ethnic backgrounds will be required.  
39  
40  
41

## 42 43 **1.BACKGROUND** 44

45 Hip fracture is a global public health problem with an incidence of more than 1.6  
46  
47 million worldwide each year [1]. Owing to the global increase of the population aged 65  
48  
49 years and over, the total number of hip fracture is expected to surpass 6 million by 2050  
50  
51 [2]. While early surgery is the most effective treatment method, the postoperative  
52  
53 mortality and disability rates are still high [3]. The elderly patients with hip fracture  
54  
55 frequently have multiple comorbidities, which put these patients at high risk of  
56  
57  
58  
59  
60

1  
2  
3  
4 morbidity and mortality after anesthesia [4,5]. Seeking appropriate anesthesia technique  
5  
6 is in urgent need to ensure that these patients can safely and effectively get through the  
7  
8 perioperative period.  
9

10  
11 Most studies assessing the relationship between anesthesia technique and  
12  
13 outcomes mainly focus on the comparisons between neuraxial anesthesia (including  
14  
15 spinal and epidural anesthesia) and general anesthesia (with an endotracheal tube or a  
16  
17 laryngeal mask airway). A recently updated systematic review and meta-analysis has  
18  
19 found no difference between regional versus general anesthesia, but they also supposed  
20  
21 that the number of participants included in the review was insufficient to eliminate a  
22  
23 difference between the two techniques in the majority of outcomes studied[6]. Some  
24  
25 other investigations have shown that neuraxial anesthesia for hip fracture can reduce  
26  
27 postoperative morbidity[7, 8], but two recent large-sample size observational studies  
28  
29 deemed that neuraxial anesthesia could not significantly improve the prognosis of  
30  
31 patients [9, 10]. However, all of the above are retrospective observational studies, in  
32  
33 which anesthesiologists might have selected the anesthesia technique based on their  
34  
35 practice style and a variety of patient-related factors. For example, patients with  
36  
37 coagulation dysfunction would have contraindication to neuraxial anesthesia and must  
38  
39 receive general anesthesia. Neuraxial anesthesia is thought to be less postoperative  
40  
41 complications, so elderly or critically ill patients might be more likely to receive  
42  
43 neuraxial anesthesia<sup>[11]</sup>, rather than being randomly assigned to different anesthesia  
44  
45 groups. Therefore, there could be selection bias that affected the clinical significance  
46  
47 of those results. In addition to general anesthesia and neuraxial anesthesia, ultrasound-  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 guided lumbar and sacral plexus block has been widely used in hip fracture surgeries  
5  
6 in recent years, especially for some high-risk patients with cardiopulmonary  
7  
8 dysfunction [12-14]. Compared with neuraxial anesthesia, combined lumbar and sacral  
9  
10 plexus block is associated with less sympathetic block and better cardiovascular  
11  
12 function stability. In addition, combined lumbar and sacral plexus block plus sedation  
13  
14 could avoid endotracheal intubation or laryngeal mask airway(LMA) insertion and  
15  
16 thereby might reduce the complications related to the general anesthesia. A recent small  
17  
18 sample size retrospective study [14] compared the effect of general endotracheal  
19  
20 anesthesia, neuraxial anesthesia and lumbar and sacral plexus block on the prognosis  
21  
22 of patients with hip fracture, and the results showed that neuraxial anesthesia and  
23  
24 combined lumbar and sacral plexus block could reduce the total mortality, and there  
25  
26 was no significant difference between neuraxial anesthesia and combined lumbar and  
27  
28 sacral plexus block. But the number of elderly and high-ASA-grade patients in the  
29  
30 combined lumbar and sacral plexus block group was significantly greater than that in  
31  
32 the neuraxial anesthesia group, suggesting that when comparing the effect of these two  
33  
34 anesthetic methods in similar conditions, combined lumbar and sacral plexus block  
35  
36 might have more advantages. However, it is not clear whether ultrasound-guided  
37  
38 combined lumbar and sacral plexus block plus sedation could improve outcomes of  
39  
40 elderly patients with hip fracture.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52  
53 This paper describes the design of a prospective, multicenter, parallel, randomized  
54  
55 controlled clinical trial to assess the effect of ultrasound-guided combined lumbar and  
56  
57 sacral plexus block plus sedation versus general anesthesia on the postoperative  
58  
59  
60

1  
2  
3  
4 outcomes in elderly patients with hip fracture.  
5

## 6 7 **2. METHODS AND ANALYSIS**

### 8 9 **2.1. Patient and public involvement**

10  
11 Patients and public were not involved in the design or conduct of the study. We  
12  
13 do not have any specific plans to disseminate our results to patients.  
14  
15

### 16 17 **2.2. Study design**

18  
19 This will be a two-arm, parallel, multicenter, prospective, randomized controlled  
20  
21 trial and the design of this study protocol has referred to the SPIRIT 2013 guideline [15,  
22  
23  
24  
25 16].

### 26 27 **2.3. Study location**

28  
29 The study will be conducted in five teaching hospitals including Shang Sixth  
30  
31 People's Hospital (Shanghai, China), Beijing Chaoyang Hospital (Beijing, China),  
32  
33 Beijing Jishuitan Hospital (Beijing, China), First Affiliated Hospital of Wenzhou  
34  
35 Medical University (Wenzhou, China), and Foshan Hospital of Traditional Chinese  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
60  
Medicine (Foshan, China).

### 61 62 **2.4. Study population**

63  
64 Although elderly population was considered to be people older than 65 years in  
65  
66 the present studies, introduction to aging population is latening owing to increasing life  
67  
68 expectancy. As shown in a recent study[17], age is the primary risk factor on first year  
69  
70 mortality in patients older than 75 years old with hip fractures. In addition, China  
71  
72 wants to increase its citizens' average life expectancy to 77.3 by 2020 and 79 by 2030,  
73  
74 up from 76.34 in 2015, according to "Plan of Health China 2030" published in 2015.  
75  
76  
77  
78  
79  
80

We thus used 75 years as an age cutoff for inclusion criteria in this study because optimal selection of anesthesia technique in this age group might have more clinical significance.

Elderly patients above 75 years scheduled for hip fracture surgery will be recruited voluntarily according to the inclusion and exclusion criteria below. All included patients are suitable for either general endotracheal anesthesia or combined lumbar and sacral plexus block plus sedation, which will not bring tendency to choose a specific type of anesthesia.

#### **2.4.1. Inclusion criteria:**

- Age  $\geq 75$  years old;
- First unilateral surgery for hip fracture including femoral neck, intertrochanteric or subtrochanteric fracture;
- Patient with planned hip fracture surgery within 24-72 h;
- Patient without peripheral nerve block within 24 h prior to surgery or patients with preoperative peripheral nerve blockade but its effect had faded away at the beginning of the operation.
- The ability to receive written informed consent from the patient or patient's legal representative.

#### **2.4.2. Exclusion criteria:**

- Refuse to participate;
- Unable to perform nerve block;
- Multiple trauma, multiple fractures or other fractures outside the inclusion criteria,

1  
2  
3  
4 such as pathological fractures, pelvic fractures, femur fractures;  
5

- 6 ● Prosthetic fracture;
- 7
- 8
- 9 ● Scheduled for bilateral hip fracture surgery;
- 10
- 11
- 12 ● Usage of bone-cement fixation in the surgery;
- 13
- 14 ● With recent cerebral stroke (<3 months);
- 15
- 16
- 17 ● Concomitant active heart disease (unstable angina, acute myocardial infarction,  
18 recent myocardial infarction; decompensated heart failure; symptomatic  
19 arrhythmia; severe mitral or aortic stenotic heart disease);
- 20
- 21
- 22 ● Patient with known severe lung and/or airway disease, acute respiratory failure,  
23 acute pulmonary infection, and acute attack of bronchial asthma;
- 24
- 25
- 26 ● Current enrolment in another clinical trial;
- 27
- 28
- 29 ● Contraindication for general endotracheal anesthesia (drug allergies to general  
30 anesthesia, difficult airway);
- 31
- 32
- 33 ● Contraindication for lumbar and sacral plexus block (infection at the site of needle  
34 insertion, coagulopathy, allergy to local anesthetics).
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42

## 43 **2.5. Interventions**

44  
45 Eligible patients will be randomly assigned into either CLSB group receiving  
46 combined lumbar and sacral plexus block plus sedation or GA group receiving general  
47 anesthesia with endotracheal intubation or LMA (Figure 1). Standard anesthetic and  
48 surgical methods will be applied to ensure the consistency of treatment in the  
49 participating centers. Experienced and qualified anesthesiologists in every clinical  
50 centers will be specifically designated to perform combined lumbar-sacral plexus block  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 plus sedative anesthesia or GA in order to minimize the potential bias. To improve  
5  
6 adherence to intervention protocols, study personnel are trained to follow the study  
7  
8 protocol in accordance with the Good Clinical Practice (GCP) principles.  
9  
10

11 In the CLSB group (Combined lumbar-sacral plexus block with sedative  
12  
13 anesthesia), the procedures will be performed as followed.  
14  
15

- 16 ● Peripheral venous access for fluid infusion will be established;
- 17 ● In the lateral decubitus position with the operated side uppermost, ultrasound-  
18  
19 guided lumbar plexus block (L<sub>2-3</sub> or/and L<sub>3-4</sub> vertebral space level, 0.375%  
20  
21 ropivacaine 25ml) will be performed, followed by sacral plexus block (0.375 %  
22  
23 ropivacaine 20ml); We used the nerve stimulator to confirm the needle's correct  
24  
25 position by a quadratus femoris twitch for lumbar plexus block and hamstring, leg,  
26  
27 or foot twitches for sacral plexus block at a current within 0.4–0.6 mA, followed  
28  
29 by relevant volume of 0.375% ropivacaine that was slowly injected in 5 ml  
30  
31 increments to surround the target nerve under ultrasound monitoring.  
32  
33 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
34  
35 pressure monitoring will be performed. Blockade effectiveness will be evaluated  
36  
37 30 minutes after nerve block; The intervention will be discontinued for a given  
38  
39 patient and convert to general anesthesia with endotracheal intubation or LMA if  
40  
41 the satisfactory blockade is not acquired. These patient are still followed up for  
42  
43 further statistical analysis according to the formal protocol because they have been  
44  
45 randomly allocated.  
46  
47 ● After confirmation of satisfactory blockade, target-controlled infusion of propofol  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 will be used to maintain Ramsay sedation score between 3-4 points.  $P_{ET}CO_2$  will  
5  
6 be monitored through nasopharyngeal airway. Small-dose sufentanil (1-2 $\mu$ g each  
7  
8 time) will be titrated to maintain spontaneous breathing.  
9

10  
11 In the GA group, the procedures will be performed as followed.  
12

- 13 ● Peripheral venous access for fluid infusion will be established;
- 14 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
15  
16 pressure monitoring will be conducted;
- 17 ● Anesthesia will be induced with propofol (1.5-3mg/kg), rocuronium(0.3-  
18  
19 0.9mg/kg), and sufentanil (0.2-0.6 $\mu$ g/kg) for tracheal intubation or LMA insertion.  
20  
21 Mechanical ventilation will be performed to maintain normal  $P_{ET}CO_2$ .  
22  
23 ● Sevoflurane, propofol and sufentanil will be used to maintain anesthesia during  
24  
25 surgery, while rocuronium will be added as needed.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 During surgery, fluid infusion and blood transfusion will be used to maintain stable  
36  
37 hemodynamics. Perioperative arterial pressure lower than 30% of the baseline will be  
38  
39 defined as hypotension, upon which ephedrine or phenylephrine will be administrated.  
40  
41 The type and dosage of infusion depends on anesthesiologist's experience. Blood  
42  
43 transfusion will be given according to blood loss and hemoglobin concentration(Hb)  
44  
45 level (80-100g/L)<sup>[18]</sup>. Following surgery, patients will be sent to the postanesthesia care  
46  
47 unit (PACU) and then transferred to orthopedic ward or intensive care unit(ICU)  
48  
49 according to the local procedures of each clinical center. Postoperative analgesia can  
50  
51 be administrated with regard to the routine clinical practice of each trial site, aiming to  
52  
53 maintain a Visual Analogue Scale (VAS) pain score  $\leq 3$ .  
54  
55  
56  
57  
58  
59  
60



## 2.6. Outcomes and measurements

### 2.6.1. Primary outcome

Postoperative 1-year all-cause mortality (follow-up time points are set as 1 month, 3 months, 6 months and 1 year after surgery);

### 2.6.2. Secondary outcomes

#### 2.6.2.1. Occurrence of intraoperative complications, including:

- Intraoperative hypotension and vasopressor dosage;
- Intraoperative arrhythmia, myocardial ischemia, myocardial infarction, massive hemorrhage, pulmonary embolism and hypoxemia;
- Intraoperative blood loss and blood transfusion volume;

2.6.2.2. High-sensitivity cardiac troponin T(hs-cTnT), measured on the 1 and 3 days after surgery;

2.6.2.3. Early mobility after surgery;

2.6.2.4. Incidence of various complications and Comprehensive Complication Index (CCI) <sup>[19]</sup> during hospitalization after surgery;

2.6.2.5. Postoperative analgesic effectiveness within three days after the surgery;

2.6.2.6. Incidence of delirium on the 1, 2 and 3 days after surgery, diagnosed with Confusion Assessment Method(CAM)<sup>[20]</sup>;

2.6.2.7. Sequential Organ Failure Assessment(SOFA) <sup>[21]</sup>, assessed on the 1 and 3 days after surgery;

2.6.2.8. Bauer Patient Satisfaction Questionnaire<sup>[22]</sup>, assessed on the 3 days after surgery;

2.6.2.9. Length of stay in ICU and hospital;

### **2.6.3. Other observational variables:**

**2.6.3.1.** Economic parameters including total cost in hospital and expenditure for anesthesia;

**2.6.3.2.** Functional recovery on the 30 days after surgery, evaluated by Barthel Activities of Daily Living Index (Barthel Index);

**2.6.3.3.** Post-discharge destination, and incidence of complications and adverse events after discharge.

### **2.7. Participant timeline**

For a given participant, assessment will be performed one day prior to surgery and again on the day of surgery to confirm whether qualified for enrollment. Randomization will perform on the day of surgery. And then intervention will be performed. There will be an initial accrual period of about 1.5 year. The patients will be followed up on the 1, 2 and 3 days after surgery and on the day of discharge. The total follow-up period will be set as 1 year and the telephone follow-up will be conducted at the 1, 3, 6 and 12 months after surgery.

### **2.8. Power and Sample Size Calculation**

We estimate the sample size using the formula by Schoendeld under the assumption of the validity of the proportional-hazards regression model [23, 24]. We take significance level 0.05 and power 0.80. Patients will be randomly assigned to one of the two anesthesia groups in five different clinical centers. The total number of patients needed for this study is 868 (with 434 patients in each of the two groups). With that many patients, we can ensure a power of 0.8 with level of significance 0.05 when the

1  
2  
3  
4 mortality rate of 55% for the GA group and a relative decrease of mortality rate for the  
5  
6 GLSB group as low as 15%. In this study, only patients with age 75 years or older will  
7  
8 be included, so we expect the actual mortality rate of the GA group will be higher than  
9  
10 55% [14]. When the mortality rate of the GA group is only 45%, the above calculated  
11  
12 sample size can still detect a 20% improvement in the CLSB group with the power of  
13  
14 at least 0.80. In consideration of the possible lost to follow up, we add an additional  
15  
16 20% to the above calculated sample size. So the total number of patients needed for this  
17  
18 study is 1086.  
19  
20  
21  
22  
23

## 2.9. Randomization and blinding

24  
25  
26  
27 Upon the receipt of informed consents, patients will be randomly assigned to the  
28  
29 two groups in any one of the five centers. Sequentially numbered sealed opaque  
30  
31 envelopes with group allocation inside altered anesthetist to use CLSB or GA. The R  
32  
33 program will be used to generate randomization block allocation for each of the five  
34  
35 centers with randomly selected block sizes of four, six, and eight. The envelopes will  
36  
37 be placed in the patient's chart before the start of each procedure by a doctor of the  
38  
39 research team. The research staff who will interview patients postoperatively are  
40  
41 blinded for the allocated treatment. The statistician will be blinded. A spreadsheet  
42  
43 linking the patient number and name will be password protected and kept on a research  
44  
45 computer. The recruitment will stop when the total number of patients reaches 1086.  
46  
47  
48 The subjects and intervention performers (anesthesiologists) know the randomized  
49  
50 allocation, but the follow-up personnel and statistician was blinded to the randomized  
51  
52 allocation and intervention.  
53  
54  
55  
56  
57  
58  
59  
60

## 2.10. Data collection and management

Data will be collected in four steps: preoperative, intraoperative and in-hospital data collection and post-discharge telephone follow-up.

### 2.10.1. Preoperative data:

**2.10.1.1.** Basic information including name, admission number, height, weight, gender, age, blood pressure, heart rate and ASA grade (American Society of Anesthesiologists grade).

**2.10.1.2.** Preoperative information including diagnosis, type of surgery, type and dosage of anticoagulants, and days passed until surgery.

**2.10.1.3.** Preoperative complications and medication related to cardiovascular disease, stroke, respiratory disease, kidney disease, diabetes, Parkinson's disease, and deep venous thrombosis of lower extremity if any.

**2.10.1.4.** Preoperative examination results including blood gas analysis, ECG, echocardiography, blood routine testing, liver and kidney function testing, coagulation testing (D-dimer), Pro-BNP, hs-cTnT, and lower extremity vascular ultrasonography.

**2.10.1.5.** Preoperative evaluation results including MMSE (Mini-mental State Examination), SOFA and Barthel Index, all of which might be associated with the postoperative complications.

### 2.10.2. Intraoperative data

**2.10.2.1.** Duration of surgery, incidence of intraoperative hypotension or hypertension, and vasoactive drug dosage.

**2.10.2.2.** Intraoperative blood loss, blood transfusion volume, and intraoperative fluid

1  
2  
3  
4 infusion volume.

5  
6 **2.10.2.3.** Intraoperative arrhythmia (sinus bradycardia, sinus tachycardia, ventricular  
7  
8 arrhythmia, atrial arrhythmia, etc.), myocardial ischemia, and myocardial infarction.

9  
10  
11 **2.10.2.4.** Intraoperative complications: massive hemorrhage, pulmonary embolism,  
12  
13 allergic reaction, hypoxemia, bronchospasm, gastric reflux and aspiration.

14  
15  
16 **2.10.2.5.** Intraoperative conversion of anesthesia and the relevant causes.

### 17 18 19 **2.10.3. In-hospital data**

20  
21  
22 **2.10.3.1.** High-sensitivity cardiac troponin T (hs-cTnT), measured on the 1 and 3 days  
23  
24 after surgery;

25  
26  
27 **2.10.3.2.** Earlier mobilization and postoperative hip rehabilitation: the daily degree of  
28  
29 maximal hip flexion and abduction will be recorded [25]. The day after surgery, all 2  
30  
31 groups will start an identical physical therapy regimen. The patients will perform  
32  
33 passive and active hip flexion and abduction exercises twice daily. Patients will be  
34  
35 encouraged to get out of bed as soon as possible and try ambulation with a walker. The  
36  
37 maximal degree of hip flexion and abduction tolerated by each patient will be recorded  
38  
39 for three days. The day of first ambulation will be also recorded for each group.

40  
41  
42 **2.10.3.3.** Postoperative complications including incidence and severity of various  
43  
44 complications and the CCI [19] value at discharge. Complications were assessed and  
45  
46 graded using the Clavien-Dindo classification. CCI will be derived from these features  
47  
48 at discharge, using the CCI calculator available online ([www.assessurgery.com](http://www.assessurgery.com)).  
49  
50

51  
52  
53  
54  
55  
56 Complications include:

- 57  
58 ● Myocardial ischemia, myocardial infarction, heart failure, arrhythmia;
- 59  
60

- Pulmonary infection, respiratory failure, pulmonary embolism;
- Postoperative delirium;
- Cerebral ischemia, cerebrovascular accident;
- Renal failure, urinary retention;
- Regurgitation and pulmonary aspiration;
- Postoperative nausea and vomiting (PONV);
- Postoperative bleeding and 24h postoperative drainage volume;
- Reoperation.

**2.10.3.4.** The intensity of postoperative pain at rest and on movement will be assessed with Visual Analogue Scale (VAS) (0 no pain, and 10 worst possible pain) at the 24, 48, and 72 hours after surgery.

**2.10.3.6.** CAM will be evaluated on the 1, 2 and 3 days after surgery.

**2.10.3.7.** SOFA <sup>[21]</sup> will be evaluated on the 1 and 3 days after surgery.

**2.10.3.8.** Bauer Patient Satisfaction Questionnaire will be assessed on the 3 days after surgery.

**2.10.3.9.** Length of ICU stay, length of hospital stay, total hospitalization cost, and expenditure for anesthesia.

#### **2.10.4. Post-discharge follow-up data**

**2.10.4.1.** Telephone follow-up will be performed on the 1, 3, 6 and 12 months after surgery to collect the following information.

- Discharge destinations. Disposition status after discharge will be classified as follows: dead, nursing home (e.g., skilled nursing facility, intermediate care facility, extended care facility, nursing home), community dwelling (e.g., home alone,

home with others), or other.

- Dead or not, specific cause and time.
- Incidence of complications and adverse events: heart, lungs, brain, liver, kidney, four limbs, and hospitalization, etc.

**2.10.4.2.** Barthel Index for evaluation of functional recovery will be collected on the 30 days after surgery.

## **2.11. Data and safety monitoring**

Preoperative, intraoperative and in-hospital data will be collected from the electronic medical record, monitor machines and relevant manual records by one of the research staff. Telephone follow-up will be conducted by the research team. Data will be securely managed by an independent contract research organization (Shanghai Ruihui Biotech Co., Ltd, Shanghai). All serious adverse events, as well as all non-serious adverse events that are unexpected and judged to be related to the study treatment, will be recorded in the study database and reported as required to local IRBs and to the Shanghai Jiao Tong University Affiliated Sixth People's Hospital IRB. Data and safety monitoring will be the responsibility of the study director/principle investigator(PI), the study biostatistician, site clinical directors and an independent Data and Safety Monitoring Board(DSMB) selected by the study PI. The DSMB will be composed of 5-7 independent, multidisciplinary experts who are not have subordinate relationships with the PI or any member of the study team. The DSMB will review study implementation and the occurrence of adverse events.

## **2.12. Statistical analysis**

1  
2  
3  
4 The data will be analyzed using intention-to-treat approach. Demographics  
5  
6 information will be compared for patients of the two groups to ensure the data are  
7  
8 balanced. Student t-test will be used for quantitative variables such as age, and heart  
9  
10 rate, blood pressure. Chi-square test will be used for categorical variables such as Sex,  
11  
12 ASA classification grades. The VAS pain scores will be analyzed using repeated  
13  
14 measure ANOVA to test the effects of treatment, time, and the interaction effect. The  
15  
16 effects of different covariates on the mortality rates measured at 1 month, 3 months, 6  
17  
18 months and 12 months will be assessed using a logistic regression model. The primary  
19  
20 analysis model will be Cox regression model with covariates. Either logistic regression  
21  
22 or ordinary multiple regression method will also be used to assess the effects of the  
23  
24 covariate on the secondary and other outcomes as well depending on the type of  
25  
26 dependent variable. The proportional-hazards regression model will be used to compare  
27  
28 the survival times of the patients in the two groups and to assess the effects of the  
29  
30 covariates. Statistical significance will be defined for P value<0.05 (two tailed).  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **2.13. Access to data**

41  
42  
43 During the study, data will be stored in a password-protected system and can be  
44  
45 accessed by the research staff who sign the confidential disclosure agreements. Data  
46  
47 without patient identification will be publicly accessible after the study.  
48  
49

### 50 **2.14. Confidentiality**

51  
52  
53 Each participant will be given an identification number and referred by the  
54  
55 identification number throughout the study and in all study-related information. This  
56  
57 information will be securely stored in a password-protected access system provided by  
58  
59  
60



1  
2  
3  
4 a local supplier. Relevant paper records will be stored in a locked cabinet in an access-  
5  
6 controlled room. All records containing any patients' personal identifiers will be  
7  
8 separately stored similarly as above.  
9  
10

### 11 **2.15. Trial status**

12  
13  
14 At the time of manuscript submission, the study is in the preparation phase for  
15  
16 recruitment.  
17  
18

## 19 **3. DISCUSSION**

20  
21  
22 Choice of anesthesia for hip fracture surgery in elderly patients is still inconclusive.  
23  
24 General anesthesia with endotracheal intubation or LMA is a common procedure for  
25  
26 hip fracture surgery, with advantages of wide indications and maintaining relatively  
27  
28 stable hemodynamics. Compared with general anesthesia, neuraxial anesthesia avoids  
29  
30 endotracheal intubation or LMA insertion. But vertebral degeneration and anatomical  
31  
32 abnormalities in elderly patients often make neuraxial anesthesia puncture difficult, and  
33  
34 most of these patients are taking anticoagulants, which are the contraindication of  
35  
36 neuraxial anesthesia. So the neuraxial anesthesia has limitations in application for the  
37  
38 elderly patient. The principle for anesthesia selection is to reduce or avoid the effect of  
39  
40 anesthesia on systemic and vital organ functions as much as possible when meeting the  
41  
42 needs of surgery. Previous lumbar and sacral plexus block depends on blind puncture  
43  
44 technique and cannot ensure the clinical effectiveness. However, ultrasound  
45  
46 visualization technology has promoted the wide application of lumbar and sacral plexus  
47  
48 block. Combined lumbar and sacral plexus block with sedative anesthesia has gradually  
49  
50 become alternative approach for hip fracture surgery in elderly patients, and this  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 anesthetic technique has been massively applied in our department and achieved  
5  
6 satisfactory clinical results in recent years, but there is few reliable clinical evidence on  
7  
8 whether it can be safely used for hip fracture surgery in elderly patients and improve  
9  
10 the short-term or long-term outcomes. Thus, we have designed this trial protocol to  
11  
12 illustrate the clinical value of combined lumbar and sacral plexus block with sedative  
13  
14 anesthesia in elderly patients undergoing hip fracture surgery. In this study, we will  
15  
16 observe the effect of the two anesthetic methods (general endotracheal anesthesia or  
17  
18 combined lumbar and sacral plexus block plus sedation on the early prognostic  
19  
20 indicators in elderly patients with hip fracture, including postoperative complications,  
21  
22 postoperative analgesic effect, postoperative early mobility, postoperative delirium,  
23  
24 patient's satisfaction to anesthesia and length of stay in ICU and hospital. This study  
25  
26 will be the first prospective, multicenter, randomized controlled clinical trial to  
27  
28 investigate the effect of the two anesthesia techniques on long-term prognostic  
29  
30 indicators in elderly patients with hip fracture, including postoperative 1-year all-cause  
31  
32 mortality and incidence of complications and adverse events. The results of this study  
33  
34 will help elucidate whether ultrasound-guided combined lumbar and sacral plexus  
35  
36 block with sedative anesthesia can be safely used in hip fracture surgery in elderly  
37  
38 patients and can reduce the incidence of perioperative complications and improve long-  
39  
40 term prognosis, so as to solve the troubling clinical problem and provide a theoretical  
41  
42 basis for elderly patients undergoing hip fracture surgery to choose the optimal  
43  
44 anesthetic method.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

## 57 **Abbreviations**

1  
2  
3  
4 ASA grade: American Society of Anesthesiologists grade; GA: General anesthesia;  
5  
6 CLSB: Combined Lumbar and Sacral Plexus Block; PACU: Postanesthesia Care Unit;  
7  
8  
9 Hb: Hemoglobin Concentration; ICU: Intensive Care Unit; CCI: Comprehensive  
10  
11 Complication Index; SOFA: Sequential Organ Failure Assessment; CAM: The  
12  
13 Confusion Assessment method; MMSE: Mini-mental State Examination; ECG:  
14  
15 Echocardiography; Pro-BNP: Pro Brain Natriuretic Peptide; hs-cTnT: High-  
16  
17 sensitivity cardiac Troponin T; PONV: Postoperative Nausea and Vomiting; VAS:  
18  
19 Visual Analog Scale  
20  
21  
22  
23

24 **Contributors** JZ and WJ designed the study and wrote the protocol. HZ and XW  
25  
26 performed statistical analysis. HZ, XW and ZS were involved in protocol conception  
27  
28 and design and manuscript revision. WJ is the principal investigator of this clinical trial.  
29  
30 All authors read and approved the final version of the manuscript.  
31  
32  
33

34  
35 **Acknowledgements** Not applicable.  
36

37  
38 **Funding** This study is supported by Shanghai Municipal Commission of Health and  
39  
40 Family Planning Foundation for Key Developing Disciplines (2015ZB0103).  
41

42  
43 **Data sharing statement** No additional data are available.  
44

45  
46 **Patient consent** Obtained.  
47

48  
49 **Competing interests** None declared.  
50

## 51 REFERENCES

- 52  
53 1. Johnell O, Kanis JA: **An estimate of the worldwide prevalence and disability associated with**  
54 **osteoporotic fractures.** *Osteoporosis international : a journal established as result of*  
55 *cooperation between the European Foundation for Osteoporosis and the National*  
56 *Osteoporosis Foundation of the USA* 2006, **17**(12):1726-1733.  
57  
58 2. Cooper C, Campion G, Melton LJ, 3rd: **Hip fractures in the elderly: a world-wide projection.**  
59 *Osteoporosis international : a journal established as result of cooperation between the*  
60


- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 1992, **2**(6):285-289.
3. Brauer CA, Coca-Perrillon M, Cutler DM, Rosen AB: **Incidence and mortality of hip fractures in the United States.** *Jama* 2009, **302**(14):1573-1579.
  4. Roche JJ, Wenn RT, Sahota O, Moran CG: **Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study.** *Bmj* 2005, **331**(7529):1374.
  5. Lawrence VA, Hilsenbeck SG, Noveck H, Poses RM, Carson JL: **Medical complications and outcomes after hip fracture repair.** *Archives of internal medicine* 2002, **162**(18):2053-2057.
  6. Guay J, Parker MJ, Gajendragadkar PR, Kopp S: **Anaesthesia for hip fracture surgery in adults.** *The Cochrane database of systematic reviews* 2016, **2**:Cd000521.
  7. Memtsoudis SG, Sun X, Chiu YL, Stundner O, Liu SS, Banerjee S, Mazumdar M, Sharrock NE: **Perioperative comparative effectiveness of anesthetic technique in orthopedic patients.** *Anesthesiology* 2013, **118**(5):1046-1058.
  8. Neuman MD, Silber JH, Elkassabany NM, Ludwig JM, Fleisher LA: **Comparative effectiveness of regional versus general anesthesia for hip fracture surgery in adults.** *Anesthesiology* 2012, **117**(1):72-92.
  9. Patorno E, Neuman MD, Schneeweiss S, Mogun H, Bateman BT: **Comparative safety of anesthetic type for hip fracture surgery in adults: retrospective cohort study.** *Bmj* 2014, **348**:g4022.
  10. Neuman MD, Rosenbaum PR, Ludwig JM, Zubizarreta JR, Silber JH: **Anesthesia technique, mortality, and length of stay after hip fracture surgery.** *Jama* 2014, **311**(24):2508-2517.
  11. White SM, Moppett IK, Griffiths R: **Outcome by mode of anaesthesia for hip fracture surgery. An observational audit of 65 535 patients in a national dataset.** *Anaesthesia* 2014, **69**(3):224-230.
  12. Gamli M, Sacan O, Baskan S, Ozciftci S, Gogus N: **Combined lumbar plexus and sciatic nerve block for hip fracture surgery in a patient with severe aortic stenosis.** *Journal of anesthesia* 2011, **25**(5):784-785.
  13. Ho AM, Karmakar MK: **Combined paravertebral lumbar plexus and parasacral sciatic nerve block for reduction of hip fracture in a patient with severe aortic stenosis.** *Canadian Journal of Anesthesia* 2002, **49**(9):946-950.
  14. Saffet K, Egemen A, Hayrettin K, Omer U: **Hip Fracture Mortality: Is It Affected by Anesthesia Techniques?** *Anesthesiology Research & Practice* 2012, **2012**(2012):708754.
  15. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA *et al*: **SPIRIT 2013 statement: defining standard protocol items for clinical trials.** *Annals of internal medicine* 2013, **158**(3):200-207.
  16. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR *et al*: **SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.** *Bmj* 2013, **346**:e7586.
  17. Karademir G, Bilgin Y, Ersen A, Polat G, Buget MI, Demirel M, Balci HI: **Hip fractures in patients older than 75 years old: Retrospective analysis for prognostic factors.** *International journal of surgery (London, England)* 2015, **24**(Pt A):101-104.
  18. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K *et al*: **Liberal or restrictive transfusion in high-risk patients after hip**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- surgery.** *The New England journal of medicine* 2011, **365**(26):2453-2462.
19. Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, Oberkofler CE, Graf R, Puhan MA, Clavien PA: **The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials.** *Annals of surgery* 2014, **260**(5):757-762; discussion 762-753.
20. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI: **Clarifying confusion: the confusion assessment method. A new method for detection of delirium.** *Annals of internal medicine* 1990, **113**(12):941-948.
21. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL: **Serial evaluation of the SOFA score to predict outcome in critically ill patients.** *Jama* 2001, **286**(14):1754-1758.
22. Bauer M, Bohrer H, Aichele G, Bach A, Martin E: **Measuring patient satisfaction with anaesthesia: perioperative questionnaire versus standardised face-to-face interview.** *Acta anaesthesiologica Scandinavica* 2001, **45**(1):65-72.
23. Cox DR: **Regression Models and Life-Tables.** *Journal of the Royal Statistical Society* 1992, **34**(2):187-220.
24. Schoenfeld DA: **Sample-size formula for the proportional-hazards regression model.** *Biometrics* 1983, **39**(2):499-503.
25. Singelyn FJ, Ferrant T, Malisse MF, Joris D: **Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty.** *Regional anesthesia and pain medicine* 2005, **30**(5):452-457.

1  
2  
3  
4 **Figure legend**  
5

6 Fig. 1 CONSORT flowchart designed for subject enrollment  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



100x99mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>3</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>n/a</u>
Protocol version	3	Date and version identifier	<u>3</u>
Funding	4	Sources and types of financial, material, and other support	<u>2-3</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>21</u>
	5b	Name and contact information for the trial sponsor	<u>n/a</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>n/a</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>6</u>



1				
2				
3	<b>Introduction</b>			
4				
5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>3-6</u>
6				
7				
8		6b	Explanation for choice of comparators	<u>4-5</u>
9				
10	Objectives	7	Specific objectives or hypotheses	<u>5-6</u>
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>6</u>
13				
14				
15	<b>Methods: Participants, interventions, and outcomes</b>			
16				
17	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>6</u>
18				
19				
20	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>7-8</u>
21				
22				
23	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>8-11</u>
24				
25				
26		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>9</u>
27				
28				
29		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>n/a</u>
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>9-11</u>
33				
34	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>11-12</u>
35				
36				
37				
38				
39	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>10,12,24</u>
40				
41				
42				
43				
44				
45				
46				
47				

1				
2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>12-13</u>
3				
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>6-7</u>
6				
7				

## 8 **Methods: Assignment of interventions (for controlled trials)**

### 9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>13-14</u>
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>13-14</u>
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>13-14</u>
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>13-14</u>
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>13-14</u>
28				
29				
30				

## 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>14-18</u>
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>n/a</u>
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>17-18</u>
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>18</u>
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>18</u>
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>n/a</u>
13				
14				
15	<b>Methods: Monitoring</b>			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>17-18</u>
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>n/a</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>17-18</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>n/a</u>
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>2-3</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>2-3</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>18-19</u>
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>n/a</u>
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>18-19</u>
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>21</u>
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>18</u>
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>n/a</u>
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>3</u>
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	<u>n/a</u>
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>n/a</u>
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>n/a</u>
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>n/a</u>
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40

# BMJ Open

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022898.R4
Article Type:	Protocol
Date Submitted by the Author:	17-Dec-2018
Complete List of Authors:	zhang, junfeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology wang, xiaofeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology zhang, hui; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology shu, zhuolin; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology jiang, wei; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	Hip fracture, Elderly, Lumbar plexus block, Sacral plexus block, General anesthesia

SCHOLARONE™  
Manuscripts

---

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Junfeng Zhang<sup>#</sup>, Xiaofeng Wang<sup>#</sup>, Hui Zhang, Zhuolin Shu, Wei Jiang\*

Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China

\*Corresponding author: Wei Jiang MD, PhD. Address: 600 Yishan Road, Shanghai 200233, China. Tel: +86 21 64369181 ext. 58328; Fax: +86 21 64369181 ext. 58330.

E-mail: jiangw@sjtu.edu.cn.

<sup>#</sup>These authors contributed equally to this work.

Email address of all authors:

JZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: zhangjunfeng@sjtu.edu.cn

XW: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: 240483680@qq.com

HZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: zhanghui12179@163.com

ZS: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email:5883434@qq.com

WJ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Email: jiangw@sjtu.edu.cn

---

## ABSTRACT

**Introduction** Hip fracture in elderly people is a global public health problem, with substantial associated mortality and disability. Nearly all patients with hip fracture undergo surgical treatment, but optimal anesthesia for hip fracture surgery in elderly patients is still inconclusive. Ultrasound-guided combined lumbar and sacral plexus block has been widely used in hip fracture surgery in recent years, especially for some high-risk patients. However, it is not clear whether it can improve the postoperative outcomes of elderly patients with hip fracture.

**Method and analysis** This research project is a two-arm, parallel, multicenter, prospective randomized controlled trial. A total of 1086 patients aged 75 and older scheduled for hip fracture surgery in five clinical trial centers of China will be randomized in a 1:1 ratio to receive either combined lumbar and sacral plexus block plus sedation or general anesthesia. The primary outcome will be the postoperative 1-year all-cause mortality. The secondary outcomes will be the incidence of postoperative complications, high-sensitivity cardiac troponin T, early mobility after surgery, postoperative VAS pain scores, postoperative delirium, length of stay in ICU and hospital, cost-effective outcomes, Barthel Index and incidence of adverse events after discharge. Assessments will be conducted in four steps: preoperative, intraoperative and in-hospital data collection and post-discharge telephone follow-up.

**Ethics and dissemination** This study has been supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103) and approved by the Ethics Committee of Shanghai Sixth

1  
2  
3  
4 People's Hospital [No: 2016-28-(2)]. At the time of manuscript submission, the  
5  
6 protocol version is v1.6 (March 2nd, 2018) with one subsequent approved amendment.  
7  
8  
9 Results will be disseminated via an international peer-reviewed publication.  
10

11 **Trial registration number** NCT03318133.  
12

13  
14 **Key words** Elderly; Hip fracture; Lumbar plexus block; Sacral plexus block; General  
15  
16 anesthesia  
17

### 18 19 **Strengths and limitations of this study** 20

- 21  
22 ▶ This study will be the first prospective, multicenter, randomized controlled clinical  
23  
24 trial to investigate the effect of the two anesthesia techniques on long-term  
25  
26 prognostic indicators in elderly patients with hip fracture.  
27  
28  
29 ▶ The results of this study will help elucidate whether CLSB plus sedation could be  
30  
31 safely used in hip fracture surgery and reduce the incidence of perioperative  
32  
33 complications and improve long-term outcome in elderly patients.  
34  
35  
36 ▶ Our study results will be limited to Chinese population, and further studies on other  
37  
38 ethnic backgrounds will be required.  
39  
40  
41

## 42 43 **1.BACKGROUND** 44

45 Hip fracture is a global public health problem with an incidence of more than 1.6  
46  
47 million worldwide each year [1]. Owing to the global increase of the population aged 65  
48  
49 years and over, the total number of hip fracture is expected to surpass 6 million by 2050  
50  
51 [2]. While early surgery is the most effective treatment method, the postoperative  
52  
53 mortality and disability rates are still high [3]. The elderly patients with hip fracture  
54  
55 frequently have multiple comorbidities, which put these patients at high risk of  
56  
57  
58  
59  
60



1  
2  
3  
4 morbidity and mortality after anesthesia [4,5]. Seeking appropriate anesthesia technique  
5  
6 is in urgent need to ensure that these patients can safely and effectively get through the  
7  
8 perioperative period.  
9  
10

11 Most studies assessing the relationship between anesthesia technique and  
12  
13 outcomes mainly focus on the comparisons between neuraxial anesthesia (including  
14  
15 spinal and epidural anesthesia) and general anesthesia (with an endotracheal tube or a  
16  
17 laryngeal mask airway). A recently updated systematic review and meta-analysis has  
18  
19 found no difference between regional versus general anesthesia, but they also supposed  
20  
21 that the number of participants included in the review was insufficient to eliminate a  
22  
23 difference between the two techniques in the majority of outcomes studied[6]. Some  
24  
25 other investigations have shown that neuraxial anesthesia for hip fracture can reduce  
26  
27 postoperative morbidity[7, 8], but two recent large-sample size observational studies  
28  
29 deemed that neuraxial anesthesia could not significantly improve the prognosis of  
30  
31 patients [9, 10]. However, all of the above are retrospective observational studies, in  
32  
33 which anesthesiologists might have selected the anesthesia technique based on their  
34  
35 practice style and a variety of patient-related factors. For example, patients with  
36  
37 coagulation dysfunction would have contraindication to neuraxial anesthesia and must  
38  
39 receive general anesthesia. Neuraxial anesthesia is thought to be less postoperative  
40  
41 complications, so elderly or critically ill patients might be more likely to receive  
42  
43 neuraxial anesthesia<sup>[11]</sup>, rather than being randomly assigned to different anesthesia  
44  
45 groups. Therefore, there could be selection bias that affected the clinical significance  
46  
47 of those results. In addition to general anesthesia and neuraxial anesthesia, ultrasound-  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

1  
2  
3  
4 guided lumbar and sacral plexus block has been widely used in hip fracture surgeries  
5  
6 in recent years, especially for some high-risk patients with cardiopulmonary  
7  
8 dysfunction [12-14]. Compared with neuraxial anesthesia, combined lumbar and sacral  
9  
10 plexus block is associated with less sympathetic block and better cardiovascular  
11  
12 function stability. In addition, combined lumbar and sacral plexus block plus sedation  
13  
14 could avoid endotracheal intubation or laryngeal mask airway(LMA) insertion and  
15  
16 thereby might reduce the complications related to the general anesthesia. A recent small  
17  
18 sample size retrospective study [14] compared the effect of general endotracheal  
19  
20 anesthesia, neuraxial anesthesia and lumbar and sacral plexus block on the prognosis  
21  
22 of patients with hip fracture, and the results showed that neuraxial anesthesia and  
23  
24 combined lumbar and sacral plexus block could reduce the total mortality, and there  
25  
26 was no significant difference between neuraxial anesthesia and combined lumbar and  
27  
28 sacral plexus block. But the number of elderly and high-ASA-grade patients in the  
29  
30 combined lumbar and sacral plexus block group was significantly greater than that in  
31  
32 the neuraxial anesthesia group, suggesting that when comparing the effect of these two  
33  
34 anesthetic methods in similar conditions, combined lumbar and sacral plexus block  
35  
36 might have more advantages. However, it is not clear whether ultrasound-guided  
37  
38 combined lumbar and sacral plexus block plus sedation could improve outcomes of  
39  
40 elderly patients with hip fracture.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52  
53 This paper describes the design of a prospective, multicenter, parallel, randomized  
54  
55 controlled clinical trial to assess the effect of ultrasound-guided combined lumbar and  
56  
57 sacral plexus block plus sedation versus general anesthesia on the postoperative  
58  
59  
60

1  
2  
3  
4 outcomes in elderly patients with hip fracture.  
5

## 6 7 **2. METHODS AND ANALYSIS**

### 8 9 **2.1. Patient and public involvement**

10  
11 Patients and public were not involved in the design or conduct of the study. We  
12  
13 do not have any specific plans to disseminate our results to patients.  
14  
15

### 16 17 **2.2. Study design**

18  
19 This will be a two-arm, parallel, multicenter, prospective, randomized controlled  
20  
21 trial and the design of this study protocol has referred to the SPIRIT 2013 guideline [15,  
22  
23  
24  
25 16].

### 26 27 **2.3. Study location**

28  
29 The study will be conducted in five teaching hospitals including Shang Sixth  
30  
31 People's Hospital (Shanghai, China), Beijing Chaoyang Hospital (Beijing, China),  
32  
33 Beijing Jishuitan Hospital (Beijing, China), First Affiliated Hospital of Wenzhou  
34  
35 Medical University (Wenzhou, China), and Foshan Hospital of Traditional Chinese  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
60  
Medicine (Foshan, China).

### 61 62 **2.4. Study population**

63  
64 Although elderly population was considered to be people older than 65 years in  
65  
66 the present studies, introduction to aging population is latening owing to increasing life  
67  
68 expectancy. As shown in a recent study[17], age is the primary risk factor on first year  
69  
70 mortality in patients older than 75 years old with hip fractures. In addition, China  
71  
72 wants to increase its citizens' average life expectancy to 77.3 by 2020 and 79 by 2030,  
73  
74 up from 76.34 in 2015, according to "Plan of Health China 2030" published in 2015.  
75  
76  
77  
78  
79  
80

We thus used 75 years as an age cutoff for inclusion criteria in this study because optimal selection of anesthesia technique in this age group might have more clinical significance.

Elderly patients above 75 years scheduled for hip fracture surgery will be recruited voluntarily according to the inclusion and exclusion criteria below. All included patients are suitable for either general endotracheal anesthesia or combined lumbar and sacral plexus block plus sedation, which will not bring tendency to choose a specific type of anesthesia.

#### **2.4.1. Inclusion criteria:**

- Age  $\geq 75$  years old;
- First unilateral surgery for hip fracture including femoral neck, intertrochanteric or subtrochanteric fracture;
- Patient with planned hip fracture surgery within 24-72 h;
- Patient without peripheral nerve block within 24 h prior to surgery or patients with preoperative peripheral nerve blockade but its effect had faded away at the beginning of the operation.
- The ability to receive written informed consent from the patient or patient's legal representative.

#### **2.4.2. Exclusion criteria:**

- Refuse to participate;
- Unable to perform nerve block;
- Multiple trauma, multiple fractures or other fractures outside the inclusion criteria,

---

such as pathological fractures, pelvic fractures, femur fractures;

- Prosthetic fracture;
- Scheduled for bilateral hip fracture surgery;
- Usage of bone-cement fixation in the surgery;
- With recent cerebral stroke (<3 months);
- Concomitant active heart disease (unstable angina, acute myocardial infarction, recent myocardial infarction; decompensated heart failure; symptomatic arrhythmia; severe mitral or aortic stenotic heart disease);
- Patient with known severe lung and/or airway disease, acute respiratory failure, acute pulmonary infection, and acute attack of bronchial asthma;
- Current enrolment in another clinical trial;
- Contraindication for general endotracheal anesthesia (drug allergies to general anesthesia, difficult airway);
- Contraindication for lumbar and sacral plexus block (infection at the site of needle insertion, coagulopathy, allergy to local anesthetics).

## 2.5. Interventions

Eligible patients will be randomly assigned into either CLSB group receiving combined lumbar and sacral plexus block plus sedation or GA group receiving general anesthesia with endotracheal intubation or LMA (Figure 1). Standard anesthetic and surgical methods will be applied to ensure the consistency of treatment in the participating centers. Experienced and qualified anesthesiologists in every clinical centers will be specifically designated to perform combined lumbar-sacral plexus block

1  
2  
3  
4 plus sedative anesthesia or GA in order to minimize the potential bias. To improve  
5  
6 adherence to intervention protocols, study personnel are trained to follow the study  
7  
8 protocol in accordance with the Good Clinical Practice (GCP) principles.  
9  
10

11 In the CLSB group (Combined lumbar-sacral plexus block with sedative  
12  
13 anesthesia), the procedures will be performed as followed.  
14  
15

- 16 ● Peripheral venous access for fluid infusion will be established;
- 17  
18 ● In the lateral decubitus position with the operated side uppermost, ultrasound-  
19  
20 guided lumbar plexus block (L<sub>2-3</sub> or/and L<sub>3-4</sub> vertebral space level, 0.375%  
21  
22 ropivacaine 25ml) will be performed, followed by sacral plexus block (0.375 %  
23  
24 ropivacaine 20ml); We used the nerve stimulator to confirm the needle's correct  
25  
26 position by a quadratus femoris twitch for lumbar plexus block and hamstring, leg,  
27  
28 or foot twitches for sacral plexus block at a current within 0.4–0.6 mA, followed  
29  
30 by relevant volume of 0.375% ropivacaine that was slowly injected in 5 ml  
31  
32 increments to surround the target nerve under ultrasound monitoring.  
33  
34 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
35  
36 pressure monitoring will be performed. Blockade effectiveness will be evaluated  
37  
38 30 minutes after nerve block; The intervention will be discontinued for a given  
39  
40 patient and convert to general anesthesia with endotracheal intubation or LMA if  
41  
42 the satisfactory blockade is not acquired. These patient are still followed up for  
43  
44 further statistical analysis according to the formal protocol because they have been  
45  
46 randomly allocated.  
47  
48 ● After confirmation of satisfactory blockade, target-controlled infusion of propofol  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

will be used to maintain Ramsay sedation score between 3-4 points.  $P_{ET}CO_2$  will be monitored through nasopharyngeal airway. Small-dose sufentanil (1-2 $\mu$ g each time) will be titrated to maintain spontaneous breathing.

In the GA group, the procedures will be performed as followed.

- Peripheral venous access for fluid infusion will be established;
- Radial arterial catheterization under local lidocaine anesthesia and arterial blood pressure monitoring will be conducted;
- Anesthesia will be induced with propofol (1.5-3mg/kg), rocuronium(0.3-0.9mg/kg), and sufentanil (0.2-0.6 $\mu$ g/kg) for tracheal intubation or LMA insertion. Mechanical ventilation will be performed to maintain normal  $P_{ET}CO_2$ .
- Sevoflurane, propofol and sufentanil will be used to maintain anesthesia during surgery, while rocuronium will be added as needed.

During surgery, fluid infusion and blood transfusion will be used to maintain stable hemodynamics. Perioperative arterial pressure lower than 30% of the baseline will be defined as hypotension, upon which ephedrine or phenylephrine will be administrated. The type and dosage of infusion depends on anesthesiologist's experience. Blood transfusion will be given according to blood loss and hemoglobin concentration(Hb) level (80-100g/L)<sup>[18]</sup>. Following surgery, patients will be sent to the postanesthesia care unit (PACU) and then transferred to orthopedic ward or intensive care unit(ICU) according to the local procedures of each clinical center. Postoperative analgesia can be administrated with regard to the routine clinical practice of each trial site, aiming to maintain a Visual Analogue Scale (VAS) pain score  $\leq 3$ .

---

## 2.6. Outcomes and measurements

### 2.6.1. Primary outcome

Postoperative 1-year all-cause mortality (follow-up time points are set as 1 month, 3 months, 6 months and 1 year after surgery);

### 2.6.2. Secondary outcomes

#### 2.6.2.1. Occurrence of intraoperative complications, including:

- Intraoperative hypotension and vasopressor dosage;
- Intraoperative arrhythmia, myocardial ischemia, myocardial infarction, massive hemorrhage, pulmonary embolism and hypoxemia;
- Intraoperative blood loss and blood transfusion volume;

2.6.2.2. High-sensitivity cardiac troponin T(hs-cTnT), measured on the 1 and 3 days after surgery;

2.6.2.3. Early mobility after surgery;

2.6.2.4. Incidence of various complications and Comprehensive Complication Index (CCI) <sup>[19]</sup> during hospitalization after surgery;

2.6.2.5. Postoperative analgesic effectiveness within three days after the surgery;

2.6.2.6. Incidence of delirium on the 1, 2 and 3 days after surgery, diagnosed with Confusion Assessment Method(CAM)<sup>[20]</sup>;

2.6.2.7. Sequential Organ Failure Assessment(SOFA) <sup>[21]</sup>, assessed on the 1 and 3 days after surgery;

2.6.2.8. Bauer Patient Satisfaction Questionnaire<sup>[22]</sup>, assessed on the 3 days after surgery;

2.6.2.9. Length of stay in ICU and hospital;



---

### 2.6.3. Other observational variables:

2.6.3.1. Economic parameters including total cost in hospital and expenditure for anesthesia;

2.6.3.2. Functional recovery on the 30 days after surgery, evaluated by Barthel Activities of Daily Living Index (Barthel Index);

2.6.3.3. Post-discharge destination, and incidence of complications and adverse events after discharge.

### 2.7. Participant timeline

For a given participant, assessment will be performed one day prior to surgery and again on the day of surgery to confirm whether qualified for enrollment. Randomization will perform on the day of surgery. And then intervention will be performed. The accrual period of this trial is expected to be about 1 year. The patients will be followed up on the 1, 2 and 3 days after surgery and on the day of discharge. The total follow-up period will be set as 1 year and the telephone follow-up will be conducted at the 1, 3, 6 and 12 months after surgery.

### 2.8. Power and Sample Size Calculation

We estimate the sample size using the formula by Schoendeld under the assumption of the validity of the proportional-hazards regression model [23, 24]. We take significance level 0.05 (two-sided) and power 0.80. Patients will be randomly assigned to one of the two anesthesia groups in five different clinical centers. A retrospective study included patients over 65 years old showed that the one-year mortality was 41.7% for GA group and 28.3% for combined peripheral nerve block (CPNB) group [14]. In

---

1  
2  
3  
4 this study, only patients with age 75 years or older will be included, so we expect the  
5  
6 actual mortality of the GA group will be higher than that in the previous study.  
7  
8 Therefore, we assume the mortality to be 55% for GA group and 46.75% for CLSB  
9  
10 group (15% relative reduction compared with GA group). Then the sample size needed  
11  
12 for this study is 868 (with 434 in each of the two groups). When the mortality of the  
13  
14 GA group is only 45%, the above calculated sample size can still detect a 20%  
15  
16 improvement in the CLSB group with the power of at least 0.80. In consideration of the  
17  
18 possible lost to follow up, we add an additional 20% to the above calculated sample  
19  
20 size. So the total number of patients needed for this study is 1086.  
21  
22  
23  
24  
25

## 26 27 **2.9. Randomization and blinding**

28  
29  
30 Upon the receipt of informed consents, patients will be randomly assigned to the  
31  
32 two groups in any one of the five centers. Sequentially numbered sealed opaque  
33  
34 envelopes with group allocation inside altered anesthetist to use CLSB or GA. The R  
35  
36 program will be used to generate randomization block allocation for each of the five  
37  
38 centers with randomly selected block sizes of four, six, and eight. The envelopes will  
39  
40 be placed in the patient's chart before the start of each procedure by a doctor of the  
41  
42 research team. The research staff who will interview patients postoperatively are  
43  
44 blinded for the allocated treatment. The statistician will be blinded. A spreadsheet  
45  
46 linking the patient number and name will be password protected and kept on a research  
47  
48 computer. The recruitment will stop when the total number of patients reaches 1086.  
49  
50  
51 The subjects and intervention performers (anesthesiologists) know the randomized  
52  
53 allocation, but the follow-up personnel and statistician was blinded to the randomized  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 allocation and intervention.  
5

## 6 **2.10. Data collection and management**

7  
8  
9 Data will be collected in four steps: preoperative, intraoperative and in-hospital  
10 data collection and post-discharge telephone follow-up.  
11

### 12 **2.10.1. Preoperative data:**

13  
14  
15 **2.10.1.1.** Basic information including name, admission number, height, weight, gender,  
16  
17 age, blood pressure, heart rate and ASA grade (American Society of Anesthesiologists  
18  
19 grade).  
20  
21

22  
23  
24 **2.10.1.2.** Preoperative information including diagnosis, type of surgery, type and  
25  
26 dosage of anticoagulants, and days passed until surgery.  
27  
28

29  
30  
31 **2.10.1.3.** Preoperative complications and medication related to cardiovascular disease,  
32  
33 stroke, respiratory disease, kidney disease, diabetes, Parkinson's disease, and deep  
34  
35 venous thrombosis of lower extremity if any.  
36  
37

38  
39  
40 **2.10.1.4.** Preoperative examination results including blood gas analysis, ECG,  
41  
42 echocardiography, blood routine testing, liver and kidney function testing, coagulation  
43  
44 testing (D-dimer), Pro-BNP, hs-cTnT, and lower extremity vascular ultrasonography.  
45

46  
47  
48 **2.10.1.5.** Preoperative evaluation results including MMSE (Mini-mental State  
49  
50 Examination), SOFA and Barthel Index, all of which might be associated with the  
51  
52 postoperative complications.  
53

### 54 **2.10.2. Intraoperative data**

55  
56  
57 **2.10.2.1.** Duration of surgery, incidence of intraoperative hypotension or hypertension,  
58  
59 and vasoactive drug dosage.  
60

1  
2  
3  
4 **2.10.2.2.** Intraoperative blood loss, blood transfusion volume, and intraoperative fluid  
5  
6 infusion volume.  
7

8  
9 **2.10.2.3.** Intraoperative arrhythmia (sinus bradycardia, sinus tachycardia, ventricular  
10  
11 arrhythmia, atrial arrhythmia, etc.), myocardial ischemia, and myocardial infarction.  
12

13  
14 **2.10.2.4.** Intraoperative complications: massive hemorrhage, pulmonary embolism,  
15  
16 allergic reaction, hypoxemia, bronchospasm, gastric reflux and aspiration.  
17

18  
19 **2.10.2.5.** Intraoperative conversion of anesthesia and the relevant causes.  
20

### 21 22 **2.10.3. In-hospital data**

23  
24 **2.10.3.1.** High-sensitivity cardiac troponin T (hs-cTnT), measured on the 1 and 3 days  
25  
26 after surgery;  
27

28  
29 **2.10.3.2.** Earlier mobilization and postoperative hip rehabilitation: the daily degree of  
30  
31 maximal hip flexion and abduction will be recorded [25]. The day after surgery, all 2  
32  
33 groups will start an identical physical therapy regimen. The patients will perform  
34  
35 passive and active hip flexion and abduction exercises twice daily. Patients will be  
36  
37 encouraged to get out of bed as soon as possible and try ambulation with a walker. The  
38  
39 maximal degree of hip flexion and abduction tolerated by each patient will be recorded  
40  
41 for three days. The day of first ambulation will be also recorded for each group.  
42  
43

44  
45 **2.10.3.3.** Postoperative complications including incidence and severity of various  
46  
47 complications and the CCI [19] value at discharge. Complications were assessed and  
48  
49 graded using the Clavien-Dindo classification. CCI will be derived from these features  
50  
51 at discharge, using the CCI calculator available online ([www.assessurgery.com](http://www.assessurgery.com)).  
52  
53

54  
55  
56  
57  
58  
59  
60  
Complications include:

- 
- Myocardial ischemia, myocardial infarction, heart failure, arrhythmia;
  - Pulmonary infection, respiratory failure, pulmonary embolism;
  - Postoperative delirium;
  - Cerebral ischemia, cerebrovascular accident;
  - Renal failure, urinary retention;
  - Regurgitation and pulmonary aspiration;
  - Postoperative nausea and vomiting (PONV);
  - Postoperative bleeding and 24h postoperative drainage volume;
  - Reoperation.

**2.10.3.4.** The intensity of postoperative pain at rest and on movement will be assessed with Visual Analogue Scale (VAS) (0 no pain, and 10 worst possible pain) at the 24, 48, and 72 hours after surgery.

**2.10.3.6.** CAM will be evaluated on the 1, 2 and 3 days after surgery.

**2.10.3.7.** SOFA <sup>[21]</sup> will be evaluated on the 1 and 3 days after surgery.

**2.10.3.8.** Bauer Patient Satisfaction Questionnaire will be assessed on the 3 days after surgery.

**2.10.3.9.** Length of ICU stay, length of hospital stay, total hospitalization cost, and expenditure for anesthesia.

#### **2.10.4. Post-discharge follow-up data**

**2.10.4.1.** Telephone follow-up will be performed on the 1, 3, 6 and 12 months after surgery to collect the following information.

- Discharge destinations. Disposition status after discharge will be classified as follows: dead, nursing home (e.g., skilled nursing facility, intermediate care facility,

extended care facility, nursing home), community dwelling (e.g., home alone, home with others), or other.

- Dead or not, specific cause and time.
- Incidence of complications and adverse events: heart, lungs, brain, liver, kidney, four limbs, and hospitalization, etc.

**2.10.4.2.** Barthel Index for evaluation of functional recovery will be collected on the 30 days after surgery.

## **2.11. Data and safety monitoring**

Preoperative, intraoperative and in-hospital data will be collected from the electronic medical record, monitor machines and relevant manual records by one of the research staff. Telephone follow-up will be conducted by the research team. Data will be securely managed by an independent contract research organization (Shanghai Ruihui Biotech Co., Ltd, Shanghai). All serious adverse events, as well as all non-serious adverse events that are unexpected and judged to be related to the study treatment, will be recorded in the study database and reported as required to local IRBs and to the Shanghai Jiao Tong University Affiliated Sixth People's Hospital IRB. Data and safety monitoring will be the responsibility of the study director/principle investigator(PI), the study biostatistician, site clinical directors and an independent Data and Safety Monitoring Board(DSMB) selected by the study PI. The DSMB will be composed of 5-7 independent, multidisciplinary experts who are not have subordinate relationships with the PI or any member of the study team. The DSMB will review study implementation and the occurrence of adverse events.

---

## 2.12. Statistical analysis

The data will be analyzed using intention-to-treat approach. Demographics information will be compared for patients of the two groups to ensure the data are balanced. Student t-test will be used for quantitative variables such as age, and heart rate, blood pressure. Chi-square test will be used for categorical variables such as Sex, ASA classification grades. The VAS pain scores will be analyzed using repeated measure ANOVA to test the effects of treatment, time, and the interaction effect. The effects of different covariates on the mortality measured at 1 month, 3 months, 6 months and 12 months will be assessed using a logistic regression model. The primary analysis model will be Cox regression model with covariates. Either logistic regression or ordinary multiple regression method will also be used to assess the effects of the covariate on the secondary and other outcomes as well depending on the type of dependent variable. The proportional-hazards regression model will be used to compare the survival times of the patients in the two groups and to assess the effects of the covariates. All tests will be two-sided and a value of  $P < 0.05$  will be considered statistically significant.

## 2.13. Access to data

During the study, data will be stored in a password-protected system and can be accessed by the research staff who sign the confidential disclosure agreements. Data without patient identification will be publicly accessible after the study.

## 2.14. Confidentiality

Each participant will be given an identification number and referred by the

---

1  
2  
3  
4 identification number throughout the study and in all study-related information. This  
5  
6 information will be securely stored in a password-protected access system provided by  
7  
8 a local supplier. Relevant paper records will be stored in a locked cabinet in an access-  
9  
10 controlled room. All records containing any patients' personal identifiers will be  
11  
12 separately stored similarly as above.  
13  
14  
15

### 16 17 **2.15. Trial status**

18  
19 At the time of manuscript submission, the study is in the preparation phase for  
20  
21 recruitment.  
22  
23

## 24 25 **3. DISCUSSION**

26  
27 Choice of anesthesia for hip fracture surgery in elderly patients is still inconclusive.  
28  
29 General anesthesia with endotracheal intubation or LMA is a common procedure for  
30  
31 hip fracture surgery, with advantages of wide indications and maintaining relatively  
32  
33 stable hemodynamics. Compared with general anesthesia, neuraxial anesthesia avoids  
34  
35 endotracheal intubation or LMA insertion. But vertebral degeneration and anatomical  
36  
37 abnormalities in elderly patients often make neuraxial anesthesia puncture difficult, and  
38  
39 most of these patients are taking anticoagulants, which are the contraindication of  
40  
41 neuraxial anesthesia. So the neuraxial anesthesia has limitations in application for the  
42  
43 elderly patient. The principle for anesthesia selection is to reduce or avoid the effect of  
44  
45 anesthesia on systemic and vital organ functions as much as possible when meeting the  
46  
47 needs of surgery. Previous lumbar and sacral plexus block depends on blind puncture  
48  
49 technique and cannot ensure the clinical effectiveness. However, ultrasound  
50  
51 visualization technology has promoted the wide application of lumbar and sacral plexus  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 block. Combined lumbar and sacral plexus block with sedative anesthesia has gradually  
5  
6 become alternative approach for hip fracture surgery in elderly patients, and this  
7  
8 anesthetic technique has been massively applied in our department and achieved  
9  
10 satisfactory clinical results in recent years, but there is few reliable clinical evidence on  
11  
12 whether it can be safely used for hip fracture surgery in elderly patients and improve  
13  
14 the short-term or long-term outcomes. Thus, we have designed this trial protocol to  
15  
16 illustrate the clinical value of combined lumbar and sacral plexus block with sedative  
17  
18 anesthesia in elderly patients undergoing hip fracture surgery. In this study, we will  
19  
20 observe the effect of the two anesthetic methods (general endotracheal anesthesia or  
21  
22 combined lumbar and sacral plexus block plus sedation on the early prognostic  
23  
24 indicators in elderly patients with hip fracture, including postoperative complications,  
25  
26 postoperative analgesic effect, postoperative early mobility, postoperative delirium,  
27  
28 patient's satisfaction to anesthesia and length of stay in ICU and hospital. This study  
29  
30 will be the first prospective, multicenter, randomized controlled clinical trial to  
31  
32 investigate the effect of the two anesthesia techniques on long-term prognostic  
33  
34 indicators in elderly patients with hip fracture, including postoperative 1-year all-cause  
35  
36 mortality and incidence of complications and adverse events. The results of this study  
37  
38 will help elucidate whether ultrasound-guided combined lumbar and sacral plexus  
39  
40 block with sedative anesthesia can be safely used in hip fracture surgery in elderly  
41  
42 patients and can reduce the incidence of perioperative complications and improve long-  
43  
44 term prognosis, so as to solve the troubling clinical problem and provide a theoretical  
45  
46 basis for elderly patients undergoing hip fracture surgery to choose the optimal  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

anesthetic method.

### Abbreviations

ASA grade: American Society of Anesthesiologists grade; GA: General anesthesia; CLSB: Combined Lumbar and Sacral Plexus Block; PACU: Postanesthesia Care Unit; Hb: Hemoglobin Concentration; ICU: Intensive Care Unit; CCI: Comprehensive Complication Index; SOFA: Sequential Organ Failure Assessment; CAM: The Confusion Assessment method; MMSE: Mini-mental State Examination; ECG: Echocardiography; Pro-BNP: Pro Brain Natriuretic Peptide; hs-cTnT: High-sensitivity cardiac Troponin T; PONV: Postoperative Nausea and Vomiting; VAS: Visual Analog Scale

**Contributors** JZ and WJ designed the study and wrote the protocol. HZ and XW performed statistical analysis. HZ, XW and ZS were involved in protocol conception and design and manuscript revision. WJ is the principal investigator of this clinical trial. All authors read and approved the final version of the manuscript.

**Acknowledgements** Not applicable.

**Funding** This study is supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103).

**Data sharing statement** No additional data are available.

**Patient consent** Obtained.

**Competing interests** None declared.

### REFERENCES

1. Johnell O, Kanis JA: **An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.** *Osteoporosis international : a journal established as result of*

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 
- cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2006, **17**(12):1726-1733.
2. Cooper C, Campion G, Melton LJ, 3rd: **Hip fractures in the elderly: a world-wide projection. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA** 1992, **2**(6):285-289.
  3. Brauer CA, Coca-Perrillon M, Cutler DM, Rosen AB: **Incidence and mortality of hip fractures in the United States. Jama** 2009, **302**(14):1573-1579.
  4. Roche JJ, Wenn RT, Sahota O, Moran CG: **Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. Bmj** 2005, **331**(7529):1374.
  5. Lawrence VA, Hilsenbeck SG, Noveck H, Poses RM, Carson JL: **Medical complications and outcomes after hip fracture repair. Archives of internal medicine** 2002, **162**(18):2053-2057.
  6. Guay J, Parker MJ, Gajendragadkar PR, Kopp S: **Anaesthesia for hip fracture surgery in adults. The Cochrane database of systematic reviews** 2016, **2**:Cd000521.
  7. Memtsoudis SG, Sun X, Chiu YL, Stundner O, Liu SS, Banerjee S, Mazumdar M, Sharrock NE: **Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. Anesthesiology** 2013, **118**(5):1046-1058.
  8. Neuman MD, Silber JH, Elkassabany NM, Ludwig JM, Fleisher LA: **Comparative effectiveness of regional versus general anesthesia for hip fracture surgery in adults. Anesthesiology** 2012, **117**(1):72-92.
  9. Patorno E, Neuman MD, Schneeweiss S, Mogun H, Bateman BT: **Comparative safety of anesthetic type for hip fracture surgery in adults: retrospective cohort study. Bmj** 2014, **348**:g4022.
  10. Neuman MD, Rosenbaum PR, Ludwig JM, Zubizarreta JR, Silber JH: **Anesthesia technique, mortality, and length of stay after hip fracture surgery. Jama** 2014, **311**(24):2508-2517.
  11. White SM, Moppett IK, Griffiths R: **Outcome by mode of anaesthesia for hip fracture surgery. An observational audit of 65 535 patients in a national dataset. Anaesthesia** 2014, **69**(3):224-230.
  12. Gamli M, Sacan O, Baskan S, Ozciftci S, Gogus N: **Combined lumbar plexus and sciatic nerve block for hip fracture surgery in a patient with severe aortic stenosis. Journal of anesthesia** 2011, **25**(5):784-785.
  13. Ho AM, Karmakar MK: **Combined paravertebral lumbar plexus and parasacral sciatic nerve block for reduction of hip fracture in a patient with severe aortic stenosis. Canadian Journal of Anesthesia** 2002, **49**(9):946-950.
  14. Karaca S, Ayhan E, Kesmezacar H, Uysal O: **Hip Fracture Mortality: Is It Affected by Anesthesia Techniques? Anesthesiology Research & Practice** 2012, **2012**(2012):708754.
  15. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA *et al*: **SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of internal medicine** 2013, **158**(3):200-207.
  16. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR *et al*: **SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Bmj** 2013, **346**:e7586.
  17. Karademir G, Bilgin Y, Ersen A, Polat G, Buget MI, Demirel M, Balci HI: **Hip fractures in patients**


- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 
- older than 75 years old: Retrospective analysis for prognostic factors.** *International journal of surgery (London, England)* 2015, **24**(Pt A):101-104.
18. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K *et al*: **Liberal or restrictive transfusion in high-risk patients after hip surgery.** *The New England journal of medicine* 2011, **365**(26):2453-2462.
19. Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, Oberkofler CE, Graf R, Puhan MA, Clavien PA: **The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials.** *Annals of surgery* 2014, **260**(5):757-762; discussion 762-753.
20. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegel AP, Horwitz RI: **Clarifying confusion: the confusion assessment method. A new method for detection of delirium.** *Annals of internal medicine* 1990, **113**(12):941-948.
21. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL: **Serial evaluation of the SOFA score to predict outcome in critically ill patients.** *Jama* 2001, **286**(14):1754-1758.
22. Bauer M, Bohrer H, Aichele G, Bach A, Martin E: **Measuring patient satisfaction with anaesthesia: perioperative questionnaire versus standardised face-to-face interview.** *Acta anaesthesiologica Scandinavica* 2001, **45**(1):65-72.
23. Cox DR: **Regression Models and Life-Tables.** *Journal of the Royal Statistical Society* 1992, **34**(2):187-220.
24. Schoenfeld DA: **Sample-size formula for the proportional-hazards regression model.** *Biometrics* 1983, **39**(2):499-503.
25. Singelyn FJ, Ferrant T, Malisse MF, Joris D: **Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty.** *Regional anesthesia and pain medicine* 2005, **30**(5):452-457.

---

1  
2  
3  
4  
5  
6  
7  
8  
9 **Figure legend**

10  
11 Fig. 1 CONSORT flowchart designed for subject enrollment  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



100x99mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>3</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>n/a</u>
Protocol version	3	Date and version identifier	<u>3</u>
Funding	4	Sources and types of financial, material, and other support	<u>2-3</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>21</u>
	5b	Name and contact information for the trial sponsor	<u>n/a</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>n/a</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>6</u>

1				
2				
3	<b>Introduction</b>			
4				
5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>3-6</u>
6				
7				
8		6b	Explanation for choice of comparators	<u>4-5</u>
9				
10	Objectives	7	Specific objectives or hypotheses	<u>5-6</u>
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>6</u>
13				
14				
15	<b>Methods: Participants, interventions, and outcomes</b>			
16				
17	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>6</u>
18				
19				
20	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>7-8</u>
21				
22				
23	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>8-11</u>
24				
25				
26		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>9</u>
27				
28				
29		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>n/a</u>
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>9-11</u>
33				
34	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>11-12</u>
35				
36				
37				
38				
39	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>10,12,24</u>
40				
41				
42				
43				
44				
45				
46				
47				



1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>12-13</u>
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>6-7</u>
6				
7				

## 8 **Methods: Assignment of interventions (for controlled trials)**

### 9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>13-14</u>
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>13-14</u>
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>13-14</u>
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>13-14</u>
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>13-14</u>
28				
29				
30				

## 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>14-18</u>
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>n/a</u>
39				
40				
41				
42				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>17-18</u>
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>18</u>
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>18</u>
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>n/a</u>
13				
14				
15	<b>Methods: Monitoring</b>			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>17-18</u>
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>n/a</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>17-18</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>n/a</u>
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>2-3</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>2-3</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>18-19</u>
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>n/a</u>
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>18-19</u>
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>21</u>
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>18</u>
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>n/a</u>
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>3</u>
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	<u>n/a</u>
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>n/a</u>
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>n/a</u>
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>n/a</u>
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40

# BMJ Open

**Comparison of combined lumbar and sacral plexus block with sedation versus general anesthesia on postoperative outcomes in elderly patients undergoing hip fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter, randomized controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022898.R5
Article Type:	Protocol
Date Submitted by the Author:	09-Jan-2019
Complete List of Authors:	zhang, junfeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology wang, xiaofeng; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology zhang, hui; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology shu, zhuolin; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology jiang, wei; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Department of Anesthesiology
<b>Primary Subject Heading</b>:	Anaesthesia
Secondary Subject Heading:	Anaesthesia
Keywords:	Hip fracture, Elderly, Lumbar plexus block, Sacral plexus block, General anesthesia

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Comparison of combined lumbar and sacral plexus block with sedation versus**  
5  
6 **general anesthesia on postoperative outcomes in elderly patients undergoing hip**  
7 **fracture surgery(CLSB-HIPELD): study protocol for a prospective, multicenter,**  
8  
9 **randomized controlled trial**  
10  
11  
12

13  
14 Junfeng Zhang<sup>#</sup>, Xiaofeng Wang<sup>#</sup>, Hui Zhang, Zhuolin Shu, Wei Jiang\*

15  
16  
17 Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
18  
19 People's Hospital, Shanghai 200233, China  
20

21  
22 \*Corresponding author: Wei Jiang MD, PhD. Address: 600 Yishan Road, Shanghai  
23  
24 200233, China. Tel: +86 21 64369181 ext. 58328; Fax: +86 21 64369181 ext. 58330.  
25

26  
27 E-mail: jiangw@sjtu.edu.cn.  
28

29  
30 <sup>#</sup>These authors contributed equally to this work.  
31

32  
33 Email address of all authors:  
34

35  
36 JZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
37  
38 People's Hospital, Email: zhangjunfeng@sjtu.edu.cn  
39

40  
41 XW: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
42  
43 People's Hospital, Email: 240483680@qq.com  
44

45  
46 HZ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
47  
48 People's Hospital, Email: zhanghui12179@163.com  
49

50  
51 ZS: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
52  
53 People's Hospital, Email:5883434@qq.com  
54

55  
56 WJ: Department of Anesthesiology, Shanghai Jiao Tong University Affiliated Sixth  
57  
58 People's Hospital, Email: jiangw@sjtu.edu.cn  
59  
60

## ABSTRACT

**Introduction** Hip fracture in elderly people is a global public health problem, with substantial associated mortality and disability. Nearly all patients with hip fracture undergo surgical treatment, but optimal anesthesia for hip fracture surgery in elderly patients is still inconclusive. Ultrasound-guided combined lumbar and sacral plexus block has been widely used in hip fracture surgery in recent years, especially for some high-risk patients. However, it is not clear whether it can improve the postoperative outcomes of elderly patients with hip fracture.

**Method and analysis** This research project is a two-arm, parallel, multicenter, prospective randomized controlled trial. A total of 1086 patients aged 75 and older scheduled for hip fracture surgery in five clinical trial centers of China will be randomized in a 1:1 ratio to receive either combined lumbar and sacral plexus block plus sedation or general anesthesia. The primary outcome will be the postoperative 1-year all-cause mortality. The secondary outcomes will be the incidence of postoperative complications, high-sensitivity cardiac troponin T, early mobility after surgery, postoperative VAS pain scores, postoperative delirium, length of stay in ICU and hospital, cost-effective outcomes, Barthel Index and incidence of adverse events after discharge. Assessments will be conducted in four steps: preoperative, intraoperative and in-hospital data collection and post-discharge telephone follow-up.

**Ethics and dissemination** This study has been supported by Shanghai Municipal Commission of Health and Family Planning Foundation for Key Developing Disciplines (2015ZB0103) and approved by the Ethics Committee of Shanghai Sixth

1  
2  
3  
4 People's Hospital [No: 2016-28-(2)]. At the time of manuscript submission, the  
5  
6 protocol version is v1.6 (March 2nd, 2018) with one subsequent approved amendment.  
7  
8  
9 Results will be disseminated via an international peer-reviewed publication.  
10

11  
12 **Trial registration number** NCT03318133.  
13

14 **Key words** Elderly; Hip fracture; Lumbar plexus block; Sacral plexus block; General  
15  
16 anesthesia  
17

### 18 19 **Strengths and limitations of this study** 20

- 21  
22 ▶ This study will be the first prospective, multicenter, randomized controlled clinical  
23  
24 trial to investigate the effect of the two anesthesia techniques on long-term  
25  
26 prognostic indicators in elderly patients with hip fracture.  
27  
28  
29 ▶ The results of this study will help elucidate whether CLSB plus sedation could be  
30  
31 safely used in hip fracture surgery and reduce the incidence of perioperative  
32  
33 complications and improve long-term outcome in elderly patients.  
34  
35  
36 ▶ Our study results will be limited to Chinese population, and further studies on other  
37  
38 ethnic backgrounds will be required.  
39  
40  
41

## 42 43 **1.BACKGROUND** 44

45 Hip fracture is a global public health problem with an incidence of more than 1.6  
46  
47 million worldwide each year [1]. Owing to the global increase of the population aged 65  
48  
49 years and over, the total number of hip fracture is expected to surpass 6 million by 2050  
50  
51 [2]. While early surgery is the most effective treatment method, the postoperative  
52  
53 mortality and disability rates are still high [3]. The elderly patients with hip fracture  
54  
55 frequently have multiple comorbidities, which put these patients at high risk of  
56  
57  
58  
59  
60

1  
2  
3  
4 morbidity and mortality after anesthesia [4,5]. Seeking appropriate anesthesia technique  
5  
6 is in urgent need to ensure that these patients can safely and effectively get through the  
7  
8 perioperative period.  
9  
10

11 Most studies assessing the relationship between anesthesia technique and  
12 outcomes mainly focus on the comparisons between neuraxial anesthesia (including  
13 spinal and epidural anesthesia) and general anesthesia (with an endotracheal tube or a  
14 laryngeal mask airway). A recently updated systematic review and meta-analysis has  
15 found no difference between regional versus general anesthesia, but they also supposed  
16 that the number of participants included in the review was insufficient to eliminate a  
17 difference between the two techniques in the majority of outcomes studied[6]. Some  
18 other investigations have shown that neuraxial anesthesia for hip fracture can reduce  
19 postoperative morbidity[7, 8], but two recent large-sample size observational studies  
20 deemed that neuraxial anesthesia could not significantly improve the prognosis of  
21 patients [9, 10]. However, all of the above are retrospective observational studies, in  
22 which anesthesiologists might have selected the anesthesia technique based on their  
23 practice style and a variety of patient-related factors. For example, patients with  
24 coagulation dysfunction would have contraindication to neuraxial anesthesia and must  
25 receive general anesthesia. Neuraxial anesthesia is thought to be less postoperative  
26 complications, so elderly or critically ill patients might be more likely to receive  
27 neuraxial anesthesia<sup>[11]</sup>, rather than being randomly assigned to different anesthesia  
28 groups. Therefore, there could be selection bias that affected the clinical significance  
29 of those results. In addition to general anesthesia and neuraxial anesthesia, ultrasound-



1  
2  
3  
4 guided lumbar and sacral plexus block has been widely used in hip fracture surgeries  
5  
6 in recent years, especially for some high-risk patients with cardiopulmonary  
7  
8 dysfunction [12-14]. Compared with neuraxial anesthesia, combined lumbar and sacral  
9  
10 plexus block is associated with less sympathetic block and better cardiovascular  
11  
12 function stability. In addition, combined lumbar and sacral plexus block plus sedation  
13  
14 could avoid endotracheal intubation or laryngeal mask airway(LMA) insertion and  
15  
16 thereby might reduce the complications related to the general anesthesia. A recent small  
17  
18 sample size retrospective study [14] compared the effect of general endotracheal  
19  
20 anesthesia, neuraxial anesthesia and lumbar and sacral plexus block on the prognosis  
21  
22 of patients with hip fracture, and the results showed that neuraxial anesthesia and  
23  
24 combined lumbar and sacral plexus block could reduce the total mortality, and there  
25  
26 was no significant difference between neuraxial anesthesia and combined lumbar and  
27  
28 sacral plexus block. But the number of elderly and high-ASA-grade patients in the  
29  
30 combined lumbar and sacral plexus block group was significantly greater than that in  
31  
32 the neuraxial anesthesia group, suggesting that when comparing the effect of these two  
33  
34 anesthetic methods in similar conditions, combined lumbar and sacral plexus block  
35  
36 might have more advantages. However, it is not clear whether ultrasound-guided  
37  
38 combined lumbar and sacral plexus block plus sedation could improve outcomes of  
39  
40 elderly patients with hip fracture.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52  
53 This paper describes the design of a prospective, multicenter, parallel, randomized  
54  
55 controlled clinical trial to assess the effect of ultrasound-guided combined lumbar and  
56  
57 sacral plexus block plus sedation versus general anesthesia on the postoperative  
58  
59  
60

1  
2  
3  
4 outcomes in elderly patients with hip fracture.  
5

## 6 7 **2. METHODS AND ANALYSIS**

### 8 9 **2.1. Patient and public involvement**

10  
11 Patients and public were not involved in the design or conduct of the study. We  
12  
13 do not have any specific plans to disseminate our results to patients.  
14  
15

### 16 17 **2.2. Study design**

18  
19 This will be a two-arm, parallel, multicenter, prospective, randomized controlled  
20  
21 trial and the design of this study protocol has referred to the SPIRIT 2013 guideline [15,  
22  
23  
24  
25 16].

### 26 27 **2.3. Study location**

28  
29 The study will be conducted in five teaching hospitals including Shang Sixth  
30  
31 People's Hospital (Shanghai, China), Beijing Chaoyang Hospital (Beijing, China),  
32  
33 Beijing Jishuitan Hospital (Beijing, China), First Affiliated Hospital of Wenzhou  
34  
35 Medical University (Wenzhou, China), and Foshan Hospital of Traditional Chinese  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
60  
Medicine (Foshan, China).

### 61 62 **2.4. Study population**

63  
64 Although elderly population was considered to be people older than 65 years in  
65  
66 the present studies, introduction to aging population is latening owing to increasing life  
67  
68 expectancy. As shown in a recent study[17], age is the primary risk factor on first year  
69  
70 mortality in patients older than 75 years old with hip fractures. In addition, China  
71  
72 wants to increase its citizens' average life expectancy to 77.3 by 2020 and 79 by 2030,  
73  
74 up from 76.34 in 2015, according to "Plan of Health China 2030" published in 2015.  
75  
76  
77  
78  
79  
80

We thus used 75 years as an age cutoff for inclusion criteria in this study because optimal selection of anesthesia technique in this age group might have more clinical significance.

Elderly patients above 75 years scheduled for hip fracture surgery will be recruited voluntarily according to the inclusion and exclusion criteria below. All included patients are suitable for either general endotracheal anesthesia or combined lumbar and sacral plexus block plus sedation, which will not bring tendency to choose a specific type of anesthesia.

#### **2.4.1. Inclusion criteria:**

- Age  $\geq$ 75 years old;
- First unilateral surgery for hip fracture including femoral neck, intertrochanteric or subtrochanteric fracture;
- Patient with planned hip fracture surgery within 24-72 h;
- Patient without peripheral nerve block within 24 h prior to surgery or patients with preoperative peripheral nerve blockade but its effect had faded away at the beginning of the operation.
- The ability to receive written informed consent from the patient or patient's legal representative.

#### **2.4.2. Exclusion criteria:**

- Refuse to participate;
- Unable to perform nerve block;
- Multiple trauma, multiple fractures or other fractures outside the inclusion criteria,

1  
2  
3  
4 such as pathological fractures, pelvic fractures, femur fractures;  
5

- 6 ● Prosthetic fracture;
- 7
- 8
- 9 ● Scheduled for bilateral hip fracture surgery;
- 10
- 11
- 12 ● Usage of bone-cement fixation in the surgery;
- 13
- 14 ● With recent cerebral stroke (<3 months);
- 15
- 16
- 17 ● Concomitant active heart disease (unstable angina, acute myocardial infarction,  
18 recent myocardial infarction; decompensated heart failure; symptomatic  
19 arrhythmia; severe mitral or aortic stenotic heart disease);  
20  
21
- 22 ● Patient with known severe lung and/or airway disease, acute respiratory failure,  
23 acute pulmonary infection, and acute attack of bronchial asthma;  
24
- 25 ● Current enrolment in another clinical trial;
- 26
- 27 ● Contraindication for general endotracheal anesthesia (drug allergies to general  
28 anesthesia, difficult airway);  
29
- 30 ● Contraindication for lumbar and sacral plexus block (infection at the site of needle  
31 insertion, coagulopathy, allergy to local anesthetics).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **2.5. Interventions**

44  
45 Eligible patients will be randomly assigned into either CLSB group receiving  
46 combined lumbar and sacral plexus block plus sedation or GA group receiving general  
47 anesthesia with endotracheal intubation or LMA (Figure 1). Standard anesthetic and  
48 surgical methods will be applied to ensure the consistency of treatment in the  
49 participating centers. Experienced and qualified anesthesiologists in every clinical  
50 centers will be specifically designated to perform combined lumbar-sacral plexus block  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 plus sedative anesthesia or GA in order to minimize the potential bias. To improve  
5  
6 adherence to intervention protocols, study personnel are trained to follow the study  
7  
8 protocol in accordance with the Good Clinical Practice (GCP) principles.  
9  
10

11 In the CLSB group (Combined lumbar-sacral plexus block with sedative  
12  
13 anesthesia), the procedures will be performed as followed.  
14  
15

- 16 ● Peripheral venous access for fluid infusion will be established;
- 17 ● In the lateral decubitus position with the operated side uppermost, ultrasound-  
18  
19 guided lumbar plexus block (L<sub>2-3</sub> or/and L<sub>3-4</sub> vertebral space level, 0.375%  
20  
21 ropivacaine 25ml) will be performed, followed by sacral plexus block (0.375 %  
22  
23 ropivacaine 20ml); We used the nerve stimulator to confirm the needle's correct  
24  
25 position by a quadratus femoris twitch for lumbar plexus block and hamstring, leg,  
26  
27 or foot twitches for sacral plexus block at a current within 0.4–0.6 mA, followed  
28  
29 by relevant volume of 0.375% ropivacaine that was slowly injected in 5 ml  
30  
31 increments to surround the target nerve under ultrasound monitoring.  
32  
33 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
34  
35 pressure monitoring will be performed. Blockade effectiveness will be evaluated  
36  
37 30 minutes after nerve block; The intervention will be discontinued for a given  
38  
39 patient and convert to general anesthesia with endotracheal intubation or LMA if  
40  
41 the satisfactory blockade is not acquired. These patient are still followed up for  
42  
43 further statistical analysis according to the formal protocol because they have been  
44  
45 randomly allocated.  
46  
47 ● After confirmation of satisfactory blockade, target-controlled infusion of propofol  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 will be used to maintain Ramsay sedation score between 3-4 points.  $P_{ET}CO_2$  will  
5  
6 be monitored through nasopharyngeal airway. Small-dose sufentanil (1-2 $\mu$ g each  
7  
8 time) will be titrated to maintain spontaneous breathing.  
9

10  
11 In the GA group, the procedures will be performed as followed.  
12

- 13 ● Peripheral venous access for fluid infusion will be established;
- 14 ● Radial arterial catheterization under local lidocaine anesthesia and arterial blood  
15  
16 pressure monitoring will be conducted;
- 17 ● Anesthesia will be induced with propofol (1.5-3mg/kg), rocuronium(0.3-  
18  
19 0.9mg/kg), and sufentanil (0.2-0.6 $\mu$ g/kg) for tracheal intubation or LMA insertion.  
20  
21 Mechanical ventilation will be performed to maintain normal  $P_{ET}CO_2$ .  
22  
23 ● Sevoflurane, propofol and sufentanil will be used to maintain anesthesia during  
24  
25 surgery, while rocuronium will be added as needed.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 During surgery, fluid infusion and blood transfusion will be used to maintain stable  
36  
37 hemodynamics. Perioperative arterial pressure lower than 30% of the baseline will be  
38  
39 defined as hypotension, upon which ephedrine or phenylephrine will be administrated.  
40  
41 The type and dosage of infusion depends on anesthesiologist's experience. Blood  
42  
43 transfusion will be given according to blood loss and hemoglobin concentration(Hb)  
44  
45 level (80-100g/L)<sup>[18]</sup>. Following surgery, patients will be sent to the postanesthesia care  
46  
47 unit (PACU) and then transferred to orthopedic ward or intensive care unit(ICU)  
48  
49 according to the local procedures of each clinical center. Postoperative analgesia can  
50  
51 be administrated with regard to the routine clinical practice of each trial site, aiming to  
52  
53 maintain a Visual Analogue Scale (VAS) pain score  $\leq 3$ .  
54  
55  
56  
57  
58  
59  
60

## 2.6. Outcomes and measurements

### 2.6.1. Primary outcome

Postoperative 1-year all-cause mortality (follow-up time points are set as 1 month, 3 months, 6 months and 1 year after surgery);

### 2.6.2. Secondary outcomes

#### 2.6.2.1. Occurrence of intraoperative complications, including:

- Intraoperative hypotension and vasopressor dosage;
- Intraoperative arrhythmia, myocardial ischemia, myocardial infarction, massive hemorrhage, pulmonary embolism and hypoxemia;
- Intraoperative blood loss and blood transfusion volume;

2.6.2.2. High-sensitivity cardiac troponin T(hs-cTnT), measured on the 1 and 3 days after surgery;

2.6.2.3. Early mobility after surgery;

2.6.2.4. Incidence of various complications and Comprehensive Complication Index (CCI) <sup>[19]</sup> during hospitalization after surgery;

2.6.2.5. Postoperative analgesic effectiveness within three days after the surgery;

2.6.2.6. Incidence of delirium on the 1, 2 and 3 days after surgery, diagnosed with Confusion Assessment Method(CAM)<sup>[20]</sup>;

2.6.2.7. Sequential Organ Failure Assessment(SOFA) <sup>[21]</sup>, assessed on the 1 and 3 days after surgery;

2.6.2.8. Bauer Patient Satisfaction Questionnaire<sup>[22]</sup>, assessed on the 3 days after surgery;

2.6.2.9. Length of stay in ICU and hospital;

### 2.6.3. Other observational variables:

2.6.3.1. Economic parameters including total cost in hospital and expenditure for anesthesia;

2.6.3.2. Functional recovery on the 30 days after surgery, evaluated by Barthel Activities of Daily Living Index (Barthel Index);

2.6.3.3. Post-discharge destination, and incidence of complications and adverse events after discharge.

### 2.7. Participant timeline

For a given participant, assessment will be performed one day prior to surgery and again on the day of surgery to confirm whether qualified for enrollment. Randomization will perform on the day of surgery. And then intervention will be performed. The accrual period of this trial is expected to be about 1 year. The patients will be followed up on the 1, 2 and 3 days after surgery and on the day of discharge. The total follow-up period will be set as 1 year and the telephone follow-up will be conducted at the 1, 3, 6 and 12 months after surgery.

### 2.8. Power and Sample Size Calculation

We estimate the sample size using the formula by Schoendeld under the assumption of the validity of the proportional-hazards regression model [23, 24]. We take significance level 0.05 (one-sided) and power 0.80. Patients will be randomly assigned to one of the two anesthesia groups in five different clinical centers. A retrospective study included patients over 65 years old showed that the one-year mortality was 41.7% for GA group and 28.3% for combined peripheral nerve block (CPNB) group [14]. In



1  
2  
3  
4 this study, only patients with age 75 years or older will be included, so we expect the  
5  
6 actual mortality of the GA group will be higher than that in the previous study.  
7  
8 Therefore, we assume the mortality to be 55% for GA group and 46.75% for CLSB  
9  
10 group (15% relative reduction compared with GA group). Then the sample size needed  
11  
12 for this study is 868 (with 434 in each of the two groups). When the mortality of the  
13  
14 GA group is only 45%, the above calculated sample size can still detect a 20%  
15  
16 improvement in the CLSB group with the power of at least 0.80. In consideration of the  
17  
18 possible lost to follow up, we add an additional 20% to the above calculated sample  
19  
20 size. So the total number of patients needed for this study is 1086.  
21  
22  
23  
24  
25

## 27 **2.9. Randomization and blinding**

28  
29  
30 Upon the receipt of informed consents, patients will be randomly assigned to the  
31  
32 two groups in any one of the five centers. Sequentially numbered sealed opaque  
33  
34 envelopes with group allocation inside altered anesthetist to use CLSB or GA. The R  
35  
36 program will be used to generate randomization block allocation for each of the five  
37  
38 centers with randomly selected block sizes of four, six, and eight. The envelopes will  
39  
40 be placed in the patient's chart before the start of each procedure by a doctor of the  
41  
42 research team. The research staff who will interview patients postoperatively are  
43  
44 blinded for the allocated treatment. The statistician will be blinded. A spreadsheet  
45  
46 linking the patient number and name will be password protected and kept on a research  
47  
48 computer. The recruitment will stop when the total number of patients reaches 1086.  
49  
50  
51 The subjects and intervention performers (anesthesiologists) know the randomized  
52  
53 allocation, but the follow-up personnel and statistician was blinded to the randomized  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 allocation and intervention.  
5

## 6 7 **2.10. Data collection and management** 8

9 Data will be collected in four steps: preoperative, intraoperative and in-hospital  
10 data collection and post-discharge telephone follow-up.  
11

### 12 13 14 **2.10.1. Preoperative data:** 15

16  
17 **2.10.1.1.** Basic information including name, admission number, height, weight, gender,  
18 age, blood pressure, heart rate and ASA grade (American Society of Anesthesiologists  
19 grade).  
20  
21

22  
23  
24 **2.10.1.2.** Preoperative information including diagnosis, type of surgery, type and  
25 dosage of anticoagulants, and days passed until surgery.  
26  
27

28  
29  
30 **2.10.1.3.** Preoperative complications and medication related to cardiovascular disease,  
31 stroke, respiratory disease, kidney disease, diabetes, Parkinson's disease, and deep  
32 venous thrombosis of lower extremity if any.  
33  
34

35  
36  
37 **2.10.1.4.** Preoperative examination results including blood gas analysis, ECG,  
38 echocardiography, blood routine testing, liver and kidney function testing, coagulation  
39 testing (D-dimer), Pro-BNP, hs-cTnT, and lower extremity vascular ultrasonography.  
40  
41

42  
43  
44 **2.10.1.5.** Preoperative evaluation results including MMSE (Mini-mental State  
45 Examination), SOFA and Barthel Index, all of which might be associated with the  
46 postoperative complications.  
47  
48

### 49 50 51 **2.10.2. Intraoperative data** 52

53  
54  
55 **2.10.2.1.** Duration of surgery, incidence of intraoperative hypotension or hypertension,  
56 and vasoactive drug dosage.  
57  
58  
59  
60

1  
2  
3  
4 **2.10.2.2.** Intraoperative blood loss, blood transfusion volume, and intraoperative fluid  
5  
6  
7 infusion volume.

8  
9 **2.10.2.3.** Intraoperative arrhythmia (sinus bradycardia, sinus tachycardia, ventricular  
10  
11 arrhythmia, atrial arrhythmia, etc.), myocardial ischemia, and myocardial infarction.

12  
13 **2.10.2.4.** Intraoperative complications: massive hemorrhage, pulmonary embolism,  
14  
15  
16 allergic reaction, hypoxemia, bronchospasm, gastric reflux and aspiration.

17  
18 **2.10.2.5.** Intraoperative conversion of anesthesia and the relevant causes.

### 22 **2.10.3. In-hospital data**

23  
24 **2.10.3.1.** High-sensitivity cardiac troponin T (hs-cTnT), measured on the 1 and 3 days  
25  
26  
27 after surgery;

28  
29 **2.10.3.2.** Earlier mobilization and postoperative hip rehabilitation: the daily degree of  
30  
31  
32 maximal hip flexion and abduction will be recorded [25]. The day after surgery, all 2  
33  
34  
35 groups will start an identical physical therapy regimen. The patients will perform  
36  
37  
38 passive and active hip flexion and abduction exercises twice daily. Patients will be  
39  
40  
41 encouraged to get out of bed as soon as possible and try ambulation with a walker. The  
42  
43  
44 maximal degree of hip flexion and abduction tolerated by each patient will be recorded  
45  
46  
47 for three days. The day of first ambulation will be also recorded for each group.

48  
49 **2.10.3.3.** Postoperative complications including incidence and severity of various  
50  
51  
52 complications and the CCI [19] value at discharge. Complications were assessed and  
53  
54  
55 graded using the Clavien-Dindo classification. CCI will be derived from these features  
56  
57  
58 at discharge, using the CCI calculator available online ([www.assessurgery.com](http://www.assessurgery.com)).

59  
60 Complications include:

- Myocardial ischemia, myocardial infarction, heart failure, arrhythmia;
- Pulmonary infection, respiratory failure, pulmonary embolism;
- Postoperative delirium;
- Cerebral ischemia, cerebrovascular accident;
- Renal failure, urinary retention;
- Regurgitation and pulmonary aspiration;
- Postoperative nausea and vomiting (PONV);
- Postoperative bleeding and 24h postoperative drainage volume;
- Reoperation.

**2.10.3.4.** The intensity of postoperative pain at rest and on movement will be assessed with Visual Analogue Scale (VAS) (0 no pain, and 10 worst possible pain) at the 24, 48, and 72 hours after surgery.

**2.10.3.6.** CAM will be evaluated on the 1, 2 and 3 days after surgery.

**2.10.3.7.** SOFA <sup>[21]</sup> will be evaluated on the 1 and 3 days after surgery.

**2.10.3.8.** Bauer Patient Satisfaction Questionnaire will be assessed on the 3 days after surgery.

**2.10.3.9.** Length of ICU stay, length of hospital stay, total hospitalization cost, and expenditure for anesthesia.

#### **2.10.4. Post-discharge follow-up data**

**2.10.4.1.** Telephone follow-up will be performed on the 1, 3, 6 and 12 months after surgery to collect the following information.

- Discharge destinations. Disposition status after discharge will be classified as follows: dead, nursing home (e.g., skilled nursing facility, intermediate care facility,

1  
2  
3  
4 extended care facility, nursing home), community dwelling (e.g., home alone,  
5  
6 home with others), or other.

- 7  
8  
9 ● Dead or not, specific cause and time.  
10  
11 ● Incidence of complications and adverse events: heart, lungs, brain, liver, kidney,  
12  
13 four limbs, and hospitalization, etc.  
14  
15

16  
17 **2.10.4.2.** Barthel Index for evaluation of functional recovery will be collected on the 30  
18  
19 days after surgery.  
20  
21

## 22 **2.11. Data and safety monitoring**

23  
24 Preoperative, intraoperative and in-hospital data will be collected from the  
25  
26 electronic medical record, monitor machines and relevant manual records by one of the  
27  
28 research staff. Telephone follow-up will be conducted by the research team. Data will  
29  
30 be securely managed by an independent contract research organization (Shanghai  
31  
32 Ruihui Biotech Co., Ltd, Shanghai). All serious adverse events, as well as all non-  
33  
34 serious adverse events that are unexpected and judged to be related to the study  
35  
36 treatment, will be recorded in the study database and reported as required to local IRBs  
37  
38 and to the Shanghai Jiao Tong University Affiliated Sixth People's Hospital IRB. Data  
39  
40 and safety monitoring will be the responsibility of the study director/principle  
41  
42 investigator(PI), the study biostatistician, site clinical directors and an independent Data  
43  
44 and Safety Monitoring Board(DSMB) selected by the study PI. The DSMB will be  
45  
46 composed of 5-7 independent, multidisciplinary experts who are not have subordinate  
47  
48 relationships with the PI or any member of the study team. The DSMB will review  
49  
50 study implementation and the occurrence of adverse events.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 2.12. Statistical analysis

The data will be analyzed using intention-to-treat approach. Demographics information will be compared for patients of the two groups to ensure the data are balanced. Student t-test will be used for quantitative variables such as age, and heart rate, blood pressure. Chi-square test will be used for categorical variables such as Sex, ASA classification grades. The VAS pain scores will be analyzed using repeated measure ANOVA to test the effects of treatment, time, and the interaction effect. The effects of different covariates on the mortality measured at 1 month, 3 months, 6 months and 12 months will be assessed using a logistic regression model. The primary analysis model will be Cox regression model with covariates. Either logistic regression or ordinary multiple regression method will also be used to assess the effects of the covariate on the secondary and other outcomes as well depending on the type of dependent variable. The proportional-hazards regression model will be used to compare the survival times of the patients in the two groups and to assess the effects of the covariates. The statistical analysis will be performed using statistical software SPSS 24.0 (IBM Corporation, Armonk, NY, USA) with a significance level of 0.05.

## 2.13. Access to data

During the study, data will be stored in a password-protected system and can be accessed by the research staff who sign the confidential disclosure agreements. Data without patient identification will be publicly accessible after the study.

## 2.14. Confidentiality

Each participant will be given an identification number and referred by the

1  
2  
3  
4 identification number throughout the study and in all study-related information. This  
5  
6 information will be securely stored in a password-protected access system provided by  
7  
8 a local supplier. Relevant paper records will be stored in a locked cabinet in an access-  
9  
10 controlled room. All records containing any patients' personal identifiers will be  
11  
12 separately stored similarly as above.  
13  
14  
15

### 16 17 **2.15. Trial status**

18  
19 At the time of manuscript submission, the study is in the preparation phase for  
20  
21 recruitment.  
22  
23

## 24 25 **3. DISCUSSION**

26  
27 Choice of anesthesia for hip fracture surgery in elderly patients is still inconclusive.  
28  
29 General anesthesia with endotracheal intubation or LMA is a common procedure for  
30  
31 hip fracture surgery, with advantages of wide indications and maintaining relatively  
32  
33 stable hemodynamics. Compared with general anesthesia, neuraxial anesthesia avoids  
34  
35 endotracheal intubation or LMA insertion. But vertebral degeneration and anatomical  
36  
37 abnormalities in elderly patients often make neuraxial anesthesia puncture difficult, and  
38  
39 most of these patients are taking anticoagulants, which are the contraindication of  
40  
41 neuraxial anesthesia. So the neuraxial anesthesia has limitations in application for the  
42  
43 elderly patient. The principle for anesthesia selection is to reduce or avoid the effect of  
44  
45 anesthesia on systemic and vital organ functions as much as possible when meeting the  
46  
47 needs of surgery. Previous lumbar and sacral plexus block depends on blind puncture  
48  
49 technique and cannot ensure the clinical effectiveness. However, ultrasound  
50  
51 visualization technology has promoted the wide application of lumbar and sacral plexus  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 block. Combined lumbar and sacral plexus block with sedative anesthesia has gradually  
5  
6 become alternative approach for hip fracture surgery in elderly patients, and this  
7  
8 anesthetic technique has been massively applied in our department and achieved  
9  
10 satisfactory clinical results in recent years, but there is few reliable clinical evidence on  
11  
12 whether it can be safely used for hip fracture surgery in elderly patients and improve  
13  
14 the short-term or long-term outcomes. Thus, we have designed this trial protocol to  
15  
16 illustrate the clinical value of combined lumbar and sacral plexus block with sedative  
17  
18 anesthesia in elderly patients undergoing hip fracture surgery. In this study, we will  
19  
20 observe the effect of the two anesthetic methods (general endotracheal anesthesia or  
21  
22 combined lumbar and sacral plexus block plus sedation on the early prognostic  
23  
24 indicators in elderly patients with hip fracture, including postoperative complications,  
25  
26 postoperative analgesic effect, postoperative early mobility, postoperative delirium,  
27  
28 patient's satisfaction to anesthesia and length of stay in ICU and hospital. This study  
29  
30 will be the first prospective, multicenter, randomized controlled clinical trial to  
31  
32 investigate the effect of the two anesthesia techniques on long-term prognostic  
33  
34 indicators in elderly patients with hip fracture, including postoperative 1-year all-cause  
35  
36 mortality and incidence of complications and adverse events. The results of this study  
37  
38 will help elucidate whether ultrasound-guided combined lumbar and sacral plexus  
39  
40 block with sedative anesthesia can be safely used in hip fracture surgery in elderly  
41  
42 patients and can reduce the incidence of perioperative complications and improve long-  
43  
44 term prognosis, so as to solve the troubling clinical problem and provide a theoretical  
45  
46 basis for elderly patients undergoing hip fracture surgery to choose the optimal  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 anesthetic method.  
5

## 6 **Abbreviations**

7  
8  
9 ASA grade: American Society of Anesthesiologists grade; GA: General anesthesia;  
10  
11 CLSB: Combined Lumbar and Sacral Plexus Block; PACU: Postanesthesia Care Unit;  
12  
13  
14 Hb: Hemoglobin Concentration; ICU: Intensive Care Unit; CCI: Comprehensive  
15  
16  
17 Complication Index; SOFA: Sequential Organ Failure Assessment; CAM: The  
18  
19 Confusion Assessment method; MMSE: Mini-mental State Examination; ECG:  
20  
21  
22 Echocardiography; Pro-BNP: Pro Brain Natriuretic Peptide; hs-cTnT: High-  
23  
24  
25 sensitivity cardiac Troponin T; PONV: Postoperative Nausea and Vomiting; VAS:  
26  
27  
28 Visual Analog Scale

29  
30 **Contributors** JZ and WJ designed the study and wrote the protocol. HZ and XW  
31  
32 performed statistical analysis. HZ, XW and ZS were involved in protocol conception  
33  
34 and design and manuscript revision. WJ is the principal investigator of this clinical trial.  
35  
36  
37 All authors read and approved the final version of the manuscript.

38  
39  
40 **Acknowledgements** Not applicable.

41  
42  
43 **Funding** This study is supported by Shanghai Municipal Commission of Health and  
44  
45 Family Planning Foundation for Key Developing Disciplines (2015ZB0103).  
46

47  
48 **Data sharing statement** No additional data are available.

49  
50  
51 **Patient consent** Obtained.

52  
53  
54 **Competing interests** None declared.

## 55 **REFERENCES**

- 56  
57  
58 1. Johnell O, Kanis JA: **An estimate of the worldwide prevalence and disability associated with**  
59 **osteoporotic fractures.** *Osteoporosis international : a journal established as result of*  
60


- 1  
2  
3 cooperation between the European Foundation for Osteoporosis and the National  
4 Osteoporosis Foundation of the USA 2006, **17**(12):1726-1733.
- 5  
6 2. Cooper C, Campion G, Melton LJ, 3rd: **Hip fractures in the elderly: a world-wide projection.**  
7 *Osteoporosis international : a journal established as result of cooperation between the*  
8 *European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*  
9 1992, **2**(6):285-289.
- 10  
11 3. Brauer CA, Coca-Perrillon M, Cutler DM, Rosen AB: **Incidence and mortality of hip fractures**  
12 **in the United States.** *Jama* 2009, **302**(14):1573-1579.
- 13  
14 4. Roche JJ, Wenn RT, Sahota O, Moran CG: **Effect of comorbidities and postoperative**  
15 **complications on mortality after hip fracture in elderly people: prospective observational**  
16 **cohort study.** *Bmj* 2005, **331**(7529):1374.
- 17  
18 5. Lawrence VA, Hilsenbeck SG, Noveck H, Poses RM, Carson JL: **Medical complications and**  
19 **outcomes after hip fracture repair.** *Archives of internal medicine* 2002, **162**(18):2053-2057.
- 20  
21 6. Guay J, Parker MJ, Gajendragadkar PR, Kopp S: **Anaesthesia for hip fracture surgery in adults.**  
22 *The Cochrane database of systematic reviews* 2016, **2**:Cd000521.
- 23  
24 7. Memtsoudis SG, Sun X, Chiu YL, Stundner O, Liu SS, Banerjee S, Mazumdar M, Sharrock NE:  
25 **Perioperative comparative effectiveness of anesthetic technique in orthopedic patients.**  
26 *Anesthesiology* 2013, **118**(5):1046-1058.
- 27  
28 8. Neuman MD, Silber JH, Elkassabany NM, Ludwig JM, Fleisher LA: **Comparative effectiveness**  
29 **of regional versus general anesthesia for hip fracture surgery in adults.** *Anesthesiology* 2012,  
30 **117**(1):72-92.
- 31  
32 9. Patorno E, Neuman MD, Schneeweiss S, Mogun H, Bateman BT: **Comparative safety of**  
33 **anesthetic type for hip fracture surgery in adults: retrospective cohort study.** *Bmj* 2014,  
34 **348**:g4022.
- 35  
36 10. Neuman MD, Rosenbaum PR, Ludwig JM, Zubizarreta JR, Silber JH: **Anesthesia technique,**  
37 **mortality, and length of stay after hip fracture surgery.** *Jama* 2014, **311**(24):2508-2517.
- 38  
39 11. White SM, Moppett IK, Griffiths R: **Outcome by mode of anaesthesia for hip fracture surgery.**  
40 **An observational audit of 65 535 patients in a national dataset.** *Anaesthesia* 2014, **69**(3):224-  
41 230.
- 42  
43 12. Gamli M, Sacan O, Baskan S, Ozciftci S, Gogus N: **Combined lumbar plexus and sciatic nerve**  
44 **block for hip fracture surgery in a patient with severe aortic stenosis.** *Journal of anesthesia*  
45 2011, **25**(5):784-785.
- 46  
47 13. Ho AM, Karmakar MK: **Combined paravertebral lumbar plexus and parasacral sciatic nerve**  
48 **block for reduction of hip fracture in a patient with severe aortic stenosis.** *Canadian Journal*  
49 *of Anesthesia* 2002, **49**(9):946-950.
- 50  
51 14. Karaca S, Ayhan E, Kesmezacar H, Uysal O: **Hip Fracture Mortality: Is It Affected by Anesthesia**  
52 **Techniques?** *Anesthesiology Research & Practice* 2012, **2012**(2012):708754.
- 53  
54 15. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A,  
55 Mann H, Dickersin K, Berlin JA *et al*: **SPIRIT 2013 statement: defining standard protocol items**  
56 **for clinical trials.** *Annals of internal medicine* 2013, **158**(3):200-207.
- 57  
58 16. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson  
59 A, Schulz KF, Parulekar WR *et al*: **SPIRIT 2013 explanation and elaboration: guidance for**  
60 **protocols of clinical trials.** *Bmj* 2013, **346**:e7586.
17. Karademir G, Bilgin Y, Ersen A, Polat G, Buget MI, Demirel M, Balci HI: **Hip fractures in patients**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- older than 75 years old: Retrospective analysis for prognostic factors.** *International journal of surgery (London, England)* 2015, **24**(Pt A):101-104.
18. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K *et al*: **Liberal or restrictive transfusion in high-risk patients after hip surgery.** *The New England journal of medicine* 2011, **365**(26):2453-2462.
19. Slankamenac K, Nederlof N, Pessaux P, de Jonge J, Wijnhoven BP, Breitenstein S, Oberkofler CE, Graf R, Puhan MA, Clavien PA: **The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials.** *Annals of surgery* 2014, **260**(5):757-762; discussion 762-753.
20. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI: **Clarifying confusion: the confusion assessment method. A new method for detection of delirium.** *Annals of internal medicine* 1990, **113**(12):941-948.
21. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL: **Serial evaluation of the SOFA score to predict outcome in critically ill patients.** *Jama* 2001, **286**(14):1754-1758.
22. Bauer M, Bohrer H, Aichele G, Bach A, Martin E: **Measuring patient satisfaction with anaesthesia: perioperative questionnaire versus standardised face-to-face interview.** *Acta anaesthesiologica Scandinavica* 2001, **45**(1):65-72.
23. Cox DR: **Regression Models and Life-Tables.** *Journal of the Royal Statistical Society* 1992, **34**(2):187-220.
24. Schoenfeld DA: **Sample-size formula for the proportional-hazards regression model.** *Biometrics* 1983, **39**(2):499-503.
25. Singelyn FJ, Ferrant T, Malisse MF, Joris D: **Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous femoral nerve sheath block on rehabilitation after unilateral total-hip arthroplasty.** *Regional anesthesia and pain medicine* 2005, **30**(5):452-457.

1  
2  
3  
4  
5  
6  
7  
8  
9 **Figure legend**

10  
11 Fig. 1 CONSORT flowchart designed for subject enrollment  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



100x99mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>3</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>n/a</u>
Protocol version	3	Date and version identifier	<u>3</u>
Funding	4	Sources and types of financial, material, and other support	<u>2-3</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>21</u>
	5b	Name and contact information for the trial sponsor	<u>n/a</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>n/a</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>6</u>

1				
2				
3	<b>Introduction</b>			
4				
5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>3-6</u>
6				
7				
8		6b	Explanation for choice of comparators	<u>4-5</u>
9				
10	Objectives	7	Specific objectives or hypotheses	<u>5-6</u>
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>6</u>
13				
14				
15	<b>Methods: Participants, interventions, and outcomes</b>			
16				
17	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>6</u>
18				
19				
20	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>7-8</u>
21				
22				
23	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>8-11</u>
24				
25				
26		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>9</u>
27				
28				
29		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>n/a</u>
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>9-11</u>
33				
34	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>11-12</u>
35				
36				
37				
38				
39	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>10,12,24</u>
40				
41				
42				
43				
44				
45				
46				
47				

1				
2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>12-13</u>
3				
4				
5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>6-7</u>
6				
7				

### 8 **Methods: Assignment of interventions (for controlled trials)**

#### 9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>13-14</u>
13				
14				
15				
16				
17	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>13-14</u>
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>13-14</u>
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>13-14</u>
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>13-14</u>
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>14-18</u>
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>n/a</u>
39				
40				
41				
42				



1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>17-18</u>
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>18</u>
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>18</u>
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>n/a</u>
13				
14				
15	<b>Methods: Monitoring</b>			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>17-18</u>
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>n/a</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>17-18</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>n/a</u>
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>2-3</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>2-3</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>18-19</u>
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>n/a</u>
7				
8	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>18-19</u>
9				
10				
11	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>21</u>
12				
13				
14	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>18</u>
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>n/a</u>
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>3</u>
21				
22				
23				
24				
25		31b	Authorship eligibility guidelines and any intended use of professional writers	<u>n/a</u>
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>n/a</u>
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>n/a</u>
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>n/a</u>
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40